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chapTer i – Introduction
the use of a battery of evoked pain models in early phase drug development  8 
 






















A case-in-point is the use of human pain models. In contrast to clinical pain, 
which is normally confounded by emotional, psychological and cognitive 
factors caused by the underlying disease, pain models have the advantage 
that they are less confounded by these factors.9 A human pain test consists 
of two parts; an external stimulus needs to be applied to evoke pain and 
this pain response needs to be measured.10 Several methods exist for the 
induction of evoked pain in humans, such as mechanical, thermal, electrical 
and chemical stimulation. A stimulus can be phasic (lasting for millisec-
onds to seconds) or tonic (lasting for minutes). Stimuli can be applied to 
different tissue types for instance skin, muscles or viscera.11 Possible 
read-outs for evoked pain can be divided into several categories; psycho-
physical read-outs, electrophysiological read-outs or imaging read-outs. 
The psychophysical readouts can be subdivided into response-dependent 
methods, stimulus dependent methods and a combination of both.11 In the 
response-dependent method the subjects rate the intensity of a given stimu-
lus (for instance using a visual analogue scale). For the stimulus-dependent 
threshold, the stimulus increases until a certain threshold (pain detection 
threshold, pain tolerance threshold) is reached.10 Electrophysiological 
readouts include microneurography, somatosensory evoked potentials and 
electroencephalography (eeg). Imaging readouts include functional mag-
netic resonance imaging (fmri) and positron emission tomography (pet). 
These methods provide a more objective measurement of pain. However, 
they have a larger variation in outcome measurements and are technically 
more difficult to perform in a large group of subjects.11⁻13 
The advantages of using human pain models versus clinical pain according 
to Arendt Nielsen et al.11 are:
 » Experimental stimulus intensity, duration and modality are controlled 
and do not vary over time.
 » Differentiated responses to different standardised stimulus modalities.
 » The response can be assessed quantitatively and compared over time. 
 » Pain sensitivity can be compared quantitatively between various 
normal/affected/treated regions.
 » Experimental models of pathological conditions can be studied and the 
effects of drugs on such mechanisms quantified.
Another advantage is that the evoked pain models can be easily performed 
in healthy subjects, who are easier to recruit into clinical studies compared 
inTroducTion 
Acute pain, defined as short-term pain of less than 12 weeks duration, is 
part of normal life and experienced regularly by almost everyone. Studies 
on the prevalence of chronic pain in adults show that in Western Countries 
19-31% of the population suffers from chronic pain, increasing with age and 
more common in women versus men.1,2 
Effective treatment of pain consists of a broad range of therapies, such as 
paracetamol, nonsteroidal anti-inflammatory drugs (nsaids) and opioids. 
Other treatment options also include antidepressants and antiepileptics.2,3 
Due to their side effects and sometimes insufficient efficacy there is still a 
need for new analgesic drugs. 
New analgesic drugs
Targets of novel analgesic drugs fall into three main classes: (1) incremental 
improvement on an existing drug mechanism, (2) a novel selective mech-
anism arising from better understanding of the mechanism of an existing 
analgesic drug and (3) a completely novel mechanism arising from basic 
biological studies or from human pathophysiological or genomic studies.4 
Fifty nine drugs identified as analgesics were introduced in 1960-2009,5 
however there is still an ongoing search for analgesics. 
Many drugs, that are promising in preclinical research, fail to show suc-
cess during their development process. In general, approximately 11% of 
the drugs that enter phase I of clinical development get approved.6 In 2011-
2012 there were a total of 148 failures between phase II and submission. In 
the failures in which reason for failure was reported; 56% failed due to lack 
of efficacy.7 One of the tools that can aid in the reduction of attrition rates of 
new compounds is the use of biomarkers. A biomarker is ‘a characteristic 
that is objectively measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes, or pharmacological responses to 
a therapeutic intervention’.8 Biomarkers intended to measure pharmaco-
logical activity can be used to assess if a specific molecular target is reached 
and affected as intended and what the range of concentrations and dose 
levels is at which pharmacological activity is exerted. Using biomarkers in 
early phase human trials has the advantage of showing proof-of-concept in 
an early phase and reduce attrition in a later phase due to lack of efficacy. It 
can also show lack of efficacy in an early phase and allow attrition to occur 
in an earlier phase of drug development.6
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Measuring pain in patients
Accurate measurement of pain in patients is important to (1) determine 
pain intensity, quality, and duration, (2) aid in diagnosis, (3) help decide 
on the choice of therapy, (4) evaluate the effectiveness of therapy and (5) 
study the mechanisms of pain and analgesia.4,18 Measuring pain intensity 
in patients can be performed by using visual analogue scales (vas), verbal 
rating scale (vrs) and numerical rating scales (nrs).19 The main disad-
vantage of these scales is that they only measure one aspect (i.e. intensity) 
of the pain, while pain consists of much more qualities. The McGill Pain 
Questionnaire was developed to address this issue; it not only measures 
pain intensity but also the sensory and affective qualities of pain.18,20 
Other measurements of pain include observational tools, which are used 
in patients who are not able to rate their pain themselves (e.g. neonates 
and critically ill or sedated patients).21 More objective measures to mea-
sure nociception and pain include monitoring changes in the autonomic 
nervous system (e.g. heart rate/blood pressure changes and pupillometry), 
biopotentials (e.g. electro-encephalography (eeg) or electromyography) 
and neuroimaging (magnetic resonance imaging (mri) and positron emis-
sion tomography (pet)).22 
In studies reporting analgesic interventions, efficacy can be reported as 
change in the patient’s report of pain or as in changes in any of the above men-
tioned outcome measures.23 As part of analgesic drug development, human 
pain models can be a valuable addition to analgesic trials in pain patients. 
If no positive evidence for the efficacy of a drug in the chosen target patient 
population can be found, the use of one or more human pain models can pro-
vide information on the possible effect of the compound for the treatment of 
pain with another etiology. Also, in several chronic pain populations, such as 
chronic whiplash and associated disorders, rheumatoid arthritis, vulvody-
nia and fibromyalgia, changes in pain tolerance levels, pain modulation and 
augmented brain responses and altered responses to analgesics have been 
found.24⁻26 Using evoked pain in these patients can provide insight into the 
analgesic mechanisms -or lack thereof- in these altered pain states.14
Pain models in drug development
Evoked pain tests have been used before in combination with existing 
analgesic compounds. Several papers have been published reviewing the 
evidence for several analgesic–pain model combinations.14,16,27,28
to patients, have no concomitant diseases and don’t use concomitant pain 
medication.
A disadvantage of human models is that the applied pain stimuli are 
short lasting and therefore do not mimic clinical pain. Since clinical pain is 
a complex sensation involving psychological, physiological and cognitive 
factors, no single pain model is able to replicate all aspects of clinical pain. 
We hypothesise that a multimodal approach in which multiple receptors 
and pathways are stimulated can be expected to resemble clinical pain to a 
higher degree.9
Clinical pain versus evoked pain
Pain in patients is a complex experience influenced by many factors such 
as emotion, fear, anxiety, but also cultural background, sex, genetics and 
educational background. Due to its complexity it can be difficult to assess 
effects of drugs on pain.14 Evoked pain models can control some of the 
influencing factors and is therefore sometimes more suited to investigate 
the analgesic effects of drugs.14 However, evoked pain is mostly short 
lasting and most stimuli are applied exogenously and are focused on skin 
nociceptor activation. In contrast to natural occurring pain which is mostly 
caused by endogenous factors, longer lasting and influenced by complex 
emotions.15 The advantages of the use of evoked pain models are its per-
formance in a controlled, standardised environment and it reproducibility, 
however one should always ask if there is any relevance to natural occur-
ring pain.15 Moore and colleagues investigated which natural occurring 
pain was physiologically most in agreement with evoking a pain response 
causing the same type of pain. For instance, intramuscular electrical stimu-
lation closely matched clinical acute musculoskeletal pain.15
Another approach was taken by Oertel and Lotsch to evaluate the differ-
ences between human pain models and clinical efficacy. First they looked at 
which drugs were effective for different pain conditions (e.g. nsaids were 
effective for inflammatory arthritis). They also investigated which drugs 
were effective for which pain model (e.g. nsaids influence pain response in 
laser evoked pain). If a certain drug was both effective in the model and in 
the particular clinical setting the model might be predictive for the clinical 
setting. Agreement for a large number of pain models with clinical efficacy 
was observed.16 In another review, the mutual agreement between pain 
models and clinical efficacy was statistically assessed. It was observed that 
a small set of pain models seemed predictive for efficacy in the clinic.17
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An overview of the most relevant previous studies reporting on analge-
sic-pain model combination for this thesis is provided in Table 1.
Some human pharmacology studies have used novel analgesics in 
combination with pain models. Chf3381, an nmda receptor agonist and 
monoamine oxidase inhibitor, attenuated secondary hyperalgesia in heat 
and capsaicin sensitised skin.33 However, later in a phase IIb trial for the 
treatment of diabetic neuropathy, a 25% reduction in pain scores compared 
to baseline was observed. There was also a marked reduction in pain scores 
in placebo-treated subjects, consequently no significant differences were 
found between treatment groups.34
The analgesic efficacy of aZd1940, a cannabinoid agonist, was inves-
tigated by using intra epidermal capsaicin injections. aZd1940 did not 
significantly attenuate pain or primary and secondary hyperalgesia.35 
Later, development of this drug was discontinued.36 Another clinical study 
showed that treatment with this compound was not effective in reducing 
pain after third molar extraction at doses exerting cannabinoid-like phar-
macodynamic effects.37 These two examples demonstrate how the use of 
pain models in early phase drug trials can aid in the decision-making in 
later stages of analgesic compound development. In the aZd1940 trials 
negative results in clinical pain were preceded by negative results in pain 
models. In the Chf3381 trials, a reduction in pain scores in a clinical study 
was preceded by positive results in human pain models. 
In the aZd1940 trial in healthy subjects, 2 methods of capsaicin admin-
istration were used to assess analgesic potency of aZd1940. No other pain 
models were included.35 Possibly using other or a combination of pain 
models would have shown analgesic properties of this new compound. 
This emphasises the importance of the use of multimodal testing. 
The PainCart
The PainCart described in this thesis is a multimodal battery of pain mod-
els (Figure 1). Multimodal testing with a battery of different pain models 
has been performed previously.9,31,38 The batteries have in common that 
they induce pain via different modalities and in different tissues. The bat-
teries differ in the individual pain models that are included. 
The pain models in the PainCart have already been extensively used in 
previous research. A unique aspect of the PainCart, however, is that it 
allows the different measurements to be performed in a combined manner 
and in large numbers of subjects in parallel. The individual models were 
chosen, based on the ability to induce pain via different modalities (elec-
trical, mechanical, thermal), in different structures (superficial and deep) 
and with different duration (phasic, tonic). The PainCart mainly consists 
of nociceptive and inflammatory pain models. It uses the following pain 
induction methods; electrical stimulation task, pressure stimulation task, 
cold pressor task, thermal stimulation (with and without ultra-violet 
inflammation).39 A typical order of PainCart measurements during a clini-
cal trial is shown in Figure 2. 
elecTrical sTimulaTion Task:
For cutaneous electrical pain, electrodes are placed on the skin. A stim-
ulator device is used to deliver an electric current. Electrical stimulation 
activates all nerve fiber populations. Advantages of this method is that 
it is widely used and that the stimuli are easy to control. However, elec-
tric current is not specific for a certain nerve; activation of certain fiber 
types depends on the intensity of the stimulus. Another limitation of 
electrical stimulation is that the stimulation directly stimulates the 
nerve and bypasses the sensory nerve endings.11,14,40 In this thesis two 
methodologies for applying electrical current are described. A single stim-
ulus method in which intensity of a current gradually increases.41,42 The 
repeated stimulus method, adapted from methods previously described,43 
in which each single stimulus pulse is repeated 5 times with a frequency 
of 2 Hz at the same current intensity and the repeated stimulus intensi-
ty increases gradually. This repeated application of a stimulus over time 
induces an integrated and more painful response, known as temporal 
summation. It is suggested that temporal summation might act as a bio-
marker of drug effects on neuropathic pain.43
pressure sTimulaTion Task:
For the pressure stimulation task, a tourniquet cuff is placed over the calf 
muscle (Figure 3). The pneumatic pressure is gradually increased until the 
subject indicates their pain tolerance. This method of mechanical pressure 
pain induction is based on methods previously described,44,45 and has 
shown to primarily assess nociception generated from the muscle with 
minimal contribution by cutaneous nociceptors. Although, setup of this 
computer controlled technique is more complex than using handheld pres-
sure algometry devices, the advantage of this technique is that the test can 
be executed in a more standardised fashion which increases reliability and 
sensitivity.14
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The method for cold stimulation is the immersion of a hand in a cold water 
bath with a temperature of ~1.0°C for 2 min or until the pain tolerance 
threshold is reached (Figure 4). The method of cold pressor pain is based 
on the methods previously described.46,47 Cold sensation is probably medi-
ated by activity of Aδ-fibers (cold sensation) and C-fibers (cold pain).14
condiTioned pain modulaTion:
The cold pressor task is also used to induce conditioned pain modulation 
(Cpm, previously known as ‘diffuse noxious inhibitory control’). Cpm is 
quantified by comparing the electrical pain detection and tolerance thresh-
olds before and within 5 min after the cold pressor task. Cpm reflects the 
principle that noxious stimulation to one part of the body inhibits noci-
ceptive neurons innervating other body parts. It is a measurement of the 
activation of the pain modulatory mechanism, as part of the descending 
endogenous analgesia system.48,49
Thermal sTimulaTion:
Contact heat pain is induced by a 3x3 cm thermode placed on the skin of the 
subject’s back which gradually increases in temperature. The pain response 
is characterised by ‘first pain response’ in which Aδ fibers are activated, fol-
lowed by a second pain response which is mediated by C-fibers.14
In addition to contact heat pain on normal skin, a 3x3 cm area of the skin is 
irradiated by uv light. This uv irradiation produces a discernible erythema 
(sunburn), which causes hyperalgesia and a decrease in heat pain thresh-
olds. This uvb model acts as a model for inflammatory pain.50,51
This thesis describes the validation of this battery of pain models, the use 
of this battery in different populations, and the application of this battery 
in the development of new compounds. The main question in this thesis is 
if this battery of pain models can be used as biomarker for clinical efficacy 
the development of new analgesic drugs.
ouTline of This Thesis
The methodology of the individual tests included in the battery of noci-
ceptive tests (PainCart) is described in Chapter 2. In Chapter 3 a study is 
described in which the PainCart is used in combination with a set of known 
analgesics. 
Xen2174 is norepinephrine transporter inhibitor, developed for the treat-
ment of acute postoperative pain and neuropathic pain. This compound 
was administered intrathecally in healthy subjects. Pharmacodynamic 
measurements in this study were performed using the PainCart. This is 
described in Chapter 4. 
Animal studies suggest that serotonin/noradrenalin re-uptake inhib-
itors co-administered with opioids have a synergistic effect. Chapter 5 
describes a study which investigated the synergistic effects of milnacipran 
and buprenorphine in healthy subjects using the PainCart.
Chapters 2 to 5 describe the use of the PainCart to measure pain in 
healthy adult subjects. Chapter 6 investigates if pain research using the 
PainCart is feasible and acceptable to healthy adolescents after the admin-
istration of paracetamol. 
The PainCart can be used in healthy subjects, but also in patients. 
Chapter 7 describes a clinical study of a novel neurotrophic factor devel-
oped for the treatment of neuropathic pain. This study was mainly set up to 
investigate the pharmacokinetics and the safety of bg00010. As exploratory 
endpoints, PainCart measurements were performed in sciatica patients to 
assess the feasibility to perform these tests in patients. 
In another study, PainCart measurements were also performed in 
patients with diabetes mellitus, patient with painful diabetic neuropathy 
(pdn) and patients with chronic idiopathic axonal polyneuropathy (Ciap). 
Possible differences between healthy subjects and patients may be import-
ant in the design of early phase clinical drug studies in which multi-modal 
pain testing is considered. Chapter 8 describes the main differences 
between performing the PainCart measurements in healthy volunteers 
versus populations with a chronic pain condition.
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Overview of different analgesic groups and their effect on different pain models. 
Drug Pain model
Electrical pain Cold pressor Pressure pain uvb and thermal Thermal grill



















































Overview and sequence of pharmacodynamic tests.
 
°C, degree Celsius; Hz, hertz; kPa, kilopascal; ms, millisecond; mA, milliampere; uvb, ultraviolet b
Mechanical
Tourniquet calf: 
0.5 kPa s-1, max 100 kPa 
ColdPressor















Single stimulus 0.2 ms at 10 Hz
Repeated stimulus: train of 5 at 2 Hz
Both increase 0.5 mA s-1, max 50 mA    
Thermode
30x30 mm, Pain Detection Threshold
Normal and ��� treated skin 
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Methodology of an integrated, Multi-Modal pain task battery
absTracT
Human pain models are useful in the assessing the analgesic effect of drugs, 
providing information about a drug’s pharmacology and identify poten-
tially suitable therapeutic populations. The need to use a comprehensive 
battery of pain models is highlighted by studies whereby only a single 
pain model, thought to relate to the clinical situation, demonstrates lack 
of efficacy. No single experimental model can mimic the complex nature of 
clinical pain. The integrated, multi-modal pain task battery presented here 
encompasses the electrical stimulation task, pressure stimulation task, 
cold pressor task, the uvb inflammatory model which includes a thermal 
task and a paradigm for inhibitory conditioned pain modulation. These 
human pain models have been tested for predicative validity and reliability 
both in their own right and in combination, and can be used repeatedly, 
quickly, in short succession, with minimum burden for the subject and with 
a modest quantity of equipment. This allows a drug to be fully character-
ised and profiled for analgesic effect which is especially useful for drugs 
with a novel or untested mechanism of action.
inTroducTion
Human pain models are useful in the evaluation of analgesics, providing 
information about a drug’s pharmacology and identifying potentially suit-
able therapeutic populations. Yet the field is plagued by studies yielding 
inconsistent findings. The reason for these differences has been put down 
to the use of different pain assessment methods and different subject pop-
ulations.1 To correctly predict clinical analgesia, the right pain model is 
needed.2,3 Nevertheless, mechanism-based pain model selection has led to 
many failures in predicting clinical efficacy.4
The need to use a comprehensive battery of pain models is highlighted 
by studies whereby only a single pain model, thought to relate to the clini-
cal situation, demonstrates lack of efficacy. No single experimental model 
can replicate the complex nature of clinical pain. Therefore, one pain model 
cannot be used exclusively to screen the pharmacological mechanism 
of action of a compound intended to treat clinical pain. Furthermore, the 
use of a panel of pain models allows a drug to be fully characterised and 
profiled. This is especially useful for drugs that have a novel or untested 
mechanism of action.
There are various paradigms for assessing validity of animal or human 
models of disease such as investigating the predictive, construct, concur-
rent or convergent, discriminant, etiological, and face validity of a model.5 A 
pain model can be considered of higher value and more relevant to human 
disease the more criteria it satisfies. However, a more simple measure of 
validity is to evaluate a model’s predictive validity and reliability.6 
With early phase drug development there are also other considerations 
that need to be taken into account to assess the value of a pharmacodynam-
ic measurement. The assessment should not be too burdensome, should 
not take too long, and the results should be quickly evaluable, automated 
and secure data collection is desirable. Also the ability to test several sub-
jects concurrently requires equipment that is technically standardised and 
well characterised.7
While other evoked pain batteries exist, their objective is more directed 
towards the classification of pain and for assessing pathophysiological pain 
mechanisms.8 Yet other batteries aim to represent a broad range of patho-
physiology including pain models for muscle and visceral pain.9 While 
suitable for testing in acute situations, their invasive nature do not make 
them suitable for testing repeatedly for longer periods.
The pain models presented here satisfy many of the above mentioned 
criteria making them especially useful for clinical studies in both healthy 





















Methodology of an integrated, Multi-Modal pain task battery
subjects and patients. The multi-modal pain task battery that is present-
ed here encompasses the electrical stimulation task, pressure stimulation 
task, cold pressor task, uvb inflammatory model that includes a thermal 
task and a inhibitory conditioned pain modulation (iCpm) paradigm that 
takes advantage of interactions between the tasks The human pain mod-
els presented here have been tested for predicative validity and reliability 
both in their own right and in combination. 
Protocol
Ethics statement: Procedures involving human subjects have been approved 
in numerous studies by an independent ethics committee the Stichting 
Beoordeling Ethiek Biomedisch Onderzoek (Foundation bebo) and the 
Leiden University Medical Center.
1 inTegraTed pain assessmenT Tasks
note: The task administration and interface is based on Spike2 software 
and an analogue-to-digital converter that performs the conversions need-
ed for stimulus triggering and signal recording. This ensures uniform task 
administration, data capture, handling and storage, and standardising the 
delivery of tasks by controlling the stimulus generation equipment while 
presenting instructions to the subject and feedback on slider position via a 
second monitor.
note: Perform the tasks in short succession and in the order presented. 
The duration of performing all the tasks is approximately 30 min. 
1. Pain scoring
note: For most tasks, stimuli of progressively increasing intensity are 
presented.
 » Prior to the task, present the subject with an electronic visual analogue 
scale (evas) slider. 
 » Instruct the subject to indicate the intensity of their pain on a scale from 
0 (none) to 100 (intolerable pain) by moving the slider from left to right. 
 » During training, and when necessary, provide the subjects with 
standardised definitions (Table 1) and instructions.
 » Inform the subject that moving the slider all the way to the left ends the 
administration of the painful stimulus.
 » Record when stimulus becomes painful (evas > 0), corresponding to the 
pain detection threshold. Record when the pain is no longer tolerable to 
the subject (evas = 100), corresponding to the pain tolerance level of the 
subject; and the area under the stimulus-response curve (auC).
note: During training, it is beneficial to provide subjects with a context of 
pain intensity. Following each task assess the maximal pain intensity using 
a 100 mm evas, with 0 and 100 defined as ‘no pain’ and ‘worst pain imagin-
able’, respectively (Table 1).
2 elecTrical sTimulaTion Task
note: The task has been shown to primarily assess nociception generated 
from the Aδ and C sensory afferent fibers, which pass nociceptive signals 
from the periphery to the spinal cord. The Aδ fibers conduct the signal rel-
atively rapidly, causing the sharp localization of pain and the rapid spinal 
response which is perceived during a transcutaneous electrical stimu-
lus.10 The method of electrical stimulation is based on methods described 
previously.11
 » Clean an area of skin with skin preparation gel overlying the tibial bone, 
100 mm distal from the caudal end of the patella. If required, shave the 
area beforehand.
 » Place two Ag-AgCl electrodes on the skin. Place the middle of the 
first electrode (anode) 100 mm distal to the caudal end of the patella. 
Place the middle of the second electrode (cathode) directly (±135 mm) 
underneath the first. 
 » Record the resistance of the 2 electrodes using an ohmmeter. Ensure it 
is <2 kΩ. Optionally, remove the electrodes and re-cleanse the skin with 
skin preparation gel. Instruct the subject to sit comfortably with their 
foot flat on the floor.
 » Connect the electrodes to a constant current stimulator and apply 
a tetanic pulse from 0 mA in steps of 0.5 mA/s (cutoff 50 mA), with a 
frequency of 10 Hz with a duration of 0.2 ms. 
3 pressure sTimulaTion Task
note: This method of pressure pain induction has been shown to 
primarily assess nociception generated from the muscle with minimal con-
tribution by cutaneous nociceptors12 and is based on methods previously 
described.13
 » Place an 11 cm wide tourniquet cuff over the gastrocnemius muscle. 
Instruct the subject to sit comfortably with their foot flat on the floor. 
Inflate with a constant pressure rate increase of 0.5 kPa/s up to 100 kPa. 
Control the pressure with an electro-pneumatic regulator. 
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4 cold pressor Task
note: The cold pressor task involves the submersion of an extremity (gen-
erally a hand) into cold water. It is used in clinical studies to investigate 
cardiovascular responses and nociception. It is also a method to induce 
iCpm (formerly known as diffuse noxious inhibitory control (dniC)-like 
effect).14 The method of cold pressor pain is based on the methods previ-
ously described.15,16
 » Prepare two thermostat-controlled, circulating water baths set at 35.0 ± 
0.5°C and 1.0 ± 0.5°C. 
 » Place a 35 cm tourniquet on the subject’s non-dominant upper-arm. 
During hand immersion, either regulate the blood pressure manually 
using a sphygmomanometer or by using a custom built electro-
pneumatic regulator.
 » Instruct the subject to sit comfortably with their palm flat, fingers 
spread wide without touching the bath and rate their pain intensity 
using the evas.
 » Instruct the subject to place their non-dominant hand into a warm 
water bath for 2 min.
 » At 1 min 45 s inflate the blood pressure cuff on their upper-arm to 20 
mmHg below resting diastolic blood pressure. 
 » At 2 min instruct the subject to move their hand from the warm water 
bath, directly placing their hand into the cold water bath to similar 
depth. 
 » After reaching pain tolerance, or after reaching a time limit (120 s), 
instruct the subject to remove their arm from the water. At this point 
deflate the blood pressure cuff and give the subject a towel to dry their 
forearm.
5 condiTioned pain modulaTion paradigm
note: iCpm is the activation of the pain-modulatory mechanism, as part 
of the descending endogenous analgesia system.14 The degree of iCpm is 
assessed by comparing the electrical pain thresholds for the single stimu-
lus paradigm before and after the cold pressor task.
 » Repeat the electrical stimulation task (section 2) within 5 min after the 
end of the cold pressor task.
6 ulTra-violeT inflammaTion model
note: The uvb “sun burn” model is a pain model in which erythema is 
induced on the skin by exposing the skin to uvb light in a well-controlled 
and reproducible manner. This exposure causes changes to the skin which 
leads to pain perception being intensified in the affected area (primary 
hyperalgesia) and is used as biomarker for inflammatory pain. This inflam-
mation model is based on the methods previously described.9 Inform 
subjects that the uvb exposure may leave long-lasting (6-12 months) skin 
marking/tanning and that exposure to uvb in general has been linked to 
premature skin aging and skin cancer.
1 Determining a subject’s minimal erythemic Dose (meD)
 » Turn on the uvb lamp and allow it to warm up for at least 10 min prior to 
use. Replace the fluorescent tubes once output is < 3.0 mW/cm2 (after 
approximately 50-100 working h).
 » Instruct the subject to stand with their right hand holding their left 
shoulder. Place the uvb lamp on the right upper back / shoulder of 
the subject, in direct contact with the skin. Only induce the erythema 
on even-toned healthy skin; moles, tattoos, nevus and acne must be 
avoided. 
 » Apply the uvb exposure at the screening visit in ascending doses (see 
Table 2) to 6 different 1 x 1 cm areas of skin on the back to determine the 
individual uvb dose that produces the first clearly discernible erythema 
(minimal erythemic dose (med). 
 » Assess the erythemic response 24 h (± 2 h) after the exposure of the 
6 doses. Determine the med visually, by means of consensus of two 
observers with good colour vision, by observing which dose produces 
the first clearly discernible erythema. Choose the 3rd uvb dose to 
approximate the mean med for the respective skin type.17
2 uvb exPosure
 » Apply a 3 x 3 cm uvb exposure equivalent to the subject’s 3-fold 
individual med. Apply this uvb exposure to the subject’s back 24 h 
prior to the first battery of tasks/dosing. Ensure the uvb exposure 
produces a homogeneous, well-demarcated area of skin erythema and 
hyperalgesia. 
3 assessment of skin thermal Detection thresholD 
 » Using a 3x3 cm thermode measure the thermal pain detection threshold 
on normal skin contralateral to the site of uvb irradiation followed by 
uvb irradiated skin. Set the temperature initially to 34°C, then ramp up 
by 0.5°C/s. Record the average pain detection threshold of 3 stimuli.
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7 subjecTs
note: In addition to standard selection criteria and to ensure a reasonably 
homogeneous subject population the following exclusion criteria should 
be considered. Exclude subjects who meet the following criteria.
 » Indicate nociceptive tasks are intolerable at screening.
 » Achieve tolerance of >80% of maximum input intensity for cold, 
pressure and electrical tasks (to exclude pain tolerant individuals which 
may obfuscate an analgesic effect).
 » Have any current, clinically significant, known medical condition, 
particularly any existing conditions that would affect sensitivity to cold 
(such as atherosclerosis, Raynaud’s disease, urticaria, hypothyroidism) 
or pain (parasthesia etc.). Use healthy subjects only.
 » Use prescription or nonprescription drugs (especially analgesics) and 
dietary/herbal supplements within 7 days or 5 half-lives (whichever is 
longer) prior to the first dose of study treatment.
 » Have dark skin (Fitzpatrick skin type v or vi), widespread acne, tattoos 
or scarring on back (due to interference with the uvb model).
 » Sunbathe or have used sunbeds in the 6 months prior to screening or 
are unable to not be exposed to excessive sunlight or to sunbathe for the 
duration of the study. Skin coloration due to sunlight and sunburn affect 
the uvb study endpoints.
note: Unless contraindicated, women should be included and where pos-
sible menstrual cycle should be either monitored or controlled for (e.g., 
testing only during luteal phase).
Representative results 
The primary outcome variable of interest is the ptt for the electrical stim-
uli, pressure and cold pressor tasks, and the pdt for the thermal (heat) 
stimuli on normal and uvb-exposed skin (Table 3). Data collected from 
the pain model assessments should be summarised descriptively (abso-
lute values and change from baseline) by time and treatment. In addition, 
plots showing the mean (95% confidence interval (Ci)) result and the mean 
change from baseline (95% Ci) at each time point by treatment should be 
presented (see Figures 1 and 2). Results following placebo treatment should 
be relatively stable throughout the study day (Figures 1 and 2). Analgesic 
responses i.e., increases in the pdt or ptt, should reflect the pharmacoki-
netic properties of the drug. For the cold pressor task, the relatively rapid 
onset of action and short half-life of fentanyl and ketamine are reflected in 
the increase in ptt times (Figure 1). In contrast, the increase in ptt follow-
ing pregabalin administration mirrors the pharmacokinetics of this drug 
which has a longer tmax and half-life (Figure 2). The known insensitivity 
of the cold pressor task for other analgesics are shown by there being lit-
tle change from placebo (Figures 1 and 2). Nonetheless, the other tasks in 
this battery are sensitive to these drugs e.g., the uvb model captures the 
analgesic properties of the nsaid ibuprofen – allowing for drugs to be fully 
characterised.
Depending on the ultimate design of the study, analyse the endpoints 
with a mixed model analysis of variance (anova) with treatment, time, sex, 
treatment by time and treatment by sex as fixed factors and subject, subject 
by treatment and subject by time as random factors and with the average 
baseline measurement as covariate. 
Discussion
For novel and established analgesics alike, a profiling approach is proposed 
that utilizes reliable and predictive multi-modal pain models. In con-
trast to other more onerous pain tasks, such as chemical (e.g., capsaicin, 
nerve growth factor) hyperalgesia or visceral pain models, the pain tasks 
mentioned in this protocol can be used repeatedly, quickly, in short suc-
cession, with minimum burden for the subject and with a modest quantity 
of equipment. By using a battery of pain biomarkers such as the one men-
tioned in this protocol, (plasma) concentration-effect relationships can be 
established leading to better estimation of a drug’s pharmacological activ-
ity. Thereby, more rational choices can be made regarding the therapeutic 
effect of a drug rather than simply using animal data and the maximum 
tolerated dose derived from adverse events.7
The design of a clinical study utilizing these pain models needs careful 
consideration. While the aforementioned pain models provide a suitable 
basis for screening potentially analgesic drugs, other factors need to be con-
sidered, especially taking into account the pharmacological mechanisms 
of the drug and its pharmacokinetics.18 Standard practice for researching 
analgesics should be applied, including the use of positive controls and 
designing studies that are randomised (balanced, where applicable), place-
bo-controlled, and double-blind. Furthermore, it is critical that pain tasks 
are performed consistently between subjects, with standardised instruc-
tions and environmental conditions. While there is risk of an interaction 
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between the tasks e.g., sensitization or additive effects, careful study design 
and consistent delivery of the tasks minimizes this. In fact, one of these 
interactions is taken advantage of in this battery by incorporating the iCpm 
paradigm.
When deciding to include pain tasks in a study, the overall burden of the 
study should be considered as this may restrict the number of treatment 
arms or the number of times a task is repeated. If other tasks are used, e.g., 
measures of sedation or alertness, this may limit the total number of tasks a 
subject can perform within a study day; this is especially true if populations 
other than healthy adult subjects are included e.g. adolescents or chronic 
pain patients.
A series of validated pain tasks early in drug development is crucial to 
bridge findings in the laboratory and those in the clinical situation, provide 
valuable information in regard to the mechanism of action of a new drug, 
choose the most applicable patient population to be studied; and ascertain 
the most relevant nociceptive test for more intensive pk/pd modelling. 
pk/pd modelling can be used to identify responders and non-responders, 
better estimate the time-course of analgesia or aid in the development 
of different formulations.19 By characterizing analgesics in both healthy 
subjects and patients, a translational connection between early phase 
development and the clinic can be established. It may also be used to pro-
vide information on the pain physiology and pathophysiology in these 
populations.20 Eventually, the ability to link the efficacy profile of a drug to 
the pain profile of a patient could help guide individualised treatments in 
the future.21
Human pain models are valuable tools used to assess the analgesic 
potential of novel compounds and predict their clinical efficacy. While the 
implementation of these models can be complex and multifaceted, with 
proper execution, these pain models can provide predictive and reliable 
results.
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Table 1 
Standard definitions of vas anchor-points. 
Threshold Verbal instructions to subject  





“Start moving the evas-slider when first change in 
sensation from non-painful to ainful is felt ”
> 0 (= 1)
ptt  
(Pain Tolerance Threshold)
“When pain intensity is no longer tolerable” = 100 (intolerable pain)
Post-task vas “An example of the worst pain imaginable could be a 
surgical treatment without anesthetic”*
max 100 (worst imaginable 
pain)
*Pain is a unique personal experience; this definition is provided only to provide a consistent (nociceptive) frame of 
reference and is chosen as it somewhat negates experiences of loss, psychological suffering, and vicarious pain.22
Table 2 
uvb dose regiment per skin type (mJ cm⁻2). 
Skin type i ii iii iv
Dose
#1 64 126 176 234
#2 91 177 248 330
#3 128 251 351 467
#4 181 355 496 660
#5 256 502 702 934
#6 362 710 993 1321
Table 3 
The outcome variables (endpoints) defined for a study. 
Task Endpoints
Primary Endpoints
Thermal Task (Normal Skin) pdt
Thermal Task (uvb Skin) pdt
Electrical Task (pre-cold pressor) ptt
Pressure Task ptt
Cold Pressor Task ptt
Secondary Endpoints
Electrical Task (pre-cold pressor) pdt, auC, and post-test vas
Pressure Task pdt, auC, and post-test vas
Cold Pressor Task pdt, auC, and post-test vas
Conditioned Pain Modulation Response 
(change from electrical pre- and post-cold pressor)
pdt, auC, and post-test vas
Pain Detection Threshold (pdt), Area Under the Visual Analogue Scale (vas) pain Curve (auC), and post-test vas.
figure 1 
Effect of intravenous analgesics on cold pressor pain tolerance thresholds. Example time 
course of the mean change from baseline profile in least squares means (95% CI error bars) 
for the pain tolerance threshold for cold pressor task after 30 min intravenous administration 
of placebo (circle), (s)-ketamine 10 mg (triangle), fentanyl 3 mcg/kg (square), and phenytoin 
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Effect of oral analgesics on cold pressor pain tolerance thresholds. Example time course of 
the mean change from baseline profile in least squares means (95% CI error bars) for the 
pain tolerance threshold for cold pressor task after oral administration of placebo (circle), 
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A bAttery of pAin models to detect AnAlgesic properties of compounds
absTracT
The aim was to investigate the ability of a battery of pain models to detect 
analgesic properties of commonly used analgesics in healthy subjects. 
The battery consisted of tests eliciting electrical, mechanical and thermal 
(contact heat and cold pressor)-pain and included a uvb model, the ther-
mal grill illusion and a paradigm of conditioned pain modulation. Subjects 
were administered fentanyl 3 µg kg⁻1, phenytoin 300 mg, (s)-ketamine 10 
mg and placebo (part i), or imipramine 100 mg, pregabalin 300 mg, ibupro-
fen 600 mg and placebo (Part ii). Pain measurements were performed at 
baseline and up to 10 h post-dose. Endpoints were analysed using a mixed 
model analysis of variance. Sixteen subjects (8 female) completed each 
part. The pain tolerance threshold (ptt) for electrical stimulation was 
increased (all P<0.05) compared to placebo for (s)-ketamine (+10.1%), phe-
nytoin (+8.5%), and pregabalin (+10.8%). The ptt for mechanical pain was 
increased by pregabalin (+14.1%). The cold pressor ptt was increased by 
fentanyl (+17.1%) and pregabalin (+46.4%). Normal skin heat pain detec-
tion threshold was increased by (s)-ketamine (+3.3%), fentanyl (+2.8%) 
and pregabalin (+4.1%). uvb treated skin pain detection threshold was 
increased by fentanyl (+2.6%) and ibuprofen (+4.0%). No differences in 
conditioned pain modulation were observed. This study shows that these 
pain models are able to detect changes in pain thresholds after adminis-
tration of different classes of analgesics in healthy subjects. The analgesic 
compounds all showed a unique profile in their effects on the pain tasks 
administered. 
inTroducTion
Pharmaceutical science continues to search for suitable biomarkers that 
can assist in predicting the therapeutic potential of analgesic medica-
tion and, therefore, its efficacy in the target population. Data intensive, 
early-phase studies provide a valuable opportunity that can offer this 
translational information.1 A series of nociceptive pain tests used early 
in drug development could bridge preclinical findings and those in the 
clinic to provide valuable information about the mechanism of action of a 
new drug and to benchmark new drugs to existing analgesics. The need 
to use a comprehensive battery of pain models is highlighted by studies in 
which only a single pain model, thought to relate to the clinical situation, 
demonstrates lack of efficacy.2,3 A single evoked model cannot replicate the 
complex nature of clinical pain. Therefore, one evoked pain model cannot 
be used exclusively to screen the pharmacological mechanism of action of a 
new compound, for which this mechanism has not been demonstrated ear-
lier. The aim of this study was to pharmacologically validate an integrated 
range of human pain models that can be used as a combined screening tool 
for early stage clinical drug development. 
Each pain model in this battery has been used before.4⁻7 However, the 
integrated execution of these tests has not yet been investigated, and it is 
mostly unclear how well-known and frequently used analgesic compounds 
influence the pain tests when used in this integrated manner. Data obtained 
from early phase clinical studies may be used for the determination or con-
firmation of a drug’s mechanism of action. Furthermore, results obtained 
from pain models could be useful for the prediction of the efficacy of the 
drug in future clinical populations or potential disease states.8 This battery 
of tests should be able to help establish whether a drug is acting centrally 
or peripherally, whether it is more suitable for a particular modality of pain 
(nociceptive, neuropathic or inflammatory), and which other effects con-
tribute to its mode of action (sedation, tolerance, etc.). Nociceptive tests, 
when used in combination with pharmacokinetic (pk) parameters, can be 
used to provide information regarding future dose selection of new drugs. 
Particularly if used in combination with pharmacokinetic-pharmacody-
namic (pk/pd) modelling and simulation techniques, the establishment of 
a threshold of pharmacological activity may be determined and used for 
dose prediction.9
The models in this study were chosen to represent a broad range of 
pain modalities and nociceptor function, combined with the possibility 
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to perform these pain tests in a standardised setting in clinical studies. 
Regarding the choice of compounds, a selection was made of distinctly 
different, relevant, targets of analgesia. The analgesic mechanism of action 
of these compounds was compared using the existing literature.4⁻6,10⁻13 
Specific compounds, representative of a range of mechanistic classes, 
were chosen if they showed analgesic efficacy in previous pain models in 
humans or if their efficacy in pain models was expected but yet unknown. 
It was hypothesised that the battery of pain models would show distinct 
response patterns for the different analgesic classes.
meThods
Subject and study design
The study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center (Leiden, The Netherlands). The study was con-
ducted according to the Dutch Act on Medical Research Involving Human 
Subjects (Wmo) and in compliance with Good Clinical Practice (iCh-gCp) 
and the Declaration of Helsinki.
Healthy male and female subjects between 18 and 45 years with a body 
mass index of 18-30 kg m⁻2 were enrolled. All subjects gave written informed 
consent. The subjects underwent a full medical screening, including taking 
medical history, a physical examination, blood chemistry and haematolo-
gy, urinalysis, electrocardiogram and assessment of the minimal erythema 
dose (med) for uvb light to assess eligibility. Subjects with a clinically 
significant known medical condition, in particular any existing condition 
that would affect sensitivity to cold or pain were excluded. Subjects with 
Fitzpatrick skin type v or vi, wide-spread acne, tattoos or scarring on the 
back were excluded due to the inability to assess med accurately. Also, sub-
jects who were regular users of any illicit drugs, had a history of drug abuse 
or a positive drug screen at screening were excluded. Smoking and the 
use of xanthine-containing products was not allowed during dosing days. 
Alcohol was not allowed at least 24 h before each scheduled visit or during 
the stay in the research unit. Except for contraception, subjects were not 
allowed to use prescription medications within 7 days and over-the-counter 
analgesics within 3 days of nociceptive assessments. Female subjects were 
required to have an intrauterine device, a contraceptive implant or were 
willing to continuously use oral contraceptives (i.e. skip their menstrua-
tion) during the study period, to prevent influences of menstrual phase.14 
This was a two-part, randomised, double blind, placebo-controlled, four-
way crossover, single dose study. The total number of planned subjects 
was 16 in each part. In part i subjects received the study drug or placebo 
intravenously over a 30 min time period in the antecubital vein. Treatment 
consisted of fentanyl 3 μg kg⁻1 (Hameln Pharmaceuticals GmbH, Hameln, 
Germany), phenytoin 300 mg (Diphantoïne, Apotex Europe Ltd, Leiden, 
The Netherlands), (s)-ketamine 10 mg (Ketanest-S, Eurocept bv, Ankeveen, 
The Netherlands) and sodium chloride 0.9% (placebo). In Part ii, subjects 
received the over encapsulated study drug or placebo orally with 150 mL 
of still water. Treatment consisted of imipramine hydrochloride 100 mg 
(Centrafarm bv, Etten-Leur, The Netherlands), pregabalin 300 mg (Lyrica, 
Pfizer Limited, Kent, uk), ibuprofen 600 mg (Nurofen oval tablet, Reckitt 
Benckiser Healthcare bv, Hoofddorp, The Netherlands) and placebo tablets 
(lactose monohydrate with 1% magnesium stearate). Subjects partici-
pated in either part i or Part ii in which they received all four treatments. 
The study treatments were randomly allocated based on a 4 x 4 William’s 
square. The randomisation code was generated by a study-independent 
statistician using sas version 9.1.3 (sas Institute Inc., Cary, nC, usa).
Each treatment period consisted of two study visits to the clinical 
research unit. During the first visit uvb erythema was induced. On the 
morning of the next day, subjects received the study treatment after which 
the pd and pk assessments were performed (Figure 1). Subjects were dis-
charged at the end of the study day. There was a 1-week washout period 
between treatment periods.
pd assessments
Nociceptive (pain) detection and tolerance thresholds were measured 
using a battery of human pain models. The battery is an integrated range of 
tests for measuring different modalities of nociception and takes approx-
imately 30 min to complete (Figure 1).15 It aims to assess as objectively 
as possible the levels of pain induced by several noxious mechanisms in 
human subjects. A training session was included as part of the screening 
examination to reduce learning effects during the study. All tests have pre-
viously been shown to be sensitive to the effects of analgesics in healthy 
adults. All measurements were performed in a quiet room with ambient 
illumination. Per session, there was only one subject in the same room. 
For the electrical stimulation tests, the pressure stimulation test and the 
cold pressor test, pain intensity was measured continuously (beginning 
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from when the first stimulus was applied until the predetermined end of 
the test) using an electronic visual analogue scale (evas) scale ranging 
from 0 (no pain) to 100 (most intense pain tolerable). Equipment was pro-
grammed to cease giving stimuli if pain intensity reaches the maximum 
possible score. For each test the pain detection threshold (pdt), pain tol-
erance threshold (ptt) and area under the curve (auC) were determined. 
The auC was calculated as the surface under the pain intensity-stimulation 
(-time for cold pressor) curve. 
Thermal grill  — The thermal grill consisted of a set of eight juxtaposed bars 
of cold and warm innocuous temperatures (18°C and 42°C) on which the sub-
ject placed their dominant hand for 20 s. During this time, the subject rated 
unpleasantness, pain sensation and thermal sensation using the evas-slider. 
Thermode testing and uvb model  — The method of uvb irradiation was 
based on methods previously described.16 uvb irradiation (tl01[narrow-
band], Phillips, Amsterdam, The Netherlands) was applied at the screening 
visit in ascending doses to determine the individual uvb dose that pro-
duced the first clearly discernible erythema. The threefold individual med 
of uvb was applied 24 h prior to dosing to the subject’s back to produce 
local cutaneous inflammation, thereby inducing a homogeneous area of 
skin erythema and hyperalgesia. The area of skin irradiated was 3 x 3 cm. 
Subsequently, a 3x3 cm thermode (tsa-ii, Medoc Ltd., St. Ramat Yishai, 
Israel) was used to measure pain detection thresholds (initially 34°C, ramp 
0.5°C s⁻1, average of three stimuli) on the normal skin contralateral to the 
site of uvb irradiation and on the uvb irradiated skin (cut-off 50°C).
Electrical stimulation test  — For cutaneous electrical pain, Ag-AgCl elec-
trodes (3M Red-Dot™) were placed on cleaned, scrubbed, and if required, 
shaved skin, 10 cm distal from the patella overlying the tibia. Electrical 
resistance between electrodes was to be <2 kW. The electrical stimulus was 
delivered as two different paradigms by a computer-controlled constant 
current stimulator (ds5, Digitimer, Cambridge, uk).
For the single stimulus, adapted from methods previously described17,18 
(10 Hz tetanic pulse with a duration of 0.2 ms), current intensity increased 
from 0 mA in steps of 0.5 mA s⁻1 (cut-off 50 mA). 
For the repeated stimulus, adapted from methods previously described,19 
each single stimulus (train of five, 1 ms square wave pulses repeated at 200 
Hz) was repeated five times with a frequency of 2 Hz at the same current 
intensity with a random interval of 3-8 s between the repetitions. Cur-
rent intensity increased from 0 mA in steps of 0.5 mA s⁻1 (cut-off 50 mA). 
Pain detection threshold was taken as the value (mA) whereby a subject 
indicated either: all 5 stimuli were painful, or the train of 5 stimuli started 
feeling nonpainful but ended feeling painful (vas > 0). The pain intensity 
for each stimulation was measured using the evas slider, until pain toler-
ance threshold or a maximum of 50 mA was reached.
Pressure stimulation test  — The method of mechanical pressure pain 
induction was based on methods previously described, and was shown 
to primarily assess nociception generated from the muscle with minimal 
contribution by cutaneous nociceptors.20,21 Briefly, an 11 cm wide tourni-
quet cuff (vbm Medizintechnik GmbH, Sulz, Germany) was placed over the 
gastrocnemius muscle with a constant pressure rate increase of 0.5 kPa s⁻1. 
The pneumatic pressure was increased until the subject indicated maxi-
mum pain tolerance using the evas slider, or a maximum pressure of 100 
kPa was achieved, at which point the device released pressure to the cuff.
Cold pressor test  — The method of cold pressor pain was based on the meth-
ods previously described22,23 and is the most commonly used test to induce 
conditioned pain modulation (Cpm, previously known as ‘diffuse noxious 
inhibitory control’).24 Subjects placed their nondominant hand into a 
water bath at 35 ± 0.5°C for 2 min. At 1 min 45 s a blood pressure cuff on the 
upper-arm was inflated to 20 mmHg below resting diastolic pressure. At 2 
min the subject then moved that hand from the warm water bath, directly 
into a similar sized water bath at 1.0 ± 0.5°C. The subjects were instruct-
ed to indicate when pain detection threshold was reached (first change in 
sensation from cold non-painful to painful) as well as the pain intensity, 
by moving the evas slider. When pain tolerance or a time limit (120 s) was 
reached, subjects were instructed to remove their hand from the water, at 
which point the blood pressure cuff deflated.
cPm  — Cpm is the activation of the pain-modulatory mechanism, as part 
of the descending endogenous analgesia system.24 The degree of Cpm was 
assessed by comparing the electrical pain thresholds for the single stimu-
lus paradigm before and within 5 min after the cold pressor test.
Measurements of drug concentrations in plasma  — Samples for determina-
tion of compounds in plasma were obtained at baseline, 0.5, 1, 2, 3, 4, 6, 8 and 
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10 h after the start of administration. Samples were collected in 6 mL k2edta 
tubes. Plasma was separated within 30 min of blood collection by centrifu-
gation at 2000 g for 10 min. All samples were stored in an upright position 
at – 40°C. Drug concentrations in plasma were determined using Liquid 
Chromatography–Mass Spectrometry (lC-ms/ms). The analytical range was 
0.200-50.0 ng ml⁻1 for fentanyl, 1.00-200 ng ml⁻1 for (s)-ketamine, 0.500-100 
ng ml⁻1 for norketamine, 20.0-10 000 ng ml⁻1 for phenytoin, 0.5 -100 ng ml⁻1 
for imipramine and desipramine, 20.0-20 000 ng ml⁻1 for pregabalin and 100-
100 000 ng ml⁻1 for ibuprofen. Quality control for the analytical performance 
of the assays for all compounds showed acceptable performance. Standard 
curves were linear for the ranges tested (R>0.99 for all compounds). Control 
runs were performed in low, medium and high concentrations of each com-
pound. Coefficients of variation varied from 1.5% to 7.9%.
Statistical analysis
The sample size calculation was based on previous studies performed in 
our centre. The detectable effect sizes using a paired t-test with a 0.050 
two-sided significance level and 16 subjects were as follows (standard devi-
ations [sds] are rounded): electrical stimulation repeated stimulus auC 225 
(6%; assuming an sd of 300), electrical stimulation single stimulus auC 450 
(16%; assuming an sd of 600), pressure stimulation auC 525 (9%; assuming 
an sd of 700), cold pressor Area Above the Curve 337 (17%; assuming an sd 
of 450).
pk analysis was performed using noncompartmental analysis. The peak 
concentration and the time to the peak concentration were recorded as 
observed. In addition, the terminal half-life, the area under the plasma con-
centration-time curve from time zero to the time of the last sample (auC0₋last) 
and from time zero to infinity (auC0₋inf), the volume of distribution (Vd ) 
and the clearance were determined for all compounds. auC’s were calcu-
lated using the linear trapezoidal method. Calculations were performed 
using R v2.12.0 (R Foundation for Statistical Computing, Vienna, Austria). 
      pdt and ptt variables follow a log-normal distribution and were there-
fore log-transformed before analysis. Transformed parameters were 
back-transformed after analysis.
To establish whether significant treatment effects could be detected on 
the pd outcome variables, variables were analysed with a mixed model 
analysis of variance with treatment, time, sex, treatment by time and 
treatment by sex as fixed factors and subject, subject by treatment and 
subject by time as random factors and the average baseline measurement 
as covariate. The Kenward-Roger approximation was used to estimate 
denominator degrees of freedom and model parameters were estimated 
using the restricted maximum likelihood method. The general treatment 
effect and specific contrasts were reported with the estimated difference 
and the 95% confidence interval, the least squares mean estimates and the 
p-value. Graphs of the least squares means estimates over time by treat-
ment were presented with 95% confidence intervals as error bars. The 
contrasts for the relevant time periods based on the pk profiles of the com-
pounds (0-1 h for (s)-ketamine, 0-5 h for fentanyl ibuprofen and pregabalin, 
0-10 h for phenytoin and imipramine) are presented. All calculations of the 
pharmacodynamic parameters were performed using sas for Windows 
version 9.1.3 (sas Institute Inc., Cary, nC, usa). The main sas procedure 
that was used in the analysis was proC mixed. No adjustments for multiple 
comparisons were employed.
resulTs
A total of 39 subjects, of whom 18 were female, were randomised by treat-
ment (Figure 2); subjects had a mean age of 22.5 ± 2.8 years and had a mean 
body mass index of 21.8 ± 1.7 kg m⁻2. In part i where we studied the effects of 
intravenous analgesics, 18 subjects received placebo treatment, 17 fentanyl, 
17 (s)-ketamine and 20 phenytoin. In one subject the dose administration 
was prematurely stopped due to an adverse event (syncope) during phe-
nytoin administration. In the oral Part ii, 16 subjects received placebo, 17 
ibuprofen, 17 imipramine and 16 pregabalin. In both parts 16 subjects com-
pleted all four study periods.
An overview of the pharmacodynamic output variables is provided in 
Table 1 (part i), Table 2 (Part ii), Figure 3 and Figure 4. Differences compared 
to placebo for the cold pressor test were observed after administration 
of fentanyl (pain tolerance threshold, ptt; estimate of difference[95% 
confidence interval] / 17.1%[2.3%-33.9%]) and pregabalin (pain detec-
tion threshold, pdt and ptt; 36.8%[5.9%-76.8%] / 46.4%[27.1%-68.6%]). 
Electrical stimulation single stimulus parameters changed after adminis-
tration of (s)-ketamine (ptt; 10.1%[0.2%-20.9%]), phenytoin (pdt and ptt; 
31.5%[10.3%-56.8%] / 8.5%[1.4%-16.1%]), and pregabalin (ptt; 10.8%[2.4%-
19.9%]). The ptt for pressure pain was only increased by pregabalin 
(14.1%[4.3%-24.9%]). The normal skin heat pdt increased after adminis-
tration of (s)-ketamine (3.3%[1.1%-5.6%]), fentanyl (2.8% [1.1%-4.5%]) 
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and pregabalin (4.1%[1.3%-7.0%]). uvb-treated skin pdt increased after 
administration of fentanyl (2.6%[1.2%-4.1%]) and ibuprofen (4.0%[1.8%-
6.3%]). Thermal grill maximum unpleasantness was not influenced by 
any of the compounds administered. After administration of ibuprofen, an 
increase was observed for the thermal grill pain intensity (1.25[0.25-2.25]). 
Inhibitory conditioned pain modulation was influenced by administration 
of imipramine and pregabalin. These compounds also caused an increase 
in the difference between pre- and post-cold pressor electrical stimulation 
pdt (0.88[0.06-1.70] / 1.95[0.84-3.06]). The effect sizes for the compounds 
during the relevant analysis period compared to placebo for the different 
pain models are shown in Figure 5.
The observed pk parameters for the compounds and their active metab-
olites are listed inTable 3. 
All subjects experienced at least one adverse event (ae) during their 
participation. In part i, the incidence of aes was 100% in the active treat-
ment groups (fentanyl, (s)-ketamine and phenytoin) compared to 33% in 
the placebo group. In Part ii, 100% of the subjects receiving imipramine, 
87.5% of the subject receiving pregabalin, 41.2% of the subjects receiving 
ibuprofen and 50% of the subjects receiving placebo tablets reported aes. 
In part i, the most reported aes were dizziness (82%), nausea (65%) and 
feeling hot (53%) for fentanyl; dizziness (82%), nausea (35%) and feeling 
abnormal (29%) for (s)-ketamine and pain in extremity at administration 
site (60%), dizziness (55%) and nausea (30%) for phenytoin. In Part ii, the 
most reported aes were nausea (12%), fatigue (12%) and dizziness (12%) 
for ibuprofen; somnolence (65%), nausea (59%) and dizziness (29%) for 
imipramine and dizziness (56%), somnolence (31%) and nausea (31%) for 
pregabalin. All aes were mild or moderate in severity.
discussion
The main objective of this study was to investigate the ability of a battery 
of pain models to detect analgesic properties of commonly used analgesics 
in healthy subjects. A biomarker can be defined as “A characteristic that 
is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a thera-
peutic intervention.”.25 This battery of different pain models was able to 
detect differences in pharmacological and analgesic properties, consistent 
with the pk properties of each individual compound. Each compound test-
ed in this study demonstrated its own profile of effects on evoked pain in 
the different models included in the pain test battery. Most of these effects 
were in line with earlier described literature and with the expected pd and 
pk profile of the drugs. The drugs and doses used had already proven to be 
efficacious analgesics in clinical practice in either acute pain or in neuro-
pathic pain. This battery of pain models can be used as biomarker to assess 
the pd responses of analgesic drugs. 
Strong opioids previously showed effects on electrical pain, cold pres-
sor, thermal pain and the thermal grill.4,11 In this study fentanyl affected 
pain thresholds in the cold pressor test and thermal testing. No effects were 
observed on the electrical pain tests, or the pressure pain paradigm. The 
effect of fentanyl on a broad range of pain tests corresponds with the many 
types of clinical pain that respond to strong opioids. Previous reports have 
shown decreases in pain intensity and unpleasantness after morphine 
administration on the thermal grill.11 Here, maximum unpleasantness and 
pain intensity did not change after fentanyl administration. 
(s)-ketamine, an n-methyl-d-aspartate (nmda) receptor antagonist, 
showed effects on the cold pressor test, electrical stimulation (both single 
and repeated stimulus) and thermal heat pain. The effects of (s)-ketamine 
on the cold pressor test have not been reported before. In a study previ-
ously performed,26 the cold pressor test was used in combination with 
(s)-ketamine, but only in order to induce a conditioned pain modulation 
(Cpm) response. In a previous review,5 no differences were observed in pdt 
during heat skin stimulation. In the current study, we found an increase in 
heat pdt on the normal skin in the first hour after dosing. Heat pdt in the 
uvb treated skin did not differ compared to placebo.
An effect of (s)-ketamine on the thermal grill pain and unpleasantness 
was expected, as these effects were shown previously.10 Here, however, 
(s)-ketamine did not result in a decrease in unpleasantness or pain sen-
sation in the thermal grill paradigm. An explanation for these differences 
could be our method of dosing, where the bolus administration of (s)-ket-
amine was not followed by a continuous infusion as described in other 
studies.10
There is limited literature available about the effect of sodium channel 
blockers on human pain models. One study has been published in which 
the effects of phenytoin and lamotrigine on cold pressor pain were inves-
tigated;12 both phenytoin and lamotrigine reduced pain scores in healthy 
subjects. In the current study we only observed an increase in pdt and ptt 
in the electrical stimulation single stimulus paradigm. The therapeutic 
range for phenytoin in epilepsy is between 8 and 25 µg ml⁻1 in plasma.27 
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The observed Cmax in the study was 8.3 µg ml⁻1, which is at the lower end of 
the therapeutic range. Higher doses or repeated dosing may lead to a more 
pronounced effect on the pain models. 
In Part ii, pregabalin showed positive effects on cold pressor (pdt and 
ptt), electrical single stimulus (ptt), Cpm (pdt) and thermal heat pain in 
normal skin. Alpha-2δ ligands have previously been shown to affect pain 
in human pain models; gabapentin showed positive effects on pain in an 
electrical hyperalgesia model in healthy subjects.28 Conversely, gabapentin 
failed to show effects on heat pdt in healthy subjects.29 Pregabalin has not 
been investigated in pain models in healthy subjects but in in patients with 
painful chronic pancreatitis, pregabalin attenuated visceral pain.30 Of all 
compounds administered pregabalin showed the largest effect on most of 
the pain paradigms (heat, cold, pressure and electrical pain). This might be 
due to the relatively large dose of pregabalin that was used. However the 
same single dose of 300 mg was also used in other studies in which dosag-
es of pregabalin of ≥300 mg showed a significant opioid sparing effect.31 
Further studies are needed to show if these large effects can be replicated. 
Currently pregabalin is mainly used in the treatment of neuropathic pain32 
and its use in acute postoperative pain is under investigation.31 The pos-
itive effects of pregabalin on several (acute) nociceptive pain models in 
this study may be an argument for its potential use also in the treatment of 
acute nociceptive pain. 
Ibuprofen increased the heat pdt in uvb treated skin. These effects 
were also previously shown by others.4 Ibuprofen was the only com-
pound administered that only increased heat pdt in uvb treated skin but 
not in normal skin. This in contrast with (s)-ketamine and pregabalin 
(increased heat pdt in normal skin, but not in uvb treated skin) and fen-
tanyl (increased heat pdt in normal and uvb treated skin). These effects of 
ibuprofen were expected and reflect its inhibition of cyclooxygenase by this 
nonsteroidal anti-inflammatory drug, given the inflammatory type of pain 
that is caused in the uvb hyperalgesia model.
Imipramine only increased Cpm, but did not affect other outcome mea-
sures. In previous research, imipramine increased acute pain tolerance 
after electrical stimulation, pressure pain and visceral pain.5,13 Compared 
to the other compounds in this study, imipramine and its active metabolite 
desipramine have a relatively long half-life of 6.54 h and 56.2 h, respective-
ly. We only performed measurements up to 10 h after dose administration, 
which may partially explain the negative findings in this study. In favour 
of this argument is that an increasing trend could still be observed at the 
last measurements in the electrical repeat stimulation paradigm ptt. 
Furthermore, in the clinical setting a titration period of several weeks is 
needed for imipramine before its efficacy can be assessed.32 Here, we only 
administered a single dose. Imipramine was used as the tricyclic antide-
pressant of choice in this study because of previous positive results in 
human pain models. However, a recent meta-analysis showed that there is 
only limited evidence for the use of imipramine in neuropathic pain.33 
In part i of the study, no effect was observed on Cpm by either (s)-ket-
amine, fentanyl or phenytoin. High variability in Cpm measurements 
was observed throughout the study, for all delta electrical stimulation 
parameters (pdt, ptt and auC). Previous research conducted has shown 
a potentiation of Cpm after administration of strong opioids.34 Others 
observed no Cpm response after ketamine treatment in healthy volunteers.26 
       In Part ii of the study, both imipramine and pregabalin increased the dif-
ference in pain detection threshold after vs before the cold pressor (delta 
pdt), which may be indicative for an increase in Cpm. A study performed 
in patients with pancreatitis did not show changes in Cpm responses after 
administration of pregabalin. To our knowledge no studies are published 
in which the Cpm responses in healthy subjects after administration of 
α2δ ligands or tricyclic antidepressants were measured. The noradren-
ergic system plays an important role in central pain modulation;35 so the 
increase in delta pdt observed after administration of imipramine is likely 
to be explained by the enhancement of the inhibitory effect on noradrena-
line reuptake.
No decrease on thermal grill maximum unpleasantness or maximum 
pain ratings could be observed in this study. However, overall, most subjects 
did not experience the thermal grill as unpleasant or painful, as reflected by 
the low scores on the vas for pain and unpleasantness, which resulted in a 
non-normal distribution of the data, making them difficult to analyse. 
Previous studies in which the thermal grill was used applied a range of 
combinations of warm and cold stimuli to assess relationships between 
painful and nonpainful sensations.11,36 In the current study a fixed tem-
perature of the warm and cold bars was used. Furthermore, the occurrence 
of paradoxical pain elicited by the thermal grill illusion can be variable. A 
study by Bouhassiara and colleagues reported a large subpopulation of 
subjects who only reported paradoxical pain when large cold-warm differ-
entials were applied37 . Due to the apparent necessity to tailor this method 
to each individual subject, it is difficult to standardise this method and 
incorporate it in a battery of pain models. 
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Multimodal testing with different pain models has been performed previ-
ously; with and without the administration of analgesic compounds.3,13,38 
Here we combined both the execution of a broad range of human pain 
models and the administration of analgesic compounds with different 
mechanisms of action. An advantage of the battery of pain models was that 
the tests could be executed repeatedly in a relatively short time (~30 min) 
in a standardised fashion. 
By repeatedly administering these pain tests in one day this battery was 
able to determine time-effect profiles of the drugs. Small individual differ-
ences between different compounds could be assessed. Although pk/pd 
modelling was not performed in this study, study designs using repeated 
application of this battery of pain models can be used to assess pk/pd 
relationships. 
Overall pk parameters measured in this study were reasonably con-
sistent with the known pk data for these analgesics. Fentanyl’s terminal 
half-life and volume of distribution were somewhat lower compared to 
values reported in literature.39 Phenytoin, (s)-ketamine and its active 
metabolite norketamine showed kinetics that were consistent with the lit-
erature.27,40 The tmax of imipramine was as expected. The terminal half-life 
was shorter, but this could have been related to the relatively short sam-
pling period; the half-life of its active metabolite desipramine was longer 
than expected.41 Ibuprofen and pregabalin showed pk that were consistent 
with the literature.42,43
A large number of pain models were used in this study. This yielded 
an even greater number of outcome variables. No correction for multiple 
testing was applied. Therefore, this multimodal test battery should be 
considered as a screening tool for analgesic properties of compounds in 
development for the treatment of pain, and not as a way to definitively prove 
effects on a specific evoked pain model with statistical significance. When 
the analgesic effect of a new drug on a certain pain mechanism has already 
been established, predefining a primary outcome measure would prevent 
the need to correct for multiple testing. Maximum effect sizes differed for 
the pain models used. For instance after pregabalin administration the con-
trast compared to placebo for heat pdt was 4.1%, while the contrast for 
cold ptt was 46.4%. Variability for these tests was also markedly different, 
with the coefficient of variation for the heat ptt being much lower than 
for the cold ptt. To account for this variation, studies using this battery of 
pain models need to be adequately powered. Only one (expected analge-
sic) dose of each compound was used in our study. Therefore, one-to-one 
comparisons between different compounds cannot be made on individual 
pain models. However, the pharmacodynamic profiles of these single doses 
matched the plasma profile of the compounds used. Reproducibility of the 
pharmacological effects of the compounds on the pain models was not 
directly assessed in this study. We were able to replicate effects of different 
analgesics on individual pain tests as described before,4⁻6 however future 
studies are needed to investigate the reproducibility of the effect profiles 
that we observed. 
One session of the battery of pain models lasted approximately 30 
min. During one study period, 10 sessions were performed. This might 
have led to fatigue and diminishing concentration during the tests. This 
is also shown in Figures 3 and 4, where variation in the placebo group is 
observed between measurements during the day. In order to correct for 
these unavoidable effects, a crossover design with a placebo arm included 
was used. Somnolence was observed by 31% and dizziness by 56% of the 
subjects receiving pregabalin. Oral doses of imipramine also caused similar 
aes, however imipramine did not show effects on the pain tasks admin-
istered. Other substances that are known to have strong sedating effects 
on the central nervous system also do not influence evoked pain tests. For 
instance cannabinoids and benzodiazepines have limited effects on pain 
thresholds.5,44 Therefore, we believe that the somnolence and the dizzi-
ness caused by the pregabalin is not responsible for the effects on the pain 
tasks administered.
Several drugs acting at different targets are currently under clinical 
development for the treatment of acute and neuropathic pain. These drugs 
are in different stages of the clinical development. Examples are selective 
sodium channel blockers, nerve growth factor antagonists and fatty acid 
amide hydrolase inhibitors.45⁻47 A recent review suggested that a limited 
set of human pain models could be sufficient to predict analgesic effica-
cy.2 With our integrated battery of pain models it is possible to profile new 
compounds against currently existing analgesic compounds to predict 
their potential clinical use. 
In conclusion, it was shown that this battery of pain models is able to 
detect changes in pain detection and pain tolerance thresholds after 
administration of different classes of analgesic compounds in healthy male 
and female subjects. The analgesic compounds all showed a unique pro-
file in their effects on the pain tests administered. These profiles were in 
most cases compatible with the expected pharmacology. The knowledge 
of these profiles can be used to benchmark analgesic properties of these 
new drugs against established analgesics in early phase clinical studies in 
healthy subjects. 
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Table 1 
Least squares means for pharmacodynamic outcome measures and estimates of difference, 
95% confidence intervals and p-values for main contrasts for part i.
ls Means Contrasts
Parameter Placebo
(0-1 h)    












3 µg kg⁻1  
Placebo  
up to 5 hours
(s)-ketamine  
10 mg  
Placebo 
up to 1 hour
Phenytoin  
300 mg  
Placebo 
up to 10 hours
Cold pdT  
(s)
4.3   
4.5   
4.4









Cold pTT  
(s)
22.0   
21.6   
 20.7












2.7   
2.7   
2.7












10.3   
10.4   
 10.5












6.7   
7.2   
7.3












21.4   
22.1   
22.3









cpm pdT  
(mA)
0.50   
0.37   
 0.68




















































heat pdT  
(°C)
43.88   
44.18   
44.13












39.11   
38.94   
 38.93












9.0   
8.5   
8.2












5.6   
4.4   
4.5









Cpm, conditioned pain modulation; ls, least squares; pdt, pain detection threshold; ptt, pain tolerance threshold; vas, visual 
analogue scale
Table 2 
Least squares means for pharmacodynamic outcome measures and estimates of difference, 
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Cpm, conditioned pain modulation; ls, least squares; pdt, pain detection threshold; ptt, pain tolerance threshold; vas, visual 
analogue scale
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Table 3 
Pharmacokinetic parameters for administered compounds. Data are means ± standard 
deviation and median (range) for tmax.

































































































n.C. n.C. n.C. n.C.








n.C. n.C. n.C. n.C.
auC0₋inf, estimated area under the plasma concentration-time curve from time of dosing to infinity; auC0₋last, area under the 
plasma concentration-time curve from time of dosing to the last observation; Cmax, maximum concentration; tmax, time at 






Tourniquet calf: 0.5 kPa s-1, 
max 100 kPa
Cold Pressor 






and 10 hrs 








Single stimulus  0.2 ms at 10 Hz
Repeated stimulus: train of 5 at 2 Hz
















30x30 mm, Pain Detection Threshold
Normal and ��� treated skin 
Thermal Grill















Completed the study (n=16)
Dropped out from study (n=6)
- Intensity study too high (n=2)
- Due to adverse event (n=3)
- Personal circumstances (n=1)     
Excluded (n=23)
 � Screen failure (n=14)
 -Not sensitive for induction of ��� (n=6)
 -Achieved tolerance for maximum > 80%
   input of nociceptive test at training (n=5)
 -��� too high (n=1)  
 -Medical history (n=1)
 -Positive drug screen(n=1)
 � Withdrew consent during screening period (n=4)
 � Reserve subjects (n=5)
����������
����������












- Excluded from analysis (n=0)  





-Phenytion (n=20)    
Completed the study (n=16)
Dropped out from study (n=1)
- Intensity study too high (n=1)
     
Analysed (n=17) 
- Excluded from analysis (n=0) 
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figure 3 
Time course of the mean change from baseline profile in least squares means for the pain 
tolerance threshold for cold pressor (a/b), electrical stimulation (C/d: repeated stimulus), 
and (e/f: single stimulus) and the electrical stimulation (single stimulus) delta pain 
detection threshold (g/h) after administration of the different compounds in Part i  
(a, C, e, g) and Part ii (b, d, f, h).
figure 4 
Time course of the mean change from baseline profile in least squares means for the pain 
tolerance threshold for pressure stimulation (a/b), the heat pain detection threshold for 
thermal testing on normal skin (C/d), and uvb-irradiated skin (e/f) and the thermal grill 
maximum unpleasantness vas (g/h) after administration of the different compounds in  
Part i (a, C, e, g) and Part ii (b, d, f, h).
95% CI error bars Placebo Ibuprofen 600 mg























0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Fentanyl 3 mcg/kg
























0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Fentanyl 3 mcg/kg

























0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Ibuprofen 600 mg



























0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Fentanyl 3 mcg/kg



















0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Ibuprofen 600 mg

















0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Fentanyl 3 mcg/kg
























0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
95% CI error bars Placebo Ibuprofen 600 mg































































































0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00







0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00



































0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00







0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00









0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
























0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00







0:00 1:00 2:00 3:00 4:00 5:00 6:00 7:00 8:00 9:00 10:00 11:00
























Radar chart of effect sizes of the compounds used. Effect sizes are given as the contrast 
between the different compounds and placebo.
chapTer iv
Pharmacokinetics and pharmacodynamics of intrathecally 
administered Xen2174, a synthetic conopeptide with 
norepinephrine reuptake inhibitor and analgesic properties
British Journal of Clinical Pharmacology 2017;83: 751-763.
P. Okkerse, J.L. Hay, E. Sitsen, A. Dahan, E. Klaassen, W. Houghton, G.J. Groeneveld
Heat ��� (normal skin)
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PK and Pd of intrathecally administered xen2174 in healthy subjects
absTracT
Xen2174 is a synthetic 13-amino acid peptide that binds specifically to the 
norepinephrine transporter, which results in inhibition of norepinephrine 
uptake. It is being developed as a possible treatment for moderate to severe 
pain and is delivered intrathecally. The current study was performed to 
assess the pharmacodynamics (pd) and the cerebrospinal fluid (Csf) phar-
macokinetics (pk) of Xen2174 in healthy subjects. This was a randomised, 
blinded, placebo-controlled study in healthy subjects. The study was divid-
ed into three treatment arms. Each group consisted of eight subjects on 
active treatment and two or three subjects on placebo. The Csf was sam-
pled for 32 h using an intrathecal catheter. pd assessments were performed 
using a battery of nociceptive tasks (electrical pain, pressure pain and cold 
pressor tasks). Twenty-five subjects were administered Xen2174. Csf pk 
analysis showed a higher area under the Csf concentration-time curve of 
Xen2174 in the highest dose group than allowed by the predefined safety 
margin based on nonclinical data. The most common adverse event was 
post lumbar puncture syndrome, with no difference in incidence between 
treatment groups. Although no statistically significant differences were 
observed in the pd assessments between the different dosages of Xen2174 
and placebo, pain tolerability in the highest dose group was higher than 
in the placebo group (contrast least squares mean pressure pain tolerance 
threshold of Xen2174 2.5 mg–placebo[95% confidence interval], / 22.2%[ 
-5.0%, 57.1%], p=0.1131). At the Xen2174 dose level of 2.5 mg, Csf concentra-
tions exceeded the prespecified exposure limit based on the nonclinical 
safety margin. No statistically significant effects on evoked pain tests were 
observed.
inTroducTion
The majority of patients undergoing surgery experience moderate to 
severe pain in the postoperative period.1 Treatment consists of multiple 
pain relief agents and strategies. Significant side effects may occur with 
the use of opioids.2 Nonsteroidal anti-inflammatory drugs (nsaids) and 
paracetamol are not sufficiently effective against moderate to severe post-
operative pain and should be administered in combination with opioids.3,4 
Thus, there remains a clinical need for the development of new efficacious 
therapies with a beneficial side effect profile. 
The venom of the marine cone snail genus Conus provides a rich source 
of pharmacologically active compounds.5 The peptide Mr1A, identified in 
the venom of Conus marmoreus, causes inhibition of norepinephrine (ne) 
uptake by the ne transporter (net) in a selective, noncompetitive manner.6,7 
Mr1A showed an antinociceptive effect after intrathecal administration in 
mice.8,9 This peptide has a relatively poor chemical stability in solution. 
To overcome this, Xen2174, modelled on Mr1A, was developed. Xen2174 is a 
synthetic 13-amino acid peptide that does not cross the blood-brain barrier 
and is being developed for the intrathecal treatment of moderate to severe 
pain. In vitro pharmacology studies have demonstrated that Xen2174 binds 
specifically to the net, but not to other central nervous system molecular 
targets, resulting in selective inhibition of ne uptake by net in a noncom-
petitive manner.10 Tricyclic antidepressants are also potent ne reuptake 
inhibitors (nris), but their poor specificity relative to other monoamine 
transporters and various G-protein-coupled receptors, results in dose-lim-
iting side effects in clinical use.9,11 In vivo pharmacology studies in rat 
models of neuropathic pain have demonstrated that intrathecal adminis-
tration of Xen2174 produces rapid and long-lasting anti-allodynic effects, 
which were found to be greater in magnitude and duration than those of 
intrathecal morphine.9 Additional pharmacology studies have demonstrat-
ed that Xen2174 also provides long lasting antinociception in a rat model of 
postsurgical pain.12 In an inflammatory pain model in rats (inflammation 
induced by injecting Freund’s Complete Adjuvant) Xen2174 did not relieve 
pain after thermal latency or paw pressure tests (Investigator’s brochure 
Xen2174. Xenome Ltd., unpublished). Toxicology studies have shown that 
Xen2174 causes convulsions and seizures when administered at high doses 
in rats and dogs. In a beagle dog study in which Xen2174 was administered 
intrathecally at doses of 0, 1, 2, 4 and 8 mg (5 animals/gender/dose), sei-
zures were observed in three dogs; one in the 1 mg and two in the 2 mg dose 
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group. In follow up dog study in which 24 animals were treated, no seizures 
or changes on eeg were observed after administration of 1, 2, 4 and 8 mg/
animal. The no-observed-adverse-effect level (noael) in dogs was 1.0 mg/
animal (Investigator’s brochure Xen2174. Xenome Ltd., unpublished). 
Xen2174 has previously been administered to humans in four clinical 
studies. However, only limited data have been available on the pharmacoki-
netic (pk) profile of Xen2174 in cerebrospinal fluid (Csf) and no conclusive 
data have been available on its analgesic properties in humans (Table 1). 
The aim of the current study was to assess the pk profile of Xen2174 in plas-
ma and Csf when administered intrathecally to healthy subjects, and to 
assess which modalities of pain were affected by treatment with Xen2174, 
using evoked pain tasks.
maTerials and meThods 
The study was approved by the Medical Ethics Committee of the bebo 
Foundation (Assen, The Netherlands). The study was conducted according 
to the Dutch Act on Medical Research Involving Human Subjects (Wmo) and 
in compliance with Good Clinical Practice (iCh-gCp) and the Declaration of 
Helsinki. 
Subjects
Healthy male and female subjects between 18 and 45 years with a body 
mass index (bmi) of 18 to 30 kg m⁻2 were enrolled. All subjects gave writ-
ten informed consent. The subjects underwent a full medical screening to 
assess eligibility. Subjects with an abnormal electroencephalogram (eeg) 
at screening, a (family) history of epilepsy, a history of seizures, complaints 
of low back pain, regular user of any illicit drugs or history of drug abuse, 
a positive drug screen or other clinical significant abnormalities were 
excluded. Use of xanthine-containing products and alcohol was not allowed 
from 1 day prior to admission to the clinical research unit and during the 
stay at the research unit. Subjects were not allowed to use any medications 
from 2 weeks prior to the start of the study days.
Experimental design
This was a randomised, double-blind, placebo-controlled, serial-cohort, 
single ascending dose study of Xen2174 or placebo, administered intrathe-
cally to healthy volunteers. At each dose stage, subjects were randomised 
to Xen2174 or placebo. Cohorts 1 and 2 consisted of eight subjects admin-
istered Xen2174 and three subjects receiving placebo. Cohort 3 consisted 
of eight subjects administered Xen2174 and two administered placebo. The 
three ascending doses of Xen2174 were 0.5 mg (cohort 1), 1.0 mg (cohort 2) 
and 2.5 mg (cohort 3). The maximum dose of 2.5 mg was chosen in order to 
have a threefold safety margin in the dose per kg body weight compared 
with the noael in dogs. The lower dose of 0.5 mg was chosen based on the 
human equivalent dose of the median effective dose (ed50) in rats exposed 
to the Brennan model of postsurgical pain.
Subjects arrived at the clinical research unit on the day before dosing 
and remained in-house for at least 56 h after study drug administration. 
The study drug was administered via a spinal needle at the l3-l4 or l4-l5 
interspace, using a median approach. After administration, an intrathecal 
sampling catheter was left in place for the following 32 h. Subjects were 
asked to stay in bed in either a recumbent or supine position as much as 
possible during the period that the spinal catheter was in place, and up to 12 
h after the spinal catheter had been removed.
Safety assessments were performed at specified time points and the 
occurrence of general symptoms was monitored continuously. The com-
puter-generated randomization list was prepared by the statistician prior 
to the start of the study. Doses were prepared by a pharmacist/technician 
not involved in any of the study procedures.
Study drug
Xen2174 in glucose 5% was given intrathecally as bolus injection of 3 ml. 
Glucose 5% was used as placebo. Before drug administration, the skin on 
the lower back was anesthetised locally with 1-2 ml lidocaine. All intra-
thecal injections of the study drug were carried out by an experienced 
anaesthesiologist under aseptic conditions using a spinal catheter set. 
Owing to difficulties with Csf sampling, different spinal catheter sets were 
used during the course of the study: a Sprotte Special 21G needle with a 
25G catheter (cohort 1) (Pajunk, Geisingen, Germany), a 19G needle with a 
23G catheter (five subjects in cohort 2) (Pajunk, Geisingen, Germany) and a 
Spinocath 22G catheter (six subjects in cohort 2 and 10 in cohort 3) (B Braun, 
Melsungen, Germany). With the Sprotte Special cannula catheter set, the 
study drug was administered using the Sprotte needle (epidural intro-
ducer with an atraumatic modified pencil point) after which the sampling 
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catheter was left in place. The Sprotte needle had a directional bevel which 
was directed cranially. The study drug was administered directly through 
the epidural introducer. The catheter was placed after drug administration 
at the same level via the introducer. For the Spinocath set, first an intro-
ducer was inserted into the epidural space. After that, the study drug was 
administered into the intrathecal space using a 25G/27G pencil point nee-
dle. Thereafter, the sampling catheter was inserted into the intrathecal 
space through the epidural introducer. With both catheter sets, the sam-
pling catheter was inserted 2-5 cm into the intrathecal space and left in 
place for the following 32 h. The Pajunk catheter had three lateral orifices 
at the distal end of the catheter. The Spinocath catheter had a central and 
lateral opening on the catheter tip. The intrathecal needle was placed with 
the subject in the sitting position. After insertion of the spinal catheter, the 
catheter was secured and subjects were placed directly in supine position 
afterwards. They were asked to stay in the supine or recumbent position 
while the catheter was in place. 
Study assessments
The primary objectives of the study were to evaluate the effects of Xen2174 
on evoked pain tasks and to assess the pk profile of Xen2174 in plasma and 
Csf. Nociceptive (pain) detection and tolerance thresholds were measured 
using a battery of evoked pain tasks. The battery takes approximately 25 
min to complete. The evoked pain tasks (electrical pain, pressure pain and 
cold pressor tasks) were performed predose (twice) and 2, 4, 6, 8, 10, 48, 72 
and 96 h after study drug administration. A training session was included 
as part of the screening examination to reduce learning effects during the 
study. All tests had previously been shown to be sensitive to the effects of 
analgesics in healthy adults. 
Pain intensity was measured continuously for each nociceptive task 
using an electronic visual analogue scale (evas) scale ranging from 0 (no 
pain) to 100 (most intense pain tolerable). The equipment was programmed 
to cease giving stimuli if pain intensity reached the maximum possible 
score. For each task, the pain detection threshold (pdt), pain tolerance 
threshold (ptt) and area under the pain intensity-stimulation (-time for 
cold pressor) curve (auC) were calculated.
Electrical stimulation task
For cutaneous electrical pain, Ag-AgCl electrodes (3M Red-Dot™, 3M 
Europe, Diegem, Belgium) were placed on the skin, 10 cm distal from the 
patella overlying the tibia. The electrical stimulus was delivered as two 
different paradigms by a computer-controlled constant current stimula-
tor (ds5, Digitimer, Cambridge, uk). For the single stimulus, adapted from 
methods described previously13,14 (10 Hz tetanic pulse with a duration of 
0.2 ms), current intensity increased from 0 mA in steps of 0.5 mA·s⁻1 (cut-
off 50 mA). For the repeated stimulus, adapted from methods described 
previously,15 each single stimulus (train of five, 1 ms square wave pulses 
repeated at 200 Hz) was repeated five times with a frequency of 2 Hz at the 
same current intensity with a random interval of 3-8 s between the rep-
etitions. Current intensity increased from 0 mA in steps of 0.5 mA (cutoff 
50 mA). The pain detection threshold was taken as the value (mA) when a 
subject indicated either that all five stimuli were painful or that the train of 
five stimuli, having started as feeling nonpainful became painful (vas > 0). 
The pain intensity for each stimulation was measured using the evas slider, 
until the ptt was reached or a maximum of 50 mA was reached.
Pressure stimulation task
The method for inducing mechanical pressure pain was based on meth-
ods described previously, and was shown to primarily assess nociception 
generated from the muscle with minimal contribution by cutaneous noci-
ceptors.16,17 Briefly, an 11 cm wide tourniquet cuff (vbm Medizintechnik 
GmbH, Sulz, Germany) was placed over the gastrocnemius muscle with a 
constant pressure rate increase of 0.5 kPa·s⁻1. The pneumatic pressure was 
increased until the subject indicated maximum pain tolerance using the 
evas slider, or a maximum pressure of 100 kPa was achieved, at which point 
the device released pressure to the cuff.
Cold pressor task
The method of cold pressor pain was based on the methods described 
previously18,19 and is the most commonly used test to induce inhibitory 
conditioned pain modulation (iCpm, also known as ‘diffuse noxious inhib-
itory control’).20 Subjects placed their nondominant hand into a water 
bath (minimal depth 200 mm) at 35 ± 0.5°C for 2 min. At 1 min 45 s a blood 
the use of a battery of evoked pain models in early phase drug development  66 
 



















PK and Pd of intrathecally administered xen2174 in healthy subjects
pressure cuff on the upper-arm was inflated to 20 mmHg below resting 
diastolic pressure. At 2 min the subject moved that hand from the warm 
water bath, directly into a similar sized bath at 1.0 ± 0.5°C. The subjects 
were instructed to indicate when the pdt was reached as well as the pain 
intensity, by moving the evas slider. When the ptt or a time limit (120 s) 
was reached, subjects were instructed to remove their hand from the water.
Conditioned pain modulation 
Conditioned pain modulation is the activation of the pain-modulatory 
mechanism, as part of the descending endogenous analgesia system.20 The 
degree of iCpm was assessed by comparing the electrical pain thresholds 
for the single stimulus paradigm before and within 5 min after the cold 
pressor task.
Measurements of drug concentrations in plasma and csf
Samples for the determination of Xen2174 in the plasma were obtained at 
baseline, and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 32, 48 and 72 h postdose. Csf 
samples were obtained using the intrathecal catheter at baseline, and at 
0.5, 1, 2, 4, 8, 12, 24, and 32 h postdose. The potential for Xen2174 to adhere 
to components of the sampling material was tested prior to study execu-
tion. Acceptable recovery was obtained. First 0.2 ml Csf, representing the 
catheter dead-space, was sampled and discarded. Subsequently 0.3 ml 
was sampled with a new syringe, divided into two cryotubes and frozen 
at -70°C within 30 min of collection. Plasma was separated within 20 min 
of blood collection by centrifugation at 2000 g for 10 min. Samples were 
stored at -70°C until analysis. Plasma and Csf concentrations of Xen2174 
were measured via high-performance liquid chromatography with tandem 
mass spectrometry detection. The lower limits of quantification were 1.0 
ng ml⁻1 and 10 ng ml⁻1 for the concentrations of Xen2174 in plasma and Csf 
respectively. Sample analysis was performed by Pharmaceutical Product 
Development, Inc., Richmond, va, usa. 
eeg
All subjects received a standard 21-lead clinical eeg at the screening visit. 
The 1-h eeg recording was performed to detect subjects with abnormal eeg 
activity or with preseizure activity when stressed, through hyperventilation 
(for at least 3 min) and photic stimulation. Study eeg recording was initi-
ated 1 h predose, and continued until 24 h postdose. Any change from the 
baseline eeg observed after dosing and interpreted in a blinded fashion by 
the clinical neurophysiologist as clinically significant, was reported as an 
adverse event (ae).
Statistics
No formal power analysis was performed. However, a previous study in 
which the electrical stimulation task was performed and where analge-
sia could be measured in healthy subjects used similar group sizes.13 The 
statistical analysis plan was part of the study protocol. For Xen2174 all pk 
parameters were analysed by noncompartmental methods. Summary 
statistics for each pk parameter were calculated for each dose group. 
The individual and median concentrations were plotted vs. time both on 
a linear and a logarithmic scale. Dose proportionality was assessed from 
dose-normalised auC.
Residual Q-Q plots were produced to check the assumption of normal-
ity of the error term in the mixed effects models. This was done by visual 
inspection, the Shapiro-Wilk test statistic and the p-value for the test of 
normality. All pdt and ptt variables followed a log-normal distribution 
and were therefore log-transformed before analysis. Transformed parame-
ters were back-transformed after analysis.
To assess the interaction effect of Xen2174 on nociceptive variables, the 
(transformed) variables were analysed with a mixed model analysis of 
variance, with treatment, time and treatment by time as fixed factor, sub-
ject as random factor and the (average) predose value as covariate. The 
contrasts calculated within the model were between the placebo and active 
treatments. Contrasts within the overall treatment effect and the time 
effect were estimated and reported, along with 95% confidence intervals. 
Subjects assigned to placebo within each cohort were treated as a single 
group. All calculations were performed using sas for windows v9.1.3 (sas 
Institute, Inc., Cary, nC, usa).
resulTs
A total of 33 healthy subjects (four females) participated in the study 
(Figure 1); subjects were aged 18-43 years (mean age 25.6 years) and had 
a bmi of 19-30 kg m⁻2(mean 24.4 kg m⁻2). The clinical phase of the study 
the use of a battery of evoked pain models in early phase drug development  68 
 



















PK and Pd of intrathecally administered xen2174 in healthy subjects
started on 28 December 2011, and the last study visit was on 18 June 2012. 
One subject in cohort 3, in whom Csf sampling was not possible was 
replaced. The replacement subject was dosed in an unblinded fashion. Only 
pk assessments were performed in this subject.
Owing to sampling problems with the spinal catheter the study was 
amended. During the cohort 1 treatment the diameter of the spinal cath-
eter was increased, and during the cohort 2 treatment, the type of spinal 
catheter was changed. Owing to a high incidence of postlumbar puncture 
syndrome in cohort 1, only male subjects with a bmi above 23 kg m⁻2 were 
recruited in cohorts 2 and 3. 
A large number of aes was observed in this study (Table 2). There was 
no clear difference in the severity or duration of aes between the different 
dosing groups and placebo. The most commonly reported ae was post lum-
bar puncture syndrome (25 out of 33 subjects). This ae was reported in all 
dose groups. In the majority of the subjects, complaints of headache as pre-
sentation of postlumbar puncture syndrome started after removal of the 
spinal sampling catheter. In two subjects, the severity of these complaints 
was mild, in 16 subjects moderate and in seven subjects severe. Subjects 
experiencing these complaints were treated with paracetamol and caf-
feine. Because of inadequate treatment response, 11 subjects were treated 
with an epidural blood patch; one subject was treated with two epidural 
blood patches. Evoked pain tasks were not performed subsequent to anal-
gesic dosing for postlumbar puncture syndrome.
Other commonly reported aes were catheter site related reaction and 
back pain. This included a bruised feeling on the back, irritation, pain and 
stiffness. Paraesthesia was experienced by six subjects; in two during 
administration, and in four during the period when the catheter was in 
place. All these complaints were mild, and resolved shortly after spinal 
catheter removal. 
One subject experienced a serious ae during the study. This subject 
continued to have headache complaints after treatment with the epidural 
blood patch. He was evaluated at the emergency room of the local univer-
sity hospital to exclude severe pathology. No abnormalities were found on 
a computed tomography scan of the head, and the subject was discharged 
from the hospital the next morning. The headache complaints resolved 
without sequelae. 
One subject reported persistent tinnitus after participation in the study, 
which persisted beyond the end of the clinical phase of the study. This sub-
ject was referred to an otolaryngologist for follow up. 
No consistent clinically relevant abnormalities in vital signs, chemistry and 
haematology blood results, urinalysis, electrocardiograms or 24-h eeg reg-
istrations were observed. 
Evoked pain tasks
The mean changes in the least squares means from baseline over 96 h fol-
lowing Xen2174/placebo administration for the different evoked pain task 
variables (auC, pdt, ptt) were evaluated. The summary statistics of the 
ptt are provided in Table 3. The time course for the mean change in the ptt 
from baseline in the first 48 h following Xen214/placebo administration for 
the different evoked pain tasks is shown in Figure 2.
Following treatment with Xen2174 2.50 mg, we observed an increase 
in the ptt over a prolonged period of time for the electrical stimulation 
tasks (single (overall treatment p-value, contrast least squares mean of the 
ptt Xen2174 2.5 mg – placebo[95% confidence interval], contrast p-value / 
p=0.1801, 17.1% [-10.4%, 53.2%], p=0.2372) and repeated stimulation 
(p=0.0713, 28.9% [-3.3%, 71.7%], p=0.0811)) and the pressure stimulation 
task (p=0.0328, 22.2% [-5.0%, 57.1%], p=0.1131). No clear differences in ptt 
between the different dose groups could be observed for iCpm (p=0.7615, 
0.68 [-1.48, 2.84], p=0.5253) or the cold pressor task (p=0.5419, -3.4% 
[-27.8%, 29.2%], p=0.8091). auCs and pdts for the different pain tasks did 
not show any significant results. Seventeen subjects missed one or more 
nociceptive tests because of concurrent postlumbar puncture headache 
and treatments.
Drug concentrations in csf and plasma
The mean pk concentration-time profiles and the corresponding pk vari-
ables of Xen2174 in Csf are shown in Figure 3 and Table 4, respectively. The 
mean half-life ranged between 4.27 h and 7.14 h in Csf. The auC (concentra-
tion-time) from time zero to infinity (auC0₋∞) values increased more than 
proportionally with dose in all dose groups. 
The pk concentration-time profiles and variables of Xen2174 in plasma 
are shown in Table 5 and Figure 4. In general, concentrations were approx-
imately 500- to 2000-fold lower in plasma than in Csf. Average plasma 
peak maximum concentration (Cmax) increased from 5.49 ng ml⁻1 at the 0.5 
mg dose level to 9.75 ng ml⁻1 at 1 mg and 15.4 ng ml⁻1 at the 2.5 mg dose 
level. Cmax appeared to increase slightly less than proportionally with dose 
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between 0.5 and 2.5 mg. The average time to reach the plasma Cmax (tmax) 
was 1.94, 3.69 and 6.89 h, for the 0.5, 1, and 2.5 mg doses, respectively. auC0₋∞ 
increased proportionally to dose. 
discussion
The present study showed that the 2.5 mg dose of Xen2174 administered 
intrathecally was able to influence pain thresholds in several evoked pain 
tasks. The pain tasks showed an increase in ptts for the electrical pain 
tasks and the pressure pain task in favour of the highest dose of Xen2174 
tested, although statistical significance was not reached.
In nonclinical experiments, intrathecal administration of Xen2174 pro-
duced anti-allodynic and antinociceptive effects in rats.9,12 The chronic 
constriction injury (CCi) model and the l5/l6 ligation model used in the 
study by Nielsen et al. are both models for neuropathic pain, while Obata 
and colleagues used a model of postincisional pain. The models used in 
the present study were mainly for acute nociceptive pain. Owing to the 
differences in etiology in these models, no direct translation can be made 
between the results in nonclinical results and the results in humans. 
Dosages in the present study were based on nonclinical data. The half max-
imal effective concentration (eC50) in a functional assay for the binding of 
Xen2174 to the net, resulting in the inhibition of ne uptake by the transport-
er, was 183 nM, which corresponds to a concentration of 0.26 mg l⁻1. The 
median effective dose (ed50) concentration in Csf for antinociception in 
the Brennan model for postoperative pain in rats was 0.86 µg intrathecally 
(hypothetical concentration in Csf 3.2 mg l⁻1). The ed50 for anti-allodynia 
in the CCi model in rats was 15.7 nmol (22.1 µg, leading to a hypothetical Csf 
concentration of 81.9 mg l⁻1).9 It was expected that dosages in the range of 
1.0-2.5 mg would lead to Csf concentrations above the observed eC50 and 
ed50, and thus induce nociceptive effects. The observed Cmax (after admin-
istration of 2.5 mg of Xen2174) in Csf of 33.2 mg l⁻1 was above the ed50 for 
the antinociception in the Brennan model, but below the ed50 for anti-allo-
dynia in the CCi model. 
The Xen2174 1.0 mg intrathecal dose in dogs was determined as the noael 
in dogs in nonclinical studies. The ratio of the auC0₋∞ measured in Csf in 
the Xen2174 2.5 mg dose group in humans compared with that in dogs after 
a 1 mg intrathecal injection was 1.43 (unpublished data). A preferred and 
expected safety margin for this auC0₋∞ ratio for single intrathecal doses of 
Xen2174 in dogs (expected ratio to be at least 10) was not reached, leading 
the sponsor to discontinue further development of this compound.
Xen2174 is one of a novel class of nris for the treatment of pain. It has 
been shown to exert its effects via spinal activation of α2-adreno-
ceptors subsequent to ne reuptake inhibition.9 Other nris include 
tricyclic antidepressants and tapentadol. The tricyclic antidepressant imip-
ramine increases the ptt for pressure pain and for electrical stimulation.21 
Tapentadol combines opioidergic activity with noradrenergic activity with 
both mechanisms accounting for the analgesic effects. It is efficacious in 
the treatment of moderate to severe acute pain compared with placebo.22 
Furthermore, tapentadol caused activation of conditioned pain modulation 
in patients with diabetes in an experimental setting.23
Several polymorphisms are known for the net gene (slC6a2). Patients 
carrying the homozygous snp2 g/g variant of this gene reported a longer 
analgesic onset time after medication administration than heterozygous 
and a/a homozygous patients.24 Hypothetically, a larger overall analgesic 
effect could have been observed if snp2 g/g subjects had been excluded 
from the study. An equipotent analgesic effect might have been achieved 
with lower Csf concentrations. Unfortunately, no genotyping for polymor-
phisms was performed in the present study. 
In addition to local anaesthetics, which are used for spinal anaesthesia, 
there are several analgesic compounds that are intrathecally administered. 
Clonidine, an α2-adrenergic receptor agonist, showed analgesic action 
after intrathecal and epidural administration.25,26 Ziconotide, a synthetic 
equivalent of the venom of a marine snail, exerts its effect by binding and 
blocking voltage-sensitive calcium channels.27 Opioids show postoperative 
analgesia when administered intrathecally.28 Intrathecal nsaids have been 
tested for their analgesic efficacy in patients but are not used in current 
clinical practice.29 Only two studies have reported the use of evoked pain 
models after intrathecal drug administration.26,30 Intrathecal ketorolac, 
an nsaid, was tested in a study in healthy volunteers but did not show an 
effect on pain from acute heat stimuli.30 Clonidine caused an increase in 
heat pain tolerance after intrathecal administration.26 In the current study 
we confirmed that intrathecal drug administration in combination with 
performing a battery of evoked pain tasks is feasible, even with concurrent 
Csf sampling.
An increase of 28.9% in least squares mean (electrical repeat ptt) and 22.2 
% (pressure ptt) was observed after administration of Xen2174 compared 
with placebo. Similar effect sizes for electrical pain (42%) and pressure 
pain (22%) testing were observed after administration of an analgesic 
dose of alfentanil in previous research,31 suggesting that the difference we 
observed in pain tolerance was clinically relevant. The observed increase in 
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ptts lasts for a long period (Figure 2), whereas the Csf concentration steadi-
ly drops (Figure 3). The prolonged analgesic effect cannot be explained by 
the Csf concentrations but it should be noted that such a measure is a sur-
rogate for tissue concentration and receptor binding, and therefore may 
reflect a similar distribution to the effect site (reflected by half-life for equil-
ibration, t½,ke0) to that observed with other analgesics and consequential 
clearance from the effect site.32 Although no mechanistic validation can 
be provided, the long duration of action has already been observed in 
nonclinical experiments, in which doses of intrathecal Xen2174 provid-
ed longer relief of tactile allodynia in CCi rats compared with morphine.9 
     An increase in pain tolerance was observed in the electrical pain tasks 
and the pressure pain task, but no differences were observed in the cold 
pressor task. Earlier research with a centrally acting nri, imipramine, also 
did not show an effect on the cold pressor task.21 The lack of effect on this 
task could suggest that administration of Xen2174 has only local effects, at 
and below the level of administration, but no effects at higher levels – for 
example, at the level of the brainstem. There was a difference in the level of 
administration of the study drug (l4-l5) and the dermatomes in which the 
cold pressor task was performed (C6-C8). In a study in which several amide 
local anaesthetics were compared, drug administration was performed at 
the second or third lumbar interspace, and the maximum level of sensory 
block to pinprick was level t2 in all dose groups.33 This might also be why 
no effects of Xen2174 on iCpm could be observed. The centrally acting nri 
tapentadol has been shown to increase iCpm.23 Other explanations for the 
conflicting outcomes might include the fact that different methods were 
used to measure iCpm, or differences in patient populations. 
Many studies employ evoked pain tasks to assess the analgesic effects of 
new drugs in healthy human subjects. Most of these studies test only one 
or two modalities of pain.34 The advantage of the method that was used in 
the current study was the combination of the different pain tasks in a stan-
dardised way. Earlier research has shown the advantages of multi-modal pain 
testing.35 Different evoked pain tests have different sensitivities for different 
analgesics.34 Using only one pain task could lead to a negative trial, while 
using a broad set of pain tasks could give a better understanding of how the 
different mechanisms that play a role in evoked pain tests are influenced, and 
therefore of the different pharmacological properties of a new compound. 
The models used in the present study represent only acute nociceptive pain 
models. No spontaneous, chronic or neuropathic pain was investigated. 
Therefore, caution should be exercised when interpreting our results. 
While it has been shown that many different analgesics that are known to 
be effective in clinical acute and chronic pain management can affect the 
different tests that were used in this pain battery,34,36,37 the acute respons-
es tested in the current study are not necessarily good models of chronic 
pain. Given the mode of action of Xen2174 to enhance descending inhibition, 
these acute measures may not adequately assess efficacy in clinical settings 
of chronic pain.
The limitation of multi-modal testing is the large number of different 
outcome variables. In the present study five pd tests, yielding 15 different 
variables were analysed without applying a correction for multiple testing. 
Only a weak signal for a dose-response relationship was observed in the 
study. Therefore, the multi-modal battery of pain tasks should be consid-
ered as a first screening tool for studying the analgesic properties of pain 
compounds in development. When the analgesic effect of a new drug on 
a certain pain mechanism has been established, predefining a primary 
outcome measure would prevent the need to correct for multiple testing. 
Furthermore, the present study was not formally powered for analgesic 
efficacy on the evoked pain tasks.
Csf sampling was limited in cohorts 1 and 2 because of catheter sam-
pling difficulties. The introduction of a different type of intrathecal catheter 
improved the sampling success rate in the second part of cohort 2 treat-
ment and in cohort 3. The total volume of Csf in humans is approximately 
170 ml.38 Administration of 2.5 mg Xen2174 intrathecally would theoret-
ically lead to a Cmax of 14,705 ng ml⁻1. We found a Cmax of 33,200 ng ml⁻1 
after administration of 2.5 mg of Xen2174. This may suggest that the study 
drug was not completely mixed throughout the Csf at tmax. Alternatively, 
the Csf volume in which the drug can freely diffuse, even if proper mixing 
had occurred, was overestimated for yet unknown reasons. Describing the 
pk in Csf is different to that in plasma. Drugs administered intravenously 
are rapidly distributed within the central distribution volume. The pk of 
drugs administered in less ‘well-stirred’, oscillating fluid systems, like the 
Csf, is more difficult to predict;38,39 as such, it is difficult to predict drug 
concentrations at a particular level in the spinal column or intracranially. 
However, describing the dose-response relationship is more feasible if the 
site of injection of a drug is directly at the target site,38 which was the case 
in the present study. 
No pk or pk/pd modelling was performed on the data. As discussed 
previously, the site of administration was the same as that of sampling. 
As a consequence, the drug concentrations of the Csf samples may have 
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been the sum of the concentration in Csf and that of the drug solution that 
had not yet fully distributed throughout the Csf, for which we could not 
quantitatively correct. The development of a pk model on these Csf data 
would have resulted in high uncertainty in parameter estimates and large 
values for variability, also contributed by to the limited number of subjects. 
As a result, the parameter estimates were not expected to have physi-
ological meaning, but merely to describe the observations in the lower 
spine. Moreover, Xen2174 has a high molecular weight and is therefore not 
expected to passively cross the blood-brain barrier to a large extent, apart 
from leakage. Finally, using the pk models that describe the Csf concen-
trations in the lower spine as the driving force for the pd would also have 
resulted in parameter estimates with high levels of uncertainty and large 
between subject variability – in our view, parameter estimates that have 
limited physiological meaning. The purpose of measuring Csf and plasma 
samples was to provide quantitative evidence of Cns exposure and limited 
plasma exposure which in our view, is sufficiently supported by the non-
compartmental analysis. Given the lack of real physiological meaning that 
pk parameter estimates would have had, it was decided not to develop a pk 
model; similarly, the development of a pk/pd model would not have been 
logical.
Based on the literature, the incidence of postlumbar puncture syndrome 
was higher than expected. In a study in which the same intrathecal catheter 
was used, one out of eight subjects reported headaches.40 A possible expla-
nation for this difference might be the age difference (63.3 years vs. 25.6 
years in our study). Younger age is an established risk factor for the occur-
rence of postlumbar puncture headache. Other reported risk factors are 
a low bmi and female gender.41 Nonetheless, the exclusion of women and 
subjects with a bmi below 23 kg m⁻2 from cohorts 2 and 3 did not reduce the 
incidence or severity of this ae. 
In the present study, there was a weak signal that Xen2174, at a dose of 2.5 
mg increased the ptt for pressure pain. However, at the highest dose level 
tested, Csf Xen2174 concentrations exceeded the required exposure limit 
based on the nonclinical safety margins, which makes it unlikely that the 
compound can be used in practice for the treatment of acute pain.
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Table 1 
Summary of previous clinical studies with Xen2174.
Study Number (n) 
of subjects
Dose Outcomes Serious adverse 
events*
Phase 1 study of Xen2174 
administered intravenously  






No effects on nociceptive testing. None
Phase 1-2 open-label study 
of Xen2174 administered 
intrathecally in oncology  





No definitive conclusions 
regarding clinical benefit due 
to small number of patients per 
dose group and variation in type 
of pain. Each cohort contained 
at least one patient with >90% 
reduction in pain scores.
Confusion and 
dysphasia (0.25 mg), 
apnea, unrespon-
siveness, grand mal 
seizure (40 mg), 
aseptic drug-induced 
meningitis (40 mg)
Phase 2 study of Xen2174 
administered intrathecally in 





1.0 mg No final conclusion regarding 
clinical efficacy.
None
Phase 1 eeg safety study of  
Xen2174 administered in healthy 






No apparent effects on eeg. None
 
*Considered related to the study drug. eeg, electroencephalogram
Table 2 
Summary of treatment emergent adverse events (aes) by frequency [n(%)]. aes occurring 









Subjects with ≥1 ae 8 (100) 8 (100) 8 (100) 9 (100)
Number of different aes 16 15 13 17
Post Lumbar Puncture Syndrome 5 (62.5) 5 (62.5) 7 (87.5) 8 (88.9)
Catheter Site Related Reaction 7 (87.5) 3 (37.5) 4 (50.0) 6 (66.7)
Back Pain 3 (37.5) 2 (25.0) 4 (50.0) 5 (55.6)
Headache 5 (62.5) 3 (37.5) 4 (50.0) 2 (22.2)
Paraesthesia 3 (37.5) 1 (12.5) 1 (12.5) 1 (11.1)
Dizziness - 3 (37.5) - 1 (11.1)
Fatigue 1 (12.5) - 1 (12.5) 2 (22.2)
Musculoskeletal Stiffness - - - 3 (33.3)
Presyncope 2 (25.0) - 1 (12.5) -
Somnolence - 1 (12.5) - 2 (22.2)
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Table 3 
Least squares means for the pain tolerance thresholds and estimates of difference, 95% 
confidence intervals and p-values for main contrasts.
ls Means Contrast









0.5 mg - 
Placebo
Xen2174  
1.0 mg –  
Placebo
Xen2174  
2.5 mg –  
Placebo
Cold pTT  
(s)




































-1.88 -1.05 -0.83 -1.20 0.7615  0.83  
(-1.29, 2.96)  
 p=0.4294
 1.05  
(-1.06, 3.16)  
 p=0.3162
 0.68  













iCpm, inhibitory conditioned pain modulation; kPa, kilopascal; ls, least squares; mA, milliampere; ptt, pain tolerance 
threshold; s, seconds
Table 4 













Xen2174 0.5 mg Mean 4080 0.50 7.14 6532 8081
sd 4090 0.00 4.69 5717 7930
Xen2174 1.0 mg Mean 5600 1.40 4.27 29655 29912
sd 3340 1.47 0.790 15348 15443
Xen2174 2.5 mg Mean 33200 0.56 4.83 157594 159146
sd 16600 0.18 0.843 63810 64089
auC0₋∞, The area under the curve from time zero to infinity; auClast, The area under the curve from time zero to the last 
measurable concentration; Cmax, peak concentration; sd, standard deviation; tmax, time to reach Cmax; t½, half-life
Table 5 













Xen2174 0.5 mg Mean 5.49 1.94 5.79 34.2 45.3
sd 3.20 1.15 2.38 12.4 10.9
Xen2174 1.0 mg Mean 9.75 3.69 5.96 69.7 87.5
sd 3.49 2.89 3.28 15.9 14.5
Xen2174 2.5 mg Mean 15.4 6.89 8.62 200 221
sd 5.83 3.14 1.41 39.7 39.3
auC0₋∞, The area under the curve from time zero to infinity; auClast, The area under the curve from time zero to the last 















������ ��� ������ �������
- Female subjects after protocol 
amendment, n =  12
- ��� too low after protocol amendment, n = 7
- Abnormal screenings ���, n = 7
- Medical history, n = 6
- Withdrew consent during screening 
period, n = 5
- Positive drug screen, n = 4
- Abnormal lab results, n = 3
- Family history of epilepsy, n = 1
- Reserve subject, n = 4
- Cancelled study participation, n = 3
- Assigned to study drug (Xen2174), n=25
- Assigned to placebo, n = 8 
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figure 2 
Time course of the mean change from baseline profile in least squares means for the pain 
tolerance threshold for electrical stimulation tasks (single [a] and repeated stimulus [b]),  
cold pressor task [C] and the pressure stimulation task [d] after administration of single 
doses of Xen2174 (0.5, 1.0 or 2.5 mg) or placebo. Vertical lines represent the 95% confidence 
intervals.
figure 3 
Mean Csf Xen2174 concentration-time by cohort. Vertical lines represent the standard 
deviation.
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No evidence of potentiation of buprenorphine by milnacipran 
in healthy subjects using a nociceptive test battery
European Journal of Pain 2017;21: 494-506
P. Okkerse*, R. Alvarez-Jimenez*, J.L. Hay, A. Tehim, R. Kumar, M.L. de Kam, G.J. Groeneveld 
*Contributed equally
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Buprenorphine and milnacipran interaction study in healthy suBjects
absTracT
Serotonin–norepinephrine reuptake inhibitors inhibit the reuptake of 
serotonin and noradrenalin and are used in the treatment of neuropath-
ic pain. Animal studies suggest that milnacipran co-administered with 
opioids may potentiate the analgesic effect of μ-opioid receptor ago-
nists. This study hypothesised that co-administration of milnacipran and 
buprenorphine would have a synergistic effect in evoked pain models in 
healthy subjects. This was a randomised double-blinded, placebo-con-
trolled, four-way cross-over, multiple dose clinical trial to investigate the 
analgesic effects of buprenorphine (placebo, 0.5, 1 and 3 μg kg⁻1) in com-
bination with milnacipran (placebo, 25 and 50 mg) in healthy subjects. 
11 healthy men were enrolled in the study. Buprenorphine alone showed 
a dose-response relationship indicative of anti-nociception in the pain 
tests. Following milnacipran administration no changes were seen in the 
pharmacodynamic measurements for pain, psychomotor function, body 
stability or eye movements. For the electrical tests, cold pressor test and 
pressure pain test, buprenorphine alone was superior when compared 
with buprenorphine plus milnacipran. No differences in pharmacodynam-
ic variables, besides an increase in pupil/iris ratio, were observed after 
repeated administration of milnacipran 50 mg. Single and multiple doses 
of 25 or 50 mg milnacipran did not further potentiate the anti-nociceptive 
effects of buprenorphine. Buprenorphine showed dose-dependent effects 
consistent with its pharmacological profile. Milnacipran alone did not 
affect any of the pain variables. The combination of both buprenorphine 
and milnacipran did not potentiate or show a synergistic effect on the pain 
models used in this study.
inTroducTion
Severe pain represents an important challenge for the clinician. Guidelines 
for moderate to severe pain treatment recommend the use of opioids. 
However, these can lead to dose-dependent side effects such as constipa-
tion, nausea, vomiting and sedation.1
Current strategies in opioid use in the clinic include administering the 
lowest dose possible with still an adequate analgesic effect. An alternative 
strategy is to combine opioids with other drugs that might have a syner-
gistic effect, which could thus lead to lower opioid dosages and therefore 
fewer side effects. Some suggested combinations are opioids in combina-
tion with norepinephrine transporter modulators, calcium channel alpha-2 
delta ligands or local anesthetics.2 
It has been demonstrated that milnacipran, a serotonin-noradrenaline 
reuptake inhibitor (snri), inhibits C-fibre-mediated nociceptive synaptic 
transmission in the spinal dorsal horn after the establishment of spinal 
long term potentiation in a neuropathic pain model, by activating both 
spinal serotonergic and noradrenergic systems.3 The inhibition of the 
C-fibre-mediated transmission by milnacipran could provide new evidence 
regarding the analgesic mechanism of snris in chronic pain. Currently, 
milnacipran is available as a pharmacological intervention to treat chronic 
neuropathic pain and fibromyalgia; however its effectiveness in the treat-
ment of pain is limited.4,5
There is nonclinical evidence that milnacipran potentiates the antihy-
peralgesic effects of opioids such as tramadol.6 Furthermore, in animal 
studies the antihyperalgesic effects of milnacipran can be blocked by nal-
oxone, an opioid receptor antagonist, suggesting a possible opioidergic 
mechanism of action of this snri.7 This is supported by findings that show 
that noradrenergic, serotonergic and endogenous opioidergic systems are 
essential for milnacipran to reduce mechanical hyperalgesia.6
Serotonin-norepinephrine reuptake inhibitors (snris) have shown 
effectiveness in human evoked pain models (single electrical stimulation 
and repetitive electrical stimulation) with venlafaxine, even with a short 
period of time (h) between the administration and the measured effect.8 
Numerous human evoked pain models are sensitive to the effects of opi-
oids9 . Currently tapentadol, a drug that is both a µ-opioid receptor agonist 
and a noradrenaline reuptake inhibitor, is marketed for the treatment of 
severe acute and chronic neuropathic pain. Synergy between the dual 
mechanism of action of tapentadol has been demonstrated in several pre-
clinical studies.10
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This study aimed to evaluate the potential synergy and potentiation – as 
shown in preclinical studies – of milnacipran, when co-administered with 
a potent µ-opioid receptor partial agonist, buprenorphine, in evoked pain 
models in healthy subjects. This study aimed to investigate whether a sub-
therapeutic dose of buprenorphine could become therapeutic through 
co-medication with single or multiple doses of milnacipran and to deter-
mine whether the analgesic effect of buprenorphine at therapeutic dose 
levels could be enhanced by milnacipran. 
meThods
The study was approved by the Medical Ethics Committee of the bebo 
Foundation (Assen, The Netherlands). The study was conducted according 
to the Dutch Act on Medical Research Involving Human Subjects (Wmo) and 
in compliance with Good Clinical Practice (iCh-gCp) and the Declaration 
of Helsinki. The trial was registered in the European Union Clinical Trials 
Register (2012-002302-43).
Subjects
Healthy male subjects between 18 and 45 years with a body mass index of 
18-30 kg m⁻2 were to be enrolled after having given written informed con-
sent. The subjects underwent a full medical screening, including medical 
history taking, a physical examination, blood chemistry and haematology, 
urinalysis and electrocardiogram (eCg) to assess eligibility. Key exclusion 
criteria were as follows: clinical significant abnormalities during screen-
ing, regular user of any illicit drugs or history of drug abuse, a positive drug 
screen at screening or smoking within 3 months prior to screening. Use of 
xanthine-containing products and alcohol was not allowed during the stay 
at the research unit. Subjects were not allowed to use any medication from 
one week prior to the start of the study days.
Study design and treatments
This was a randomised, double-blind, placebo-controlled, four-way cross-
over study with three different doses of buprenorphine or placebo in 
combination with milnacipran or placebo. The total number of planned 
subjects was 10. 
The four treatment arms were as follows: buprenorphine active treatment 
in combination with milnacipran 25 mg (bup+mil-25), buprenorphine 
active treatment in combination with milnacipran 50 mg (bup+mil-50), 
buprenorphine-placebo in combination with milnacipran 50 mg (bup-
p+mil-50) and buprenorphine active treatment in combination with 
milnacipran-placebo (bup+mil-p). The computer-generated random-
ization list was prepared by the statistician prior to the start of the study. 
Doses were prepared by a pharmacist/technician not involved in any of the 
study procedures. Buprenorphine (Temgesic; rb Pharmaceuticals Limited, 
Slough Berkshire, uk) was administered as an intravenous solution on day 1 
and day 8 in three different doses. The buprenorphine dosing schedule was 
based on a published population pharmacokinetic and pharmacodynamic 
(poppk/pd) model with the electric pain tolerance threshold as a phar-
macodynamic endpoint.11 At the end of each buprenorphine intravenous 
infusion, the pharmacodynamic effects of buprenorphine were expected to 
remain reasonably stable, which would allow the performance of the pain 
tests (Figure 1). First, a 30 min 0.5 µg kg⁻1 infusion, which was expected 
to lead to subtherapeutic plasma concentrations, followed 1.5 h later by a 
second 30 min 1 µg kg⁻1 infusion, which was expected to lead to minimally 
therapeutic plasma concentrations, finally followed 1.5 h later by a 30 min 
3 µg kg⁻1 infusion, which was expected to lead to therapeutic plasma con-
centrations of buprenorphine. Milnacipran hydrochloride (Pierre Fabre, 
Castres, France) was administered orally twice daily starting from day 1 and 
until the morning of day 8. Intravenous metoclopramide 10 mg (Primperan; 
Sanofi-Aventis, Paris, France) was administered prophylactically before 
the second buprenorphine/placebo infusion to prevent nausea and vom-
iting. Additional doses of metoclopramide were administered if needed. 
     Each of the four study periods lasted 8 days. On the morning of day 1, 
subjects arrived at the clinical research unit and received the first oral 
dose of milnacipran or placebo. Thereafter, they received the three intra-
venous administrations of buprenorphine or placebo according to the 
different infusion schedules, separated by 1.5 h. After each infusion, the 
pharmacodynamic tasks were performed (evoked pain tasks and neuro-
physiological tests). At the end of the study day, subjects were discharged 
and were instructed to orally administer milnacipran or placebo twice 
a day at home. On day 8, subjects returned to the unit and the same pro-
cedures as on day 1 were followed. There was a 14-day wash-out interval 
between study periods. An overview of a study period is shown in Figure 2.
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Pharmacodynamics
Pharmacodynamic measurements were performed pre-dose (twice) and 
1 h after the start of each buprenorphine administration. A training ses-
sion was included as part of the screening examination to reduce learning 
effects during the study. All measurements were performed in a quiet room 
with ambient illumination. Tests were performed in a fixed order (Figure 3). 
     Nociceptive (pain) detection and tolerance thresholds were measured 
using a battery of evoked pain tasks. The battery is an integrated range of 
tasks for measuring different modalities of nociception (electrical pain, 
pressure pain and cold pressor tasks). It aims to assess as objectively as 
possible the levels of pain induced by several noxious mechanisms in 
human subjects. All nociceptive tests had previously been shown to be sen-
sitive to the effects of analgesics in healthy adults. Other pharmacodynamic 
tests included pupil size measurements, adaptive tracking, saccadic eye 
movements and body sway. These tests have previously been shown to be 
sensitive to the effects of several different classes of drugs.12,13
Pain intensity was measured continuously (beginning from when the 
first stimulus was applied until the predetermined end of the test) for each 
nociceptive task using an electronic visual analogue scale (evas) ranging 
from 0 (no pain) to 100 (most intense pain tolerable). Equipment was pro-
grammed to cease giving stimuli if pain intensity reached the maximum 
possible score. For each task the pain detection threshold (pdt), pain toler-
ance threshold (ptt) and area under the pain intensity-stimulation (-time 
for cold pressor) curve (auC) were calculated.
Electrical stimulation task
For cutaneous electrical pain, Ag-AgCl electrodes (3M Red-Dot™) were 
placed on cleaned, scrubbed, and if required, shaved skin, 10 cm distal from 
the patella overlying the tibia. Electrical resistance between electrodes 
was to be <2 kW. The electrical stimulus was delivered as two different 
paradigms by a computer-controlled constant current stimulator (ds5; 
Digitimer, Cambridge, uk).
For the single stimulus, adapted from methods previously described,14,15 
(10 Hz tetanic pulse with a duration of 0.2 ms), current intensity increased 
from 0 mA in steps of 0.5 mA s⁻1 until the pain tolerance threshold was 
reached or up to a cutoff of 50 mA. 
For the repeated stimulus, adapted from methods previously described,16 
each single stimulus (train of five, 1 ms square wave pulses repeated at 200 
Hz) was repeated five times with a frequency of 2 Hz at the same current 
intensity with a random interval of 3 to 8 seconds between the repeti-
tions. Current intensity increased from 0 to 50 mA in steps of 0.5 mA. Pain 
detection threshold (pdt) was taken as the value (mA) whereby a subject 
indicated either: all five stimuli were painful, or the train of five stimuli 
started feeling non-painful but ended feeling painful (vas > 0). The pain 
intensity for each stimulation was measured using the evas slider, until 
pain tolerance threshold was reached or a maximum of 50 mA was reached.
Pressure stimulation task
The method of mechanical pressure pain induction was based on meth-
ods previously described and was shown to primarily assess nociception 
generated from the muscle with minimal contribution by cutaneous noci-
ceptors.17,18 Briefly, an 11 cm wide tourniquet cuff (vbm Medizintechnik 
GmbH, Sulz, Germany) was placed over the gastrocnemius muscle with a 
constant pressure rate increase of 0.5 kPa s⁻1. The pneumatic pressure was 
increased until the subject indicated maximum pain tolerance using the 
evas slider, or a maximum pressure of 100 kPa was achieved, at which point 
the device released pressure to the cuff.
Cold pressor task
The method of cold pressor pain was based on the methods previously 
described19,20 and is the most commonly used test to induce inhibitory 
conditioned pain modulation (iCpm, also known as ‘diffuse noxious inhib-
itory control’).21 Subjects placed their non-dominant hand into a water 
bath (minimal depth 200 mm) (Lauda, Germany) at 35 ± 0.5°C for 2 min. 
At 1 min 45 s, a blood pressure cuff on the upper-arm was inflated to 20 
mmHg below resting diastolic pressure. At 2 min, the subject then moved 
that hand from the warm water bath, directly into a similar sized bath at 
1.0 ± 0.5°C. The subjects were instructed to indicate when pdt was reached 
(first change in sensation from cold non-painful to painful) as well as the 
pain intensity, by moving the evas slider. When ptt or a time limit (120 s) 
was reached, subjects were instructed to remove their hand from the water, 
at which point the blood pressure cuff deflated.
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Conditioned pain modulation 
Conditioned pain modulation is the activation of the pain-modulatory 
mechanism, as part of the descending endogenous analgesia system.21 The 
degree of iCpm was assessed by comparing the electrical pain thresholds 
for the single stimulus paradigm before and within 5 min after the end of 
cold pressor task.
Pupil size
Pupil diameter was determined using a digital camera and a flash. The 
pupil/iris ratio was calculated as a measure of pupil size (Qpupil, Leiden 
University Medical Center, Leiden, the Netherlands).
Adaptive tracking
The adaptive tracker is a psychomotor task and is sensitive to impairment 
of eye-hand coordination. The adaptive tracking test was performed as 
originally described by Borland and Nicholson,22 using customised equip-
ment (Hobbs & Strutt, uk). A circle moves randomly about a screen. The 
subject must try to keep a dot inside the moving circle by operating a joy-
stick. If this effort is successful, the speed of the moving circle increases. 
Conversely, the velocity is reduced if the test subject cannot maintain the 
dot inside the circle. The average performance over 3.5 min was used for 
analysis. The outcome is the average velocity of the circle as percentage of 
maximal velocity possible. 
Saccadic eye movements
Saccadic peak velocity is one of the most sensitive parameters for sedation 
and was described previously.23,24 Recording and analysis of saccadic eye 
movements was conducted with a microcomputer-based system for sam-
pling and analysis of eye movements. The program for signal collection 
and the ad-converter was from Cambridge Electronic Design (Ced Ltd., 
Cambridge, uk), the amplification by Grass (Grass-Telefactor, An Astro-
Med, Inc. Product Group, Braintree, ma, usa) and the sampling and analysis 
scripts were developed at Chdr (Leiden, the Netherlands). Disposable sil-
ver-silver chloride electrodes (Ambu BlueSensor N, Ballerup, Denmark) 
were applied on the forehead and beside the lateral canthi of both eyes of 
the subject for registration of the electro-oculographic signals. The target 
consists of a moving dot that is displayed on a computer screen. Saccadic 
eye movements were recorded for stimulus amplitudes of approximately 15 
degrees to either side. Fifteen saccades were recorded with interstimulus 
intervals varying randomly between 3 and 6 s. Average values of latency 
(reaction time), saccadic peak velocity of all correct saccades and inaccura-
cy of all saccades were analysed. 
Body sway
The body sway meter allows measurement of body movements in a single 
plane, providing a measure of postural stability. Body sway was measured 
with pot string meter (Celesco, Chatsworth, Ca, usa) based on the Wright 
ataxiameter.25 Subjects were asked to stand still and comfortable, with 
their feet approximately 10 cm part and their hands in a relaxed position 
alongside the body and eyes closed. With a string attached to the waist, all 
body movements over a period of two min were integrated and expressed 
as mm sway. 
Measurements of drug concentrations in plasma
Samples for determination of milnacipran in plasma were obtained at 
baseline, 1, 2, 3, 4, 5, 6, 7 and 11 h after oral administration on days 1 and 
8. Samples for determination of buprenorphine and its active metabolite 
nor-buprenorphine were obtained 1 and 2 h after the start of each infusion. 
Samples were collected in lithium heparin tubes and stored in ice. 
Plasma was separated within 30 min of blood collection by centrifuga-
tion at 2000 g for 10 min. Samples were stored at -70°C until analysis. 
Drug concentrations in plasma were determined using a validated Liquid 
Chromatography–Mass Spectrometry (lC-ms/ms) technique. The analyti-
cal range of the assay was 1.00-500 ng/mL for milnacipran and 0.100-20.0 
ng/mL for buprenorphine and nor-buprenorphine.
Statistics
The sample size calculation was based on previous experiments in healthy 
young men. An average cold pressor auC of 10,000 s mm was expected. We 
expected that the highest dose of buprenorphine would cause a decrease in 
the cold pressor auC of 30%. If an increase of that difference to 37% was to 
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be established due to co-administration of milnacipran, then assuming an 
sd of 617 (based on data on file), with 80% power and a two-sided alpha = 
0.05, a sample size of eight subjects was needed.
Pharmacokinetic analysis was performed using a non-compartmental 
model approach. For milnacipran and buprenorphine, the peak concentra-
tion (Cmax) and the time to the peak concentration (tmax) was recorded as 
observed. In addition, the area under the plasma concentration-time curve 
from time zero to the time of the last sample (auC0₋last) was determined for 
both drugs. Calculations were performed using R v2.14.1 (R Foundation for 
Statistical Computing, Vienna, Austria).
The pharmacodynamic data were compared, per day, with a mixed 
model analysis of variance with treatment, period, time and treatment by 
time as fixed factors, subject, subject by treatment and subject by time as 
random factors and the average prevalue (per treatment average of mea-
surements before time=0 on day 1, also for the day 8 analysis) as covariate. 
This analysis was carried out on the four original treatments. The contrast 
between buprenorphine alone and buprenorphine and milnacipran 50 mg 
during the baseline measurements on day 8 was assessed to determine the 
effects of repeated milnacipran dosing. 
Variables that followed a log-normal distribution were log-transformed 
before analysis. Transformed parameters were back-transformed after 
analysis.
Synergy was tested as the contrast of (buprenorphine alone) plus (mil-
nacipran 50 mg alone) minus the overall average pre value (day 1) versus 
(buprenorphine and milnacipran 50 mg). The average overall prevalue of 
day 1 is used as there is no milnacipran-placebo and buprenorphine-pla-
cebo treatment. The values of the buprenorphine alone plus milnacipran 
50 mg alone minus the overall average pre value were calculated prior to 
analysis. Together with the buprenorphine plus 25 mg milnacipran and the 
buprenorphine plus 50 mg milnacipran, the calculated synergy values were 
analysed in a separate repeated measure mixed model, with fixed factors of 
treatment, time and treatment by time, random factors of subject, subject 
by treatment and subject by time and the average pre-value per treatment 
of day 1 as covariates. All calculations of the pharmacodynamic parameters 
were performed using sas for Windows version 9.1.3 (sas Institute Inc., 
Cary, nC, usa). The main sas procedure that was used in the analysis was 
proC mixed. No adjustments for multiple comparisons were employed.
resulTs 
A total of 11 subjects participated in the trial (see Figure s1 for study flow-
chart); subjects were aged 21-31 years (mean age 24.2 years) and had a body 
mass index of between 20 and 26 kg m⁻2 (mean 22.4 kg m⁻2). Nine subjects 
completed the trial until the last study occasions. Two subjects dropped 
out from the study. One subject was withdrawn by the investigator due to 
side effects categorised as probably related to milnacipran (shortness of 
breath, palpitations, dizziness, urinary hesitation and paraesthesias). The 
other subject withdrew consent due to side effects (nausea and vomiting) 
caused by buprenorphine. 
Nociceptive tests
The least squares means and the analysis results for the ptts for the differ-
ent nociceptive tests are presented in Table 1, Table 2 and figure 4. On day 1, 
a significant overall treatment effect was found for the ptt of the electrical 
stimulation tasks, the pressure stimulation task and the cold pressor tasks. 
On day 8, no significant overall treatment effect was found for any of the 
pain tests. None of the contrasts of buprenorphine plus milnacipran ver-
sus buprenorphine alone showed a significant increase of pain tolerance 
or detection. Buprenorphine in combination with milnacipran 50 mg sig-
nificantly decreased the repeated electrical stimulation ptt and the cold 
pressor pdt compared with buprenorphine alone (pdt data not shown). 
The effects were not observed on day 8. Buprenorphine in combination 
with milnacipran did not lead to greater analgesic effects compared with 
buprenorphine alone. On day 8, buprenorphine in combination with mil-
nacipran 50 mg and buprenorphine in combination with 25 mg milnacipran 
increased the cold pressor ptt compared with buprenorphine alone. The 
contrast between buprenorphine in combination with milnacipran 50 and 
25 mg after 8 days of repeated dosing was statistically significant; however 
no overall treatment effect was observed for the cold pressor test on day 8 
(p = 0.0777).
No treatment effects could be observed on iCpm on day 1 or day 8. 
Repeated milnacipran dosing did not affect any of the pain variables during 
the day 8 baseline measurements. 
Synergy between treatments was assessed in a separate analysis (Table 3). 
No synergy was observed when buprenorphine and milnacipran were 
administered together, either after a single dose or after repeated dosing. 
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Pharmacodynamic tests of psychomotor function, body 
stability, eye movements and pupil size 
The least squares means and the analysis results for pharmacodynamic 
tests for psychomotor function, body stability, eye movements and pupil 
size are presented in Table 4 and Figure 5. The pupil/iris ratio decreased 
in all treatment groups receiving buprenorphine both on day 1 and day 8, 
compared with milnacipran alone. On day 1, no differences were observed 
in pupil size between buprenorphine/milnacipran combination groups 
compared with buprenorphine alone. On day 8, the pupil/iris ratio was sig-
nificantly larger in the buprenorphine/milnacipran combination groups 
compared with buprenorphine alone after the first and second buprenor-
phine dose. Saccadic peak velocity and adaptive tracking performance 
decreased after receiving the buprenorphine combinations compared 
with milnacipran alone. Milnacipran did not significantly potentiate the 
decrease due to buprenorphine in saccadic peak velocity or adaptive 
tracking. A significant treatment effect was observed for the body sway 
measurements on day 8, and no significant differences between buprenor-
phine combinations versus buprenorphine alone were observed. Repeated 
milnacipran dosing only lead to an increase in pupil/iris ratio (0.071; 95% 
Ci 0.024-0.119; p = 0.0045; data not shown). No differences in eye movement, 
psychomotor function or body stability were observed during day 8 base-
line measurements. 
Pharmacokinetics
The sampling of buprenorphine and milnacipran was intended to cor-
roborate adequate exposure and to detect possible pharmacokinetic 
interactions when co-administered. Samples taken after the first buprenor-
phine infusion were not analysed as it was expected that these samples 
would be below the lower limit of quantification. After the second and third 
buprenorphine infusions the measured concentrations were as expected. 
The mean (population) expected buprenorphine concentrations values of 
the pharmacokinetic model that was used to define the study is shown with 
the actual concentrations achieved in the study also plotted on top (Figure 
6). The samples for buprenorphine near to the trough show a slight overes-
timation in comparison to the prediction by the model. Samples were also 
assayed for nor-buprenorphine but due to its low concentration in plasma, 
all determinations were below the lower limit of quantification (lloQ). 
Pharmacokinetic parameters for milnacipran on days 1 and 8 after adminis-
tration are shown in Table 5. Cmax and auC0₋last for milnacipran increased in 
a dose dependent manner. auC0₋last and Cmax were approximately two-fold 
greater on day 8 compared with day 1.
Safety
As shown in Table 6, all subjects experienced at least one treatment emer-
gent adverse event in each study period. The most reported adverse events 
were nausea, somnolence and vomiting. Vomiting occurred in all subjects 
receiving buprenorphine and the high dose of milnacipran. In subjects only 
receiving milnacipran 50 mg, only three subjects reported vomiting. 
discussion 
The study aimed to evaluate the possibility of potentiation or synergy of 
milnacipran, when co-administered with buprenorphine in evoked pain 
models in healthy subjects, both after single and multiple doses of milnacip-
ran. Furthermore, the interaction of both compounds on psychomotor 
function, body stability, eye movements and pharmacokinetic parameters 
and safety was investigated. 
Nociceptive tests and measurements of psychomotor function, body 
stability and eye movements following buprenorphine administration 
were consistent with the drug being a partial opioid receptor agonist. 
Buprenorphine showed a dose-response relationship indicative of anti-
nociception for the variables evaluated in the electrical, cold and pressure 
tests. Also, a decline in the performance was seen in the adaptive track-
er and saccadic eye movements after the buprenorphine administration, 
indicative of a mild level of sedation. Following single and repeated 
milnacipran (alone) administration, no changes were observed in the noci-
ceptive tasks or other pharmacodynamic measurements. No earlier studies 
were performed with milnacipran using pain models. Effects of other snris 
in human pain models have been reported before.8 Venlafaxine increased 
pain tolerance thresholds on single electrical stimulation and pain sum-
mation on repetitive stimulation; however in that study no differences on 
the cold pressor test and on a pressure pain paradigm could be observed. 
These reported findings could not be replicated in our study.
Acute, single doses of 25 and 50 mg milnacipran did not potentiate 
the antinociceptive effects or the effects on psychomotor function, body 
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stability, eye movements and pupil size when given in combination with 
buprenorphine 0.5, 1 and 3 μg kg⁻1 and the combination did not lead to 
synergy. In fact, for the repeated electrical stimulation task (repeated 
stimulus), the combination buprenorphine and milnacipran 50 mg lead 
to a lower ptt compared with buprenorphine alone. For the saccadic 
peak velocity, the addition of milnacipran 50 mg diminished the pharma-
codynamic effects (i.e. decrease in saccadic peak velocity) observed after 
buprenorphine alone, which may be an indication of less sedation. 
On day 8, after repeated administration of milnacipran 25 or 50 mg, no 
potentiation or synergy was observed between buprenorphine and mil-
nacipran on the pain variables or the other pharmacodynamic variables. 
A significant difference in the effect on cold pressor ptt was observed 
between buprenorphine alone and buprenorphine in combination with 
milnacipran 25 and 50 mg on day 8. However, no overall significant treat-
ment effect was observed for the cold pressor ptt on day 8. Moreover, no 
adjustments for multiple testing were applied in this study, so we consider 
this finding not sufficiently indicative of the existence of potentiation due 
to the combined treatment with buprenorphine and milnacipran. 
The pupil/iris ratio decreased after treatment with buprenorphine 
(with and without co-administration of milnacipran). However, after 8 days 
of treatment with milnacipran 50 mg, the pupil/iris ratio after the first and 
second buprenorphine infusion was significantly larger in the buprenor-
phine/milnacipran combination group compared with buprenorphine 
alone. Miosis after treatment with buprenorphine is a well-known effect 
of µ-opioid receptor agonists.26 Mydriasis after treatment with an snri has 
been shown before for duloxetine27 and for venlafaxine.28 Here, we show 
both the mydriasis effect of milnacipran after 8 days of treatment and the 
acute miosis effect of buprenorphine. The mydriasis effect of milnacipran 
could only be reversed at the highest dose of buprenorphine. 
In the cases that an overall treatment effect was observed for nociceptive 
endpoints on day 1, which were due to the effect of buprenorphine versus 
no buprenorphine, no overall treatment effects were observed on day 8. 
This may indicate that some tolerance may have occurred for the antinoci-
ceptive effects of buprenorphine or an increased (but not significant) effect 
of milnacipran after 8 days of treatment. In contrast, for the endpoints of 
psychomotor function, body stability and eye movements, when an over-
all treatment (buprenorphine) effect was observed on day 1, it was also 
observed on day 8.
Milnacipran has a modulating effect on serotonin (5-ht) and norepineph-
rine (ne) neurotransmitters. 5-ht and ne are involved in the modulation 
of endogenous analgesic mechanisms via inhibitory pain pathways in the 
central nervous system.29,30 Opioids can also influence descending pain 
pathways.31 Earlier, it was shown that buprenorphine is able to potentiate 
iCpm in a human pain model.32 This study was not able to replicate these 
findings. No effects were observed in conditioned pain modulation after 
treatment with milnacipran, buprenorphine or the combination of the two. 
In animal studies, milnacipran inhibited C-fibre-mediated nociceptive 
synaptic transmission in the spinal dorsal horn after the establishment of 
spinal long term potentiation in a neuropathic pain model.3 Furthermore, 
it has been shown that milnacipran reduces thermal and mechanical allo-
dynia in a rat model of neuropathic pain (chronic constriction injury of the 
sciatic nerve).33 However, in another model of neuropathic pain in mice 
(central post-stroke pain model), milnacipran did not affect mechanical 
allodynia thresholds.34 Co-administration of milnacipran with tramadol 
potentiated the antihyperalgesic effect of tramadol,6 which used chronic 
constriction injury model as a model for neuropathic pain. Considering 
the effects of milnacipran in several hyperalgesia models in animals, a pain 
model which is able to measure antihyperalgesia in humans would have 
been a valuable addition to this study.
Only models for acute pain were used in this study. It is important to note 
that differences exist between these models and clinical chronic (neuro-
pathic) pain. In a recent review Lötsch et al. suggested that hyperalgesia 
and electrical pain models might be used to predict clinical analgesia in 
neuropathic pain.35 However, several pharmacological (nmda receptor 
antagonists, tricyclic antidepressants, snris, gabapentin) and non-phar-
macological therapies (such as repetitive transcranial stimulation) that are 
used to treat neuropathic pain have shown contradictive results on acute 
pain models.36,37 Therefore, although we were not able to show potentia-
tion or synergy in these acute pain models, no conclusions can be drawn on 
a possible synergistic effect of milnacipran and buprenorphine in chronic 
pain conditions.
In the milnacipran pharmacokinetic analysis, Cmax and auC0₋last for mil-
nacipran increased in a dose proportional manner. Milnacipran showed 
accumulation after 7 days of treatment with 25 or 50 mg twice a day and 
resulted in higher concentrations in all subjects on day 8 of treatment. For 
buprenorphine, no formal pharmacokinetic analysis was possible due to 
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the sparse sampling. The plasma buprenorphine concentrations were in 
agreement with what was expected based on the simulation prior to the 
study.11 No pharmacokinetic interaction was observed between milnacip-
ran and buprenorphine.
This was a four-way crossover study and no study period with a double 
placebo was included. To assess synergy between buprenorphine and mil-
nacipran, the milnacipran only plus the buprenorphine only value minus 
the average pre-value over all occasions were calculated. The buprenor-
phine plus 25 mg milnacipran, the buprenorphine plus 50 mg milnacipran 
and the new values of milnacipran plus buprenorphine minus pre-values 
were analysed in a separate repeated measure mixed model. No synergy 
between these treatments could be observed, although it can be argued 
that the lack of a complete placebo profile made formal testing for synergy 
difficult. 
In conclusion, buprenorphine showed dose-dependent effects consis-
tent with its pharmacological profile; antinociception and a decrease in 
neurophysiological functions. Milnacipran alone did not affect any of the 
pain variables. The combination of both buprenorphine and milnacipran 
did not potentiate or show a synergistic effect on the pain models used in 
this study. No conclusions can be drawn on a possible synergistic effect of 
milnacipran and buprenorphine in clinical, chronic pain conditions.
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Table 1 
Least squares means for pharmacodynamic outcome measures.

















Electrical Repeat ptt (mA) 14.11 12.33 14.18 11.23 15.03 11.28 14.11 11.34
Electrical Single ptt (mA) 26.70 22.83 24.39 20.42 27.31 23.89 27.63 19.96
Pressure ptt (kPa) 57.79 54.81 58.44 43.45 59.93 53.68 51.99 46.63
Cold Pressor ptt (s) 29.16 28.37 26.56 19.54 32.14 32.23 25.25 26.44
Conditioned Pain Modulation (mA) 1.46 0.87 1.63 0.78 2.06 1.45 0.20 0.97
Left Pupil/Iris ratio 0.328 0.304 0.321 0.484 0.377 0.355 0.308 0.554
Saccadic Peak Velocity (deg s⁻1) 418.1 430.1 391.1 463.3 430.2 416.5 426.0 479.1
Body Sway (mm) 387.5 399.3 442.4 358.5 362.5 419.3 409.2 315.0
Adaptive Tracking (%) 20.42 19.67 19.34 26.86 22.07 22.95 21.39 27.18
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Table 2 
Estimates of difference, 95% confidence intervals and p-values for main contrasts for 
nociceptive measurements
















Overall 0.0016  0.5%  
(-12.1%, 14.8%) 
p=0.9418
 15.0%  
(1.9%, 29.7%) 
p=0.0258
0.2504 -6.1%  
(-38.4%, 43.0%) 
p=0.7310
 25.1%  
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Overall 0.0107 -8.6% 
(-22.2%, 7.3%) 
p=0.2357
 6.8%  
(-8.9%, 25.3%) 
p=0.3712
0.2552  1.2%  
(-31.5%, 49.4%) 
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p=0.4232














 5.7%  
p=0.5720








































 13.9%  
p=0.2615
 16.5%  
p=0.1797




After third  
bup
 0.1%  
p=0.9910





















































Overall 0.7541  0.16  
(-2.01, 2.33) 
p=0.8748
 0.76  
(-1.51, 3.02) 
p=0.4875


















 1.29  
p=0.4917






After third  
bup
 0.61  
p=0.7772







Estimates of difference, 95% confidence intervals and p-values for contrasts to assess 
synergy for the nociceptive measurements 



















12.08 11.07  -8.4% 
(-24.5%, 11.2%) 
 p=0.3504





21.42 19.49  -9.0% 
(-26.9%, 13.2%) 
 p=0.3493





28.53 23.89  -16.3% 
(-32.6%, 4.0%) 
 p=0.1020





53.13 51.95  -2.2% 
(-15.3%, 12.8%) 
 p=0.7377






1.52 1.37  -0.15  
(-2.33, 2.04)  
 p=0.8446
1.58 0.50 -1.08  
(-4.32, 2.17)  
 p=0.4718
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Buprenorphine and milnacipran interaction study in healthy suBjects
Table 5 
Plasma pharmacokinetic parameters for milnacipran
Day 1 Day 8
Parameter bup+mil-25 bup+mil-50 bup-p+mil-50 bup+mil-25 bup+mil-50 bup-p+mil-50
Cmax (ng ml⁻1) 46.9 ± 15.9 99.8 ± 37.2 105.2 ± 26.9 93.8 ± 11.7 188.3 ± 66.7 201.2 ± 41.6
Cthrough (ng ml⁻1) na na na 33.2 ± 8.7 61.2 ± 24.6 58.5 ± 14.2
tmax (h) 3.2 ± 0.8 3.2 ± 1.0 3.2 ± 0.6 2.6 ± 0.5 3.1 ± 1.0 1.8 ± 1.0
auC0₋last (ng hr ml⁻1) 318.1 ± 102.3 633.0 ±154.0 696.5 ±160.6 629.2 ± 94.1 1251.0 ± 306.7 1281.0 ± 178.6
 
Table 6 
Summary of treatment emergent adverse events (aes) by frequency [n(%)]. aes occurring 
more than 3 times within one treatment are reported.
bup+mil-25 bup+mil-50 bup+mil-p bup-p+mil-50
Preferred term n (%) n (%) n (%) n (%)
Number of subjects 
with at least one ae
9 (100%) 10 (100%) 10 (100%) 11 (100%)
Nausea 8 (88.9%) 7 (70.0%) 9 (90.0%) 8 (72.7%)
Somnolence 8 (88.9%) 8 (80.0%) 8 (80.0%) 7 (63.6%)
Vomiting 6 (66.7%) 10 (100.0%) 7 (70.0%) 3 (27.3%)
Dizziness 6 (66.7%) 7 (70.0%) 6 (60.0%) 2 (18.2%)
Fatigue 6 (66.7%) 7 (70.0%) 3 (30.0%) 3 (27.3%)
Headache 4 (44.4%) 6 (60.0%) 3 (30.0%) 4 (36.4%)
Feeling hot 2 (22.2%) 1 (10.0%) 3 (30.0%) 3 (27.3%)
Hot flush 3 (33.3%) 2 (20.0%) 2 (20.0%) 2 (18.2%)
Dry mouth 2 (22.2%) 2 (20.0%) 3 (30.0%) 1 (9.1%)
Pruritus 2 (22.2%) 2 (20.0%) 3 (30.0%) 1 (9.1%)
Table 4 
Estimates of difference, 95% confidence intervals and p-values for main contrasts for the 
neuropsychological measurements




























































Overall 0.0005  -27.0  
(-59.5, 5.4) 
 p=0.0986
 -39.0  
(-71.4, -6.6) 
 p=0.0204
0.0016 -4.2  
(-34.2, 25.7) 
 p=0.7682
 9.5  
(-20.7, 39.7) 
 p=0.5157
After first  
bup




 -27.8  
 p=0.1419
 -18.3  
 p=0.3328
After second  
bup
 -13.6  
 p=0.5629






After third  
bup
 -45.4  
 p=0.0840








Overall 0.3082 14.2% 












































Overall <.0001  -1.08  
(-3.62, 1.46) 
 p=0.3883
 -0.32  
(-2.90, 2.25) 
 p=0.7971
0.0014  -0.68  
(-3.42, 2.05) 
 p=0.6062
 -1.56  
(-4.38, 1.27) 
 p=0.2628










After second  
bup
 -0.15  
 p=0.9326
 -2.90  
 p=0.0964
 -0.07  
 p=0.9686
 -1.92  
 p=0.2982
After third  
bup
 -3.60  
 p=0.0527
 -0.88  
 p=0.6432
 -1.48  
 p=0.4280
 -3.22  
 p=0.0829
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Buprenorphine and milnacipran interaction study in healthy suBjects
figure 1 
Simulated plasma buprenorphine concentrations and electrical pain tolerance threshold 
(12h). Black solid line represents the mean (population) plasma concentration after three 
different 0.5-h buprenorphine infusions in a 70-kg subject: 0.5 (subtherapeutic), 1 (minimum 
therapeutic) and 3 (therapeutic) μg kg⁻1. Dotted line represents the pain tolerance threshold. 
figure 2 
Study period overview. 
PD, pharmacodynamic; t, time in hours.
figure 3 
Overview and sequence of pharmacodynamic tests.
�������� ����������� ����
Tourniquet calf: 0.5 kPa s-1, max 100 kPa 










Single stimulus 0.2 ms at 10 Hz 
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Single stimulus 0.2 ms at 10 Hz
Repeated stimuli: train of 5 stimuli at 2 Hz
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Study day
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Buprenorphine and milnacipran interaction study in healthy suBjects
figure 4 
Time course of the mean change from baseline profile in least squares means for the pain 
tolerance threshold for electrical stimulation (repeated stimulus) [a/b], pressure pain [C/d] 
and the cold pressor task [e/f] after administration of milnacipran (mil), buprenorphine  
0.5 µg kg⁻1(bup 1), buprenorphine 1.5 µg kg⁻1 (bup 2) and buprenorphine 3.0 µg kg⁻1(bup 3) 
on day 1 [left] and day 8 [right].
figure 5 
Time course of the mean change from baseline profile in least squares means for the left 
pupil/iris ratio [a/b] and saccadic peak velocity [C/d] after administration of milnacipran 
(mil), buprenorphine 0.5 µg kg⁻1(bup 1), buprenorphine 1.5 µg kg⁻1 (bup 2) and buprenor-
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Buprenorphine and milnacipran interaction study in healthy suBjects
figure 6 
Plasma buprenorphine concentrations and poppk buprenorphine model on day 8 of the  
trial. The circles represent the measured concentrations and the solid line represents the 
mean (population) buprenorphine concentration after three different 0.5-h buprenorphine 
infusions in a 70-kg subject: 0.5 (sub-therapeutic), 1 (minimum therapeutic) and  
3 (therapeutic) μg kg⁻1. Vertical lines at time points 0, 120 and 240 min represent the start  
of the infusion for buprenorphine. The horizontal discontinuous line represents the lower 
limit of quantification for buprenorphine. 
figure supplemenTary 1 
Consort Flowchart
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inTroducTion
Analgesics are among the most commonly used drugs in children. 
Paracetamol is the most frequently used on-label drug and among the most 
commonly used off-label drugs in this age group,1 because of its favorable 
safety profile. However, there is a wide discrepancy between the consump-
tion of this analgesic drug and knowledge of its pharmacokinetic (pk) and 
pharmacodynamic (pd) properties in children and adolescents. Pediatric 
studies investigating the effects of paracetamol and other analgesics on 
pain are limited, as they have mainly explored postoperative pain, for 
example after tonsillectomy, using pain scales.2,3 
In adults, nociceptive pain tests are used in clinical drug development to 
assess efficacy of analgesics. A battery of pain models previously showed 
distinct profiles in pain detection and tolerance between different class-
es of analgesic compounds.4 This battery can be used to benchmark new 
analgesics against established drugs in adults. It is already known that 
experimental pain thresholds and tolerance differ between children and 
adolescents. For instance, conditioned pain modulation, measured in an 
experimental setting, is lower in younger children (aged 8-11) compared 
to adolescents (aged 12-17 years).5 Also, up to the age of 14, pain threshold 
and endurance for the cold pressor task increases.6 Although no studies are 
available where a direct comparison is made between adults and children, 
it is unlikely that results from the adult population can be directly extrap-
olated to children or adolescents. Therefore, execution of a battery of pain 
tests in adolescents and children would be valuable in order to bridge the 
gap between the large consumption of analgesics and the limited informa-
tion about the pk and pd in this population.
The current study was performed to investigate the antinociceptive 
effect profile of the commonly used analgesic, paracetamol, in healthy ado-
lescents. Nociceptive effects of paracetamol were evaluated using a battery 
of evoked pain tests, which aims to assess as objectively as possible the 
levels of pain induced by a variety of painful stimuli, including electric stim-
ulation, pressure, cold and heat. Some of these tests have been previously 
used in children and adolescents, however not for the assessment of pain 
relief after paracetamol, and not in an integrated manner. We, therefore, 
also investigated the suitability of these tests to be applied in this group of 
adolescent subjects. As blood sampling is less desirable in adolescents in 
the setting of a non-therapeutic study, and may hinder recruitment, saliva 
samples were collected to measure paracetamol concentrations. 
absTracT
In this two-day crossover, randomised, double-blind, placebo-controlled 
study, 16 adolescents (aged 16 or 17 years) received 1000 mg paracetamol or 
placebo on separate days. Paracetamol concentrations were measured in 
saliva. Plasma paracetamol concentrations were predicted using measured 
saliva paracetamol concentrations and pharmacokinetic data taken from 
published studies. Nociceptive effects of paracetamol were evaluated using 
a battery of pain tests (heat thermode test, electrical stimulation test, pres-
sure stimulation test, cold pressor test and conditioned pain modulation) 
and analysed by mixed-model analysis of variance. A questionnaire was 
taken to evaluate study participation. The saliva Cmax of paracetamol was 
9.4 µg l⁻1, tmax 1.5 h and the half-life was 0.9 h; predicted plasma Cmax was 
14.5 µg l⁻1, tmax 0.6 h, and half-life 0.9 h. 1000mg paracetamol did not have 
a statistically significant effect on any of the pain parameters. 75% of the 
adolescents would participate again. Although no significant differences in 
pain detection and tolerance thresholds after paracetamol administration 
were observed, this study demonstrates that pain research using a compre-
hensive battery of evoked pain tests is feasible and acceptable to healthy 
adolescents. As induced pain is likely to be used increasingly in children 
and adolescents given the need for pediatric research on analgesics, gain-
ing knowledge and experience in this field is an important step forward.
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meThods
The Central Committee on Research involving Human Subjects (CCmo, The 
Hague, The Netherlands) approved the study protocol. The study was con-
ducted according to the Dutch Act on Medical Research Involving Human 
Subjects (Wmo) and in compliance with Good Clinical Practice (iCh-gCp) 
and the Declaration of Helsinki. The trial was registered in the European 
Union Clinical Trials Register (2011-005086-20). 
Study design
This was a randomised, double-blind, placebo-controlled, two-way cross-
over study. All subjects received 1000 mg paracetamol or placebo on 
separate days. Capsules were taken with water and administration was 
observed for compliance. This dose was chosen as oral paracetamol has 
clinically proven analgesic effects with oral doses of 500 to 1000 mg in 
adults.7 The washout period between study days was at least one day and 
paracetamol was administered at the same time of day in all subjects to 
avoid confounding effects from circadian variability. As pk sampling was 
done in saliva, paracetamol was administered as a capsule to prevent oral 
contamination. Capsules containing 500 mg paracetamol or placebo were 
prepared and provided by the pharmacy of the Leiden University Medical 
Center (Leiden, The Netherlands) according to gmp standards. 
Subjects were not allowed to consume alcohol for 24 h and consume 
caffeine-containing drinks or smoke for 12 h before and during study days. 
Subjects were to refrain from heavy exercise from 48 h before and during 
study days and should have a regular day-and-night rhythm prior to study 
days. A standardised light breakfast was offered 1 h pre-dose and a stan-
dardised lunch was offered at 3.5 h after paracetamol administration. Water 
was allowed ad libitum. Subjects were confined to the clinical research unit 
for approximately 6.5 h after paracetamol administration. At the end of the 
study a questionnaire was taken to evaluate the way how adolescents expe-
rienced study participation. 
Subjects
Healthy male and female subjects aged 16 and 17 years were included. The 
subjects were not allowed to smoke more than 4 cigarettes per day or 
use more than 14 units alcohol per week. After the informed consent was 
signed by the subject and parents/legal guardians, subjects were medi-
cally screened within 3 weeks prior to study participation and excluded if 
relevant clinical abnormalities were found. Subjects indicating nociceptive 
tests intolerable at screening or achieving tolerance at >70% of maxi-
mum input intensity for any nociceptive test were also excluded. Subjects 
were not allowed to participate in case of liver disease, renal disease, cur-
rent conditions that could affect sensitivity to cold (e.g., atherosclerosis, 
Raynaud’s disease, urticaria, hypothyroidism) or pain (e.g., paraesthesia, 
etc.), a previous allergic reaction to paracetamol or medical history of 
fainting or syncope without a known cause. Use of medications and agents 
known to affect paracetamol metabolism and/or effect were not allowed. 
Alcohol breath test and urinary drug and pregnancy tests were performed 
during screening and prior to each test day. Use of over-the-count-
er analgesic medications was not allowed within 3 days of nociceptive 
assessments. 
Pharmacokinetics
To minimise the burden on study subjects, saliva paracetamol concen-
trations were measured as a surrogate marker for plasma or target site 
concentrations. Saliva was collected in polyester Salivette tubes (Sarstedt, 
Numbrecht, Germany) prior to paracetamol administration (to ensure 
compliance) and every 30 min (until 2 h), at 3 h and at 5 h after adminis-
tration. Saliva sampling time points after administration of paracetamol 
were determined based on a pk-model using data available in the litera-
ture for orally and intravenously administered paracetamol in serum8⁻10 
(see Figure 1). Saliva concentrations were assumed to be a fraction of the 
serum concentrations.11 After stimulated collection (by moving swab 
through mouth), swabs were centrifuged as soon as possible for 10 min 
(4°C, 2000G). The supernatant was frozen and stored at a maximum tem-
perature of -20°C. At the end of the study day, samples were stored in a 
freezer at -80°C. 
Analytical assay 
Saliva paracetamol concentrations were determined using a commer-
cially-available enzymatic assay (Cambridge Life Sciences Ltd., Ely, uk). 
In short, the method is based on the hydrolysis of paracetamol by aryl 
acylamidase yielding acetate and p-aminophenol, the latter reacting with 
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o-cresol in the presence of ammoniacal copper sulfate to produce a blue 
color. The assay is specific for the parent compound and does not detect 
paracetamol metabolites. The limit of quantification was 1.5 mg l⁻1 with 
50 µL sample volume. Coefficients of variation for the intra-assay preci-
sion varied from 1.0% – 2.4% and for the inter-assay precision from 1.4% 
– 2.6%.
Pharmacodynamics
An extensive nociceptive test battery was incorporated to provide infor-
mation on nociceptive detection and tolerance thresholds of an integrated 
range of tests measuring different modalities of nociception that could be 
affected by paracetamol.12 Pharmacodynamic measurements were per-
formed at baseline, hourly (until 3 hours) and 5 h after administration of 
paracetamol or placebo. Measurements were performed in a quiet room 
with ambient illumination with only one subject in the room per ses-
sion. During screening, subjects were familiarised with the experimental 
procedure and given a practice session on the tests to minimise learning 
effects during test days. The tests were performed as described below. Pain 
intensity was measured continuously (beginning when the first stimulus 
was applied until the predetermined end of the test) for each nociceptive 
test. Equipment was programmed to cease giving stimuli if pain intensity 
reached the maximum possible score. Continuous pain intensity was mea-
sured using an electronic visual analogue scale (evas) ranging from 0 (no 
pain) to 100 (most intense pain tolerable). For the heat thermode test the 
heat pain detection threshold (pdt) and the pain tolerance threshold (ptt) 
were assessed. For the electrical stimulation test, the pressure stimulation 
test and the cold pressor test, pdt and ptt were calculated. In addition, for 
the cold pressor test, area above the pain intensity-stimulation-time curve 
(aaC) was calculated; for all other tests, area under the pain intensity-stim-
ulation curve (auC) was calculated. 
heaT Thermode TesT
The tsa-ii Neurosensory Analyzer (Medoc Ltd., Ramat Yishai, Israel) is a 
computerised device that is designed to administer thermal heat or cold 
stimuli via a thermode to a part of the subject’s body. In this study, a ther-
mal stimulus was administered to the volar side of the dominant lower 
arm with an intensity that gradually increased at a constant rate. First the 
subject halted the stimulus when the pdt was reached, then the subject 
halted the stimulus when the ptt was reached. Both measurements were 
repeated three times. 
elecTrical sTimulaTion TesT
For cutaneous electrical pain, Ag-AgCl electrodes (3M Red-Dot™) were 
placed on cleaned, scrubbed, and if required, shaved skin, 10 cm distal from 
the patella overlying the tibia. Electrical resistance between electrodes was 
to be less than 2 kW. The electrical stimulus was delivered by a comput-
er-controlled constant current stimulator (ds5, Digitimer, Cambridge, uk).
For the single stimulus, a method was used which was adapted from 
methods previously described13,14 (10 Hz tetanic pulse with a duration of 
0.2 ms); current intensity increased from 0 mA in steps of 0.5 mA·s⁻1 (cutoff 
50 mA). The pain intensity for each stimulation was measured using the 
evas slider, until pain tolerance threshold was reached or a maximum of 
50 mA was reached. The delta electrical stair was used as a measure for 
inhibitory conditioned pain modulation (iCpm).
pressure sTimulaTion TesT
The method of mechanical pressure pain induction was based on meth-
ods previously described, and was shown to primarily assess nociception 
generated from the muscle with minimal contribution by cutaneous noci-
ceptors.15,16 Briefly, an 11 cm wide tourniquet cuff (vbm Medizintechnik 
GmbH, Sulz, Germany) was placed over the gastrocnemius muscle with a 
constant pressure rate increase of 0.5 kPa·s⁻1. The pneumatic pressure was 
increased until the subject indicated maximum pain tolerance using the 
evas slider, or a maximum pressure of 100 kPa was achieved, at which point 
the device released pressure to the cuff.
cold pressor TesT
The method of cold pressor pain was based on the methods previously 
described17,18 and is the most commonly used test to induce inhibitory 
conditioned pain modulation (iCpm, also known as ‘diffuse noxious inhibi-
tory control’).19 Subjects placed their non-dominant hand into a water bath 
(minimal depth 200 mm) at 35 ± 0.5°C for 2 min. At 1 min 45 s a blood pres-
sure cuff on the upper-arm was inflated to 20 mmHg below resting diastolic 
pressure. At 2 min the subject then moved that hand from the warm water 
bath, directly into a similar sized bath at 1.0 ± 0.5°C. The subjects were 
instructed to indicate when pain detection threshold was reached (first 
change in sensation from cold non-painful to painful) as well as the pain 
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intensity, by moving the evas slider. When pain tolerance or a time limit 
(120 s) was reached, subjects were instructed to remove their hand from 
the water, at which point the blood pressure cuff deflated.
condiTioned pain modulaTion 
iCpm is the activation of the pain-modulatory mechanism, as part of the 
descending endogenous analgesia system.19 The degree of iCpm was 
assessed by comparing the electrical pain thresholds before and within 5 
min after the cold pressor test.
Statistical analysis 
This was an exploratory study in adolescents. The aaC of the cold pres-
sure test was used for the power analysis. This variable had the least 
intra-subject variability both within and between visits compared to other 
parameters of the different pain tests included in the battery of evoked pain 
tests (in-house data). In order to estimate the sample size for a study that 
has 80% power of detecting a difference in means of 5.5% in vas% sec⁻1of 
the cold aaC as observed in previous studies in adults at Chdr, a sample 
size of 12 was calculated (two-sided test, alpha = 0.05) for a balanced design.
Pharmacodynamics 
The pharmacodynamic endpoints were analysed by mixed-model analyses 
of variance (using sas proC mixed, sas version 9.1.3) with subject, subject 
by treatment and subject by time as random effects, with treatment, test day, 
time and treatment by time as fixed effects, and the average baseline value 
as covariate. ptt and pdt variables were log transformed prior to analysis 
to correct for the expected log-normal distribution of the data. Analysis was 
performed on log-transformed data. Delta electrical stairs ptt, pdt and 
auC were calculated as the difference between the electrical stair measure-
ment before and after the cold test (after minus before). The measurement 
after the cold test was not used for the analysis of the electrical stairs vari-
ables, only to calculate the delta electrical stairs. Contrasts were estimated 
within the overall treatment effect and contrasts between treatments over 
300 min were calculated. The statistical null hypothesis in this study was 
‘there is no difference between paracetamol and placebo’ (alpha=0.05, 
two-sided). No adjustments for multiple comparisons were employed. 
 
Pharmacokinetics
Pharmacokinetic analysis of saliva paracetamol concentrations was initial-
ly performed using a non-compartmental model approach. The mean peak 
concentration (Cmax) and the time to the peak concentration (tmax) were 
recorded as observed. In addition, the area under the saliva concentra-
tion-time curve from time zero to the time of the last sample (auC0₋last) was 
calculated using the trapezoidal rule. Calculations were performed using R 
v2.12.0 (R Foundation for Statistical Computing, Vienna, Austria).
Paracetamol plasma concentrations were expected to more closely 
resemble central exposure than saliva concentrations. In order to estimate 
central exposure of paracetamol, a pk model that correlated unobserved 
plasma and saliva concentrations was developed using literature data 
in nonmem© v7.2 (Icon Development Solutions, Ellicott City, Maryland, 
United States). The basis for the pk model was a four-compartmental 
model originally developed by Wang et al.,20 which was built on data only 
containing patients whom were rectally dosed. To allow adequate oral 
absorption prediction, absorption parameters (first order absorption con-
stant, absorption lag time, and respective variabilities) for oral dosing were 
derived from Owens et al.21 Finally, data from Wade et al.22 regarding the 
correlation between plasma and saliva concentrations were used to extend 
the model based on the Wang and Owens data with an additional saliva 
compartment. The complete model consisted of one dosing compartment, 
one central plasma compartment, and three peripheral compartments 
(with one describing the saliva concentrations). Following estimation of 
saliva compartment parameters, simulations of plasma paracetamol con-
centrations were performed using individual parameter values.
resulTs
Subjects
None of the screened subjects were excluded because they indicated 
nociceptive tests as intolerable. A total of 12 adolescent subjects (5 males, 
7 females) aged 16 or 17 years (mean 16.8 years) were enrolled between 
December 2011 and August 2014. All adolescent subjects attended pre-univer-
sity secondary education (vWo, Voortgezet Wetenschappelijk Onderwijs). 
None of the subjects discontinued the study. Subjects had a median weight 
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of 64.5 kg (range, 60-90 kg) and a mean height of 1.75 m (range, 1.62-1.90 




1000 mg paracetamol did not have a statistically significant effect on any of 
the pain test parameters (Table 1). A non-significant increase in pdt was 
observed during the heat thermode test (2.5%°C; 95% Ci -0.7-5.7%; p=0.11; 
Figure 2) and the pressure stimulation test (17.5% kPa; 95% Ci -1.2%, 39.7%; 
p=0.07; Figure 3) following paracetamol administration. In addition, a 
non-significant decrease occurred in the auC of the pain pressure test fol-
lowing paracetamol administration (-477 kPa*%; 95% Ci -1005.63 – 52.57; 
p=0.07; Figure 4). 
Pharmacokinetic results 
Individual concentration time plots for the saliva paracetamol concentra-
tions are shown in figure 5. Secondary pharmacokinetic parameters for 
paracetamol based on predicted plasma and saliva concentrations over 
time by the constructed literature model taking into account individual 
saliva concentration data are shown in Table 2. In saliva the Cmax was 9.4 
µg l⁻1 (7.4–12.2), the tmax 1.5 h (1-3) and the half-life was 0.9 h (0.4-1.6). The 
predicted plasma Cmax was 14.5 µg l⁻1 (8.5-28.7), tmax 0.6 h (0.3-2.1), and 
half-life 0.9 h (0.4-1.6). Median terminal half-life and volume of distribution 
as determined by the non-compartmental analysis were 2.2 h and 70.4 l 
respectively. 
Questionnaire
The results of the evaluation questionnaire are listed in Table 3. All subjects 
enjoyed participating in the study. 75% of the adolescents participating in 
the trial would participate again. 50% of the subjects indicated the cold 
pressor pain test as most painful. The pain test experienced as least painful 
was the pressure test. 
discussion
This is the first reported study in which the pharmacokinetics and phar-
macodynamics of paracetamol in adolescents have been explored. An 
extensive nociceptive test battery was used to provide information about 
different modalities of nociception that could potentially be affected by 
paracetamol. Saliva samples were collected to measure paracetamol con-
centrations. Although no significant differences in pain detection and 
tolerance thresholds after paracetamol administration were observed, we 
demonstrated that pain research using a battery of nociceptive tests is fea-
sible and acceptable in adolescents.
The prevalence of moderate to severe pain in hospitalised children 
remains high and adolescents especially are at risk of moderate to severe 
pain.23 Children and adolescents are particularly prone to unfair exclu-
sion from pain research.24 Fortunately, some progress is being made in 
pediatric pain research. For example, recently published preliminary 
data illustrated the utility of pupillometry as a non-invasive method to 
objectively quantitate pain response/intensity in children.25 In general, it 
is ethically preferable to avoid causing pain for research purposes, espe-
cially in children. However, there are some important questions in pain 
and analgesia research that cannot be answered without an evoked pain 
stimulus.26 Pain models offer important control over the environment and 
provide standardisation of nociceptive stimuli, thereby enabling a more 
rigorous exploration of individual differences and/or the environmental 
factors that can affect the subjective pain experience. As the induction of 
pain can lack direct benefit, it is usually not deemed appropriate for use 
in either therapeutic or non-therapeutic research. However, as the factors 
that can affect the relationship between drug concentration and pain relief 
can differ between children and adults, findings obtained from adult stud-
ies may not necessarily translate directly to children or even adolescents. 
In addition to potential developmental changes in endogenous analgesic 
mechanisms and developmental modulation,27,28 placebo-responses may 
be more robust3 and a child’s thoughts and attitudes regarding pain can 
change with age, thereby contributing to more intense feelings of pain 
during adolescence than in childhood.29 As our current understanding of 
age-dependent effects and side-effects between children, adolescents and 
adults is based largely on data collected from animal studies, evaluating 
age-dependent differences in pk and pd in pediatric clinical trials will be an 
important step forward. Therefore, it is necessary to include adolescents 
and children in studies where analgesics and pain are being investigated. 
Paracetamol serum and saliva concentrations were compared pre-
viously, with variable study outcomes. Rittau and colleagues compared 
paracetamol concentrations using venous and capillary blood and saliva 
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sampling.30 They reported saliva collection as a reliable sampling method 
for the evaluation of paracetamol’s plasma pk, as was confirmed by a study 
performed in patients with paracetamol concentrations in the toxic range.31 
Another study reported significant correlations between serum and saliva 
pk, but with a poor agreement between the two matrices.32 In our study, 
in which only the paracetamol concentrations in saliva were measured, 
we found that these concentration data were well suitable to describe the 
pharmacokinetics in adolescents. Previous studies reported that, despite 
a difference in paracetamol metabolism between children and adults, the 
half-life and volume of distribution are almost identical.33 In line with these 
previous findings, the median terminal half-life (2.2 h) and volume of distri-
bution (70.4 L) that were observed in our study are in agreement with the 
reported kinetics of paracetamol in adults and children.33
1000 mg oral paracetamol did not affect the tests using electrical, ther-
mal, pressure or cold stimuli. In adults, the cold-pressor method has been 
used most frequently to measure pain reduction after paracetamol.34⁻36 
Oral paracetamol has dose-related analgesic activity using the cold-pres-
sor test, with no effect of doses lower than 1000 mg.34 Using electrical and 
thermal stimuli, oral doses of paracetamol of 1000 mg or lower could not 
be discriminated from placebo.37⁻39 In our study, the lack of (significant) 
effects on these pain stimuli may be due to the (low) dose of paracetamol 
administered, or the insensitivity of these tests for detecting the effects 
of paracetamol. The median weight in our study was relatively low (64 
kg), and the weight range was relatively wide (60-90 kg); as a result, the 
dose per kg was relatively variable. Intravenous paracetamol exerted 
dose-dependent antinociceptive effects up to 2000 mg in response to 
selective transcutaneous electrical stimulation40,41 and intravenous 
infusion of 650 mg paracetamol led to pain reduction with sustained anti-
hyperalgesic effects.42 Therefore, the different time course of paracetamol 
concentrations after intravenous administration may account for differ-
ences in paracetamol effects on electrical stimuli after intravenous versus 
oral administration. Paracetamol also previously showed an effect on pain 
detection threshold on laser-induced pain in adults.43,44 As laser-induced 
pain tests has the potential to cause skin burns this test was not applied 
in our study. An alternative explanation for the lack of a significant anti-
nociceptive effect in this study may be the larger intra-subject variability 
both within and between visits in adolescents. Furthermore, in some of 
the pain tests an increase in pain detection or tolerance threshold was also 
observed in the placebo group. It is suggested that placebo responses are 
higher in children and adolescents, but that drug responses are equal.45 
This could be a good explanation for lack of a significant difference between 
placebo and paracetamol in our study. Finally, the lack of a significant effect 
of paracetamol may be in part be explained by developmental differenc-
es in pain systems; for example, paracetamol may have positive effects on 
the serotonergic descending inhibitory pathways46 and recent research 
suggests that central pain inhibitory mechanisms develop with age, as was 
demonstrated by a greater inhibitory conditioned pain modulation in ado-
lescents compared to younger children.5
We expect that evoked pain tests will be used increasingly in children 
and adolescents. Anesthetics and analgesics are among the most com-
monly cited therapeutic subgroups with a pediatric research need on 
the European Medicines Agency Needs Lists.47 As adolescents are rarely 
waived from pediatric development under the Pediatric Regulation (recent 
European legislation facilitating development of pediatric medicines), 
this age group will likely be involved in more studies in the near future.48 
Therefore, additional knowledge and experience should be gained in the 
pediatric field of evoked pain modalities. The current study demonstrates 
that pain research using a comprehensive battery of nociceptive tests is fea-
sible and acceptable to healthy adolescents. It can also assist in designing 
future clinical studies with analgesics using nociceptive tasks in adoles-
cents and children.
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Table 1
Pharmacodynamic outcome parameters for a single dose of 1000 mg paracetamol or placebo 
in healthy adolescents.
Contrasts LS Means change from baseline














(-12.9%, 36.3%)  p=0.4088
-5.7% 2.7%
Electrical Stair auC 
(mA*%)
92.55 
(-206, 390.7)  p=0.4977
-310.83 -218.28
Electrical Stair pdt 
(mA)
-12.7% 
(-28.3%, 6.3%)  p=0.1544
44.3% 26.0%
Electrical Stair ptt 
(mA)
 0.9% 
(-10.9%, 14.2%)  p=0.8759
9.2% 10.2%
Delta Electrical Stair auC 
(mA*%)
17.95 
(-180, 215.4)  p=0.8349
48.28 66.23
Delta Electrical Stair pdt 
(mA); iCpm
0.303 
(-1.63, 2.234)  p=0.7308
-0.439 -0.136
Delta Electrical Stair ptt 
(mA)
-.505 
(-1.80, 0.793)  p=0.3993
-0.271 -0.776
Pressure auC  
(kPa*%)
 -477 
(-1006, 52.57)  p=0.0726
-125.34 -601.87
Pressure pdt  
(kPa)
 17.5% 
(-1.2%, 39.7%)  p=0.0656
11.4% 30.8%
Pressure ptt  
(kPa)
 3.4% 
(-11.6%, 20.9%)  p=0.6460
6.2% 9.7%
Heat pdt  
(°C)
 2.5% 
(-0.7%, 5.7%)  p=0.1096
-1.4% 1.0%
Heat ptt  
(°C)
 -0.1% 
(-2.4%, 2.3%)  p=0.8946
0.3% 0.2%
Table 2 
Secondary pharmacokinetic parameters for paracetamol based on predicted plasma and 
saliva concentrations over time by the constructed literature model taking into account 
individual saliva concentration data.
Plasma Saliva
Parameter Median 95% CI Median 95% CI
Cmax (mg l⁻1) 14.5 8.5-28.7 9.4 7.4-12.2
tmax (h) 0.6 0.3-2.1 1.5 1-3
Halflife (h) 0.9 0.4-1.6 0.9 0.4-1.6
auC0₋6h (mg h l⁻1) 38.2 30.7-51.1 30.9 23.3-43.4
Table 3 
Subject evaluation questionnaire
Question Response (n [%])
Did you enjoy participation? Not at all (0 [0%])
Not really (0 [0%])
Neutral (0 [0%])
Reasonably nice (9 [75%])
Nice (3 [25%])
How did you experience saliva sampling? Very bothersome (0 [0%])
A bit bothersome (2 [16.7%])
Neutral (1 [8.3%])
Not that bothersome (3 [25%])
Not bothersome at all (6 [50%])
Which test did you experience as least bothersome? Heat pain test (4 [33.3%])
Electrical stimulation test (1 [8.3%])
Pressure stimulation test (6 [50%])
Cold pressor test (1 [8.3%])
Which test did you experience as most bothersome? Heat pain test (0 [0%])
Electrical stimulation test (4 [33.3%])
Pressure stimulation test (0 [0%])
Cold pressor test (8 [66.7%])
Which test did you experience as least painful? Heat pain test (1 [9.3%])
Electrical stimulation test (2 [18.2%])
Pressure stimulation test (8 [72.7%])
Cold pressor test (0 [0%])
Which test did you experience as most painful? Heat pain test (1 [8.3%])
Electrical stimulation test (4 [33.3%])
Pressure stimulation test (1 [8.3%])
Cold pressor test (6 [50%])
Would you participate again? Yes (9 [75%])
No (1 [8.3%])
Not sure (2 [16.7%])
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figure 1 
Expected plasma paracetamol concentration after a single 1000 mg oral dose based on three 
PK-models from literature. The solid line represents Ogungbenro (2010), the dotted line 
Anderson (2005), and the dashed line Wurthheim (2005). The vertical lines represent the 
saliva sampling times used in this study.
figure 2 
Heat pain detection threshold change in least squares mean from baseline profile with 95% 
CI as error bars.
figure 3 
Pressure pain detection threshold change in least squares mean from baseline profile with 
95% CI as error bars.
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Individual plots of paracetamol concentrations in saliva
chapTer vii
Pharmacokinetics and pharmacodynamics of multiple doses 
of BG00010, a neurotrophic factor with anti-hyperalgesic 
effects, in patients with sciatica
British Journal of Clinical Pharmacology 2016;82: 108-117.
P. Okkerse, J.L. Hay, E. Versage, Y. Tang, G. Galluppi, B. Ravina, A. Verma, L. Williams, E. Aycardi, 
G.J. Groeneveld
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bg00010 is a protein in the glial cell line-derived neurotrophic factor (gdnf) 
family. It is a selective ligand for the gdnf family receptor alpha-3 (gfrα3) 
co-receptor that normalises cellular changes resulting from damage or 
disease, and potentially alleviates neuropathic pain. The main objectives 
of this study were to evaluate the pharmacokinetic and safety profiles and 
to determine the effects on pain of ascending doses of intravenous injec-
tions of bg00010 in patients with sciatica. This was a randomised, blinded, 
placebo-controlled multiple-dose study in subjects with sciatica. In Part i 
(16 patients), four iv dose levels were examined (50, 150, 400, 800 µg kg⁻1) 
and in Part ii (12 patients), three dose levels were examined (400, 600 and 
1200 µg kg⁻1). Safety and efficacy assessments were used as endpoints. 
The bg00010 concentration-time data indicated relatively low inter-pa-
tient variability and there was a dose-dependent (not dose-proportional) 
increase in serum exposure from 150 to 1200 µg kg⁻1. The effective half-life 
was between 40 and 60 h. The most frequently occurring adverse events 
(aes) reported by patients receiving bg00010 were headache (67-83%), 
feeling hot (50-100%) and pruritus (42-67%). Most aes were mild; no seri-
ous aes, or aes leading to discontinuation occurred. Higher dose regimens 
of bg00010 resulted in greater pain reduction than placebo or lower dose 
regimens, although a clear dose-response relationship was not seen. The 
pharmacokinetic profile of bg00010 was characterised by low intra-patient 
variability. These data from a small sample suggest that bg00010 may have 
a benefit for patients with sciatica. 
inTroducTion
bg00010 (neublastin, artemin) is a glial cell-derived neurotrophic factor 
(gdnf) family member1 that can act as a survival factor for sensory and 
sympathetic neurons. bg00010 is a selective ligand for the gdnf family 
receptor alpha-3 (gfrα3) co-receptor. The interaction of bg00010 with 
gfrα3 on nociceptive sensory neurons activates downstream signalling 
to normalise damage- or disease-induced cellular changes and potentially 
alleviate neuropathic pain. gfrα3 expression is highly restricted to small 
dorsal root ganglion (drg) sensory neurons, reducing the likelihood of 
unintended side effects.2
Preclinical data from surgical and chemical nerve-injury models demon-
strate that bg00010 attenuates pain-related behaviours and normalises the 
neurochemical status of injured small drg neurons without loss of neu-
ronal or axonal function or integrity. Along with promoting re-entry of 
sensory fibres into the spinal cord and re-establishing synaptic function 
after crush injury, bg00010 can promote recovery of simple and complex 
behaviours in preclinical models.3⁻5 bg00010 is being developed as a first-
in-class molecule for the treatment of neuropathic pain.
Neuropathic pain results from lesions or disease affecting the peripheral 
or central somatosensory nervous system. Neuropathic pain is especially 
problematic because of its severity, chronicity and resistance to simple 
analgesics. Affecting 2–3% of the population, neuropathic pain is costly to 
the healthcare system, personally devastating for patients,6 and can sub-
stantially impair health-related quality of life.7
Sciatica is caused by spinal nerve root compression, often due to lum-
bar disc prolapse, and is associated with back pain radiating to the leg, 
occasionally accompanied by neurological deficit.8 Sciatica is common, 
with reported lifetime incidence of 13–40%9 and an annual incidence of 
1–5%, peaking in the fifth decade of life.10 Most patients with acute sciatica 
respond to conservative symptom management, with symptom resolution 
over weeks to months, although some require surgical decompression of 
the affected nerve root. Nevertheless, 10–40% of patients will develop a 
chronic pain syndrome.11 Common pharmacotherapies for chronic neu-
ropathic pain include tricyclic antidepressants, serotonin-norepinephrine 
reuptake inhibitors, calcium channel α2-δ ligands, topical lidocaine, opioid 
agonists and capsaicin. For sciatica, epidural steroid injections have been 
used for decades despite inconclusive efficacy data.9 Treatment remains 
challenging, as many patients do not experience sufficient relief.12 A 
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significant unmet medical need exists for a therapeutic agent with an 
acceptable safety profile to provide sustained neuropathic pain relief.
In a previous single-centre study (nCt00961766), bg00010 was adminis-
tered to 48 patients with sciatica as single intravenous (iv; 0.3–800 µgkg⁻1) 
or subcutaneous (50 µg kg⁻1) doses.13 The results suggested nearly linear 
pharmacokinetics (pk) over the tested dose range. The most frequently 
reported adverse events (aes) were feeling hot, pruritus, headache and 
rash. In this second study of bg00010 in humans, the main objectives were 
to evaluate the pk, safety and pharmacodynamics of three iv injections of 
bg00010 given as two fixed dosing schedules.
meThods
Patients
Eligible patients were aged 18–85 years with a diagnosis of unilateral 
sciatica, including pain radiating down the leg following a dermatome, sug-
gesting L4, L5, or S1 nerve root involvement, with symptoms present for 
≥3 months prior to the Screening Visit and pain rated at ≥40 mm on a 100 
mm visual analogue scale (vas) of the Dutch translation of the Short-Form 
McGill Pain Questionnaire (sf-mpQ)14 at Screening and Baseline Visits.
Key exclusion criteria included: history of severe pain or signs/symp-
toms of peripheral neuropathy (other than that caused by sciatica) during 
the 3 months prior to the Screening Visit; major surgery within the 3 months 
prior to the Screening Visit or planned sciatica surgery within 6 months 
of the Screening Visit; current generalised myalgia; history of severe 
allergic or anaphylactic drug-related reaction; history of malignancy or 
clinically relevant allergy; and/or cardiac, endocrine, haematologic, hepat-
ic, immunologic, metabolic, urologic, pulmonary, neurologic (not related to 
sciatica), dermatologic, rheumatic/joint, psychiatric, renal and/or other 
major disease.
Patients were allowed treatment with a selective serotonin reuptake 
inhibitor, a serotonin noradrenaline reuptake inhibitor, gabapentin, or a tri-
cyclic antidepressant if doses were stable for 4 weeks prior to the Baseline 
Visit and pregabalin if the dose was stable for 1 week prior to the Baseline 
Visit. Doses of other prescription medications and/or over-the-counter 
products were to have been stable for 2 weeks prior to the Baseline Visit. 
Previous participation in a study with neurotrophic factors and participation 
in a study with another investigational drug or approved therapy for inves-
tigational use within 3 months prior to the Baseline Visit was not allowed. 
Study design and treatment
This was a single-centre, randomised, blinded, placebo-controlled, 
serial-cohort, multiple-dose ascending study that examined two dose 
schedules (ClinicalTrials.gov nCt01405833). The study was approved by the 
Medical Ethics Committee (bebo Foundation, Assen, The Netherlands) and 
all patients gave written informed consent. ‘bg00010’ is specific for the iso-
form of the protein used in this study (50:50 mix of 103 and 104 amino acid 
isoforms). The generic names ‘artemin’ and ‘neublastin’ cover all forms 
of the protein (104, 113, 125 and full length) and do not accurately describe 
bg00010. All other drug/target nomenclature is consistent with the British 
Journal of Pharmacology’s ‘Guide to Receptors and Channels’.15 Since 
bg000010 is intravenously administered, less frequent dosing is preferable, 
and unpublished non-clinical data suggested that less frequent administra-
tion with higher doses and more frequent administration at lower doses 
could be explored clinically, providing the rationale for studying two dos-
ing schedules. In Part i (Cohorts a–d), patients received bg00010 (50, 150, 
400, or 800 μg kg⁻1) or placebo once weekly for 3 weeks. In Part ii (Cohorts 
e–g), patients received bg00010 or placebo dosed every 48 h. The starting 
dose in Part ii was to be no more than 400 μg kg⁻1 and at least one dose level 
below the maximum tolerated dose (mtd) established with the once-week-
ly schedule.
Patients were enrolled sequentially, cohort by cohort. For each cohort, 
patients were randomised (three patients to bg00010 and one to place-
bo) to receive three iv administrations of study treatment. Following the 
completion of treatment for each cohort, the data safety review commit-
tee (dsrC) determined if it was appropriate to escalate to the next planned 
dose level. If none of the three bg00010-treated patients within a cohort 
experienced a treatment-related dose-limiting toxicity (dlt; defined as 
all bg00010-related serious aes [saes] and bg00010-related aes coded 
as severe by the principal investigator), dose escalation proceeded to 
the next cohort. If one of three bg00010-treated patients experienced 
a treatment-related dlt, three additional patients were to be enrolled at 
that dose level and escalation was to continue if there were no other dlts 
among the additional bg00010-treated patients. If two or more bg00010-
treated patients experienced the same or a similar treatment-related dlt, 
dosing was to stop and the previous dose level was to be considered the 
mtd. If patients experienced dlts that were not the same or similar in 
nature, the cohort could be expanded or dosing stopped, as recommended 
by the dsrC.
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The primary objective of the study was to evaluate the pk and safety of 
three iv injections of bg00010 in two fixed dosing schedules: weekly and as 
frequently as every 48 h (no more than three times in 1 week). Secondary 
objectives were to explore the potential of bg00010 to reduce pain follow-
ing multiple-dose administration (as measured by a Numerical Rating Scale 
(nrs) and the sf-mpQ vas) and to explore the repeated-dose immunogenic-
ity of bg00010 (as measured by the incidence of anti-bg00010 antibodies).
In Parts I and II of the study, blood samples for pk analysis were taken: 30 
min pre-dose and then 15 min and 1, 2.5, 4, 6, 9, 12, 18, 24 and 48 h following 
the first dose of bg00010; 30 min pre-dose and then 15 min and 4, 24 and 
48 h following the second dose of bg00010; 30 min pre-dose and then 15 
min and 1, 2.5, 4. 6, 9, 12, 18, 24, 48, 72 and 120 h following the third dose of 
bg00010. The concentration of bg00010 in serum was determined using a 
chemiluminescent enzyme-linked immunosorbent assay (quantification 
range 0.1 – 10 ng ml⁻1) based on the binding of bg00010 to immobilised anti-
bg00010 antibody (P3B3) using streptavidin conjugated with horseradish 
peroxidase, which upon addition of luminol substrate produced a chemilu-
minescent signal. At the lower limit of quantification, assay precision and 
bias were 12.5% and 13.6% respectively. Assay performance was fully vali-
dated in accordance with regulatory guidance and industry best practices.
Safety assessments included recording aes and saes, measurements of 
haematology, clinical chemistry and urinalysis variables; vital signs; phys-
ical examinations; neurologic examinations; electrocardiograms (eCgs); 
numerical pain rating assessments; and longitudinal assessment of quan-
titative sensory testing (Qst) in the unaffected leg (vibratory, cool thermal 
and heat pain). For vibratory measurements, a Rydel-Seiffer Vibratory 
Tuning Fork was used. The Rydel-Seiffer Vibratory tuning fork is an instru-
ment that can determine the vibration extinction threshold. The tuning 
fork was set to a vibratory frequency of 64 Hz and then placed on the sub-
ject’s skin. The vibration threshold was the point where the vibration was 
no longer perceived by the subject.16 Measurements were performed in 
triplicate on the medial malleolus. 
Cold and heat stimuli were applied with a thermode device (tsa-ii – 
NeuroSensory Analyzer, Medoc) which gradually increased or decreased 
in temperature. The thermode was applied to the inner aspect of the calf 
muscle of the unaffected leg. Cold sensation, cold pain threshold, heat pain 
threshold and heat pain tolerance were assessed. For the Qst, the change 
from baseline was noted if there was a change of ≥2 standard deviations 
(sd) of laboratory normative data from the baseline measurement. 
As bg00010 is involved in nerve growth, intra-epidermal nerve fibre 
density (ienfd) was measured as a safety precaution. A punch biopsy of 
the distal part (10 cm proximal to the lateral malleolus) of the unaffected 
leg was performed twice (on the same leg within 1 h) to minimise patient 
variance.
The presence of anti-bg00010 antibodies was determined using a tiered 
assay approach involving a screening assay and a confirmation assay, 
followed by titration of positive samples. The presence of anti-bg00010 
antibodies in human serum was determined using an electrochemilumi-
nescent assay format. Samples that tested positive for binding antibodies 
were further evaluated in a neutralising antibody assay that measured the 
ability of bg00010 to bind to and activate the extracellular gfrα3 receptor. 
Assay performance was fully validated in accordance with regulatory guid-
ance and industry best practices.
Plasma and serum samples were also drawn to explore potential phar-
macodynamic markers: Substance P, chemokine receptor 2 (CCr2) and 
norepinephrine.
The efficacy assessments were an 11-point nrs assessment (general sci-
atic pain, back pain and leg pain) and pain as measured by the vas of the 
sf-mpQ. Nociceptive testing was performed as exploratory assessment. 
Electrical, mechanical and cold pressor tests were performed to assess 
pain detection and pain tolerance thresholds.
Statistical analyses
This was an exploratory study; therefore, the sample size was not based on 
statistical considerations. pk parameters were calculated using noncom-
partmental methods and summary statistics for each pk parameter were 
calculated by dose. The mean concentration values for each dose group were 
plotted over time and dose proportionality was assessed. Calculations were 
performed using WinNonlin Phoenix version 6.2 (Certara, Princeton, usa). 
      All patients who were randomised were analysed. aes were coded using 
the Medical Dictionary for Regulatory Activities (Meddra) version 15.0. 
The incidences of aes, saes and development of antibodies to bg00010, as 
well as changes in safety parameters were summarised by study dose and 
compared with placebo. Placebo patients were pooled together separately 
in Parts i and ii.
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The efficacy analysis population was defined as all patients who received 
study treatment and had pain data collected post-dose. Changes in the 




Twenty-eight patients were randomised (see Figure S1 for study flow-
chart); 16 in Part i of the study to BG00010 (50, 150, 400, or 800 μg kg⁻1 once 
weekly) or placebo and 12 in Part ii to bg00010 (400, 600, or 1200 μg kg⁻1 up 
to every 48 h and no more than 3 times in 1 week) or placebo. The first dose 
of study treatment was administered on 25 July, 2011 and the last study visit 
was on 20 September, 2012.
In Part i, 10 patients (63%) were women; in Part ii, 9 patients (75%) 
were women. The mean age was 53.5 years (range 33–75 years) in Part i and 
51.4 years (range 19–74 years) in Part ii. The majority of patients were white 
(22[79%]). Concomitant medications were taken by 15/16 (94%) patients 
in Part I and 9/12 (75%) patients in Part ii. The most frequent concomitant 
medication was paracetamol (9/15 [60%] patients in Part i and 3/9[33%] 
patients in Part ii).
Pharmacokinetics
In all study cohorts, the bg00010 concentration-time data indicated rel-
atively low inter-patient variability in the time course of bg00010 serum 
exposure. Serum bg00010 concentrations over time are shown in Figure 
1. There was a dose-dependent increase in serum exposure from 150 to 
1200 µg kg⁻1, but the increase was less than dose-proportional. The log-lin-
ear bg00010 concentration vs. time course at all dose levels showed a 
distinct multiphasic disposition in which peak concentrations dropped 
more than tenfold in the first 2–3 h post-dose and declined more slowly 
thereafter. There was no trend toward increasing or decreasing clearance 
(Cl) or steady-state volume of distribution (vss) across the body weight 
range tested (62.6–106.4 kg).
A summary of the pk parameters for Parts i and ii of the study is given in 
Table 1. In Part i of the study, the area under the concentration-time curve 
from time zero to infinity (auCinf) increased approximately in proportion 
to dose from 0 to 400 µg kg⁻1 and somewhat less than dose proportionally 
from 400 to 800 µg kg⁻1 (Table 1). There was no difference in auCinf between 
the first (Dose 1) and third (Dose 3) dose within each cohort, indicating lit-
tle or no bg00010 accumulation. The maximal plasma concentration (Cmax) 
also increased with bg00010 dose, but reached a plateau from 400 to 800 µg 
kg⁻1 (Table 1). Reaching a plateau in Cmax between these dose levels was 
expected due to increasing iv infusion time. Cl was relatively constant over 
the dose range tested for Cohorts a to d. Mean vss for all cohorts increased 
as a function of dose. Estimation of vss at the lower dose levels (Cohorts a 
and B) was influenced by the limited range of concentration-time data and 
therefore produced underestimates of the true volume. At the higher dose 
levels (Cohorts C and d), mean vss fell within a tighter range (Table 1).
In Part II of the study, the increase in auC during a dosing interval (0–48 h) 
at steady state (auCtau) was less than proportional to dose and auCtau for 
Dose 3 was higher than that for Dose 1 in all cohorts, indicating some degree 
of accumulation (Table 1). Cmax for Cohorts e–g increased with dose, but 
formed a similar plateau as observed in Cohorts a–d. There was little or 
no bg00010 accumulation with a 168-h dose interval in Cohorts a to d and 
some accumulation (29–55%) with a 48-h dose interval in Cohorts e–g, 
indicating an effective half-life (t½(eff )) for bg00010 between 30 and 60 h. 
 
Safety
All patients experienced aes. The most frequently reported aes report-
ed by patients receiving bg00010 were headache (10 bg00010-treated 
patients[83%] vs 3 placebo-treated patients[75%] in Part I and 6[67%] vs. 
1 [33%] in Part ii), feeling hot (6[50%] vs. 0 in Part i and 9[100%] vs. 0 in 
Part II), generalised pruritus (8 [67%] vs. 1[25%] in Part i and 3[33%] vs. 
0 in Part ii) and pruritus (5 [42%] vs. 2[50%] in Part i and 6 [67%] vs. 0 in 
Part ii). The majority of aes were mild; no severe aes, saes or aes leading 
to discontinuation were observed. There was no indication for increased 
reporting of aes with increasing bg00010 dose or increasing frequency of 
bg00010 dosing.
An overview of pruritus-related aes is shown in Figure 2. All aes pertain-
ing to pruritus were considered related to study treatment and resolved by 
the end of the follow-up period. Pruritus that lasted >28 days was report-
ed in five patients: this was mild in severity and no modification of study 
treatment was required in any of the five patients. One patient reported 
a generalised rash during the study. The patient was in the bg00010 50 μg 
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kg⁻1 group and the ae was mild in severity and lasted 5 days. One patient in 
the bg00010 150 μg kg⁻1 group had a temperature-related ae of moderate 
severity (feeling hot) that lasted 3 days. The same event occurred after the 
second and third dose, but were of mild severity. Five patients in Part i expe-
rienced mild temperature-related aes that lasted between 1-5 days. Nine 
patients in Part ii experienced mild temperature-related aes with duration 
of 1-2 days. No clear trends in response to multiple doses of bg00010 were 
observed in blood levels of Substance P or CCr2 in Parts I or II of the study.
In Parts i and ii, the most frequent concomitant medication was parac-
etamol. Use of concomitant medications as permitted by the protocol was 
not expected to affect study results.
No clinically significant changes were found in vital signs, eCg, ienfd, 
Qst or safety laboratory tests. Although some patients, at some points, had 
Qst values outside the normal range, none of these changes were deter-
mined to be a reason for concern. Observed changes were considered 
within the expected variability of Qst assessments (data not shown). The 
change in ienfd from baseline is shown in Figure 3. No trends in ienfd data 
were observed and no clear dose effect was documented in Parts i or ii of 
the study. There was no correlation between changes in ienfd and clini-
cal findings and the changes that were seen were considered not clinically 
significant.
The only case of anti-bg00010 antibodies detected in the study was in a 
patient receiving placebo. This was a false positive result on Day 20; results 
were negative on Day 43. No neutralising antibodies were detected.
Pharmacodynamics
Change from baseline in nrs over time is shown in Figure 4. On the nrs 
in Part i, there was little differentiation between placebo-treated patients 
and patients treated with bg00010 50 or 150 μg kg⁻1 in mean change in 
general sciatica pain from baseline. There was more differentiation for 
patients treated with bg00010 400 or 800 μg kg⁻1, observed particularly 
after Dose2. After Dose 2, patients receiving bg00010 ≥400 μg kg⁻1 report-
ed greater reductions in general sciatica pain and these reductions were 
maintained after Dose 3. However, overall there was substantial variability 
in the nrs data. In Part ii of the study, mean changes from baseline among 
placebo-treated patients remained within a lower range relative to that 
observed for placebo treatment in Part i and the treatment response was 
far more evident with the Part ii dosing regimen. Results for leg pain and 
back pain, as measured by the nrs, were similar to those seen for general 
pain.
In Part i, bg00010 800 μg kg⁻1 resulted in the greatest mean (sd) de crease 
from baseline in vas score (-34 [14] mm at Week 6). The greatest mean 
decrease from baseline for placebo-treated patients was seen at Week 10 
(-20.67 [31.63] mm). For the other doses tested in Part i, no pain reduction 
was seen compared with placebo-treated patients. In Part ii of the study, 
the greatest mean decrease from baseline was seen 56 days after Dose 3 in 
the 600 μg kg⁻1 dose group (mean[sd] of -33.33 [33.38] mm vs. -3.67 [20.03] 
mm with placebo). A trend in pain reduction from baseline as measured by 
the vas of the sf-mpQ was seen in the bg00010 600 and 1200 μg kg⁻1 dose 
groups compared with placebo. No notable trends were seen in the noci-
ceptive testing data (Table 2a-f; Figure 5).
discussion
Overall, bg00010 dosed weekly or every 48 h demonstrated dose-depen-
dent pk in this ascending-dose study in patients with sciatica. There were 
no dlts, the mtd was not identified and bg00010 administration appeared 
to lead to a reduction in back pain and leg pain in some patients.
When administered as multiple doses by iv infusion at 48- or 168-h dose 
intervals, serum bg00010 exposure increased in a dose-dependent, but 
less than dose-proportional, manner with relatively low variability within 
dose cohorts. At all dose levels, the log-linear bg00010 concentration-time 
course showed a distinct multiphasic disposition in which peak concentra-
tions dropped more than tenfold in the first 2–3 h after administration and 
then declined more slowly over the following days with a t½ that general-
ly fell between 40 and 60 h. There was no accumulation of bg00010 when 
dosed at a 168-h interval, but there was some accumulation when dosed 
every 48 h (accumulation ratio: 29–55%), suggesting a t½ (eff) for bg00010 
of approximately 30-60 h. The pk results in the current study are consis-
tent with those observed in the previous single ascending-dose study with 
bg00010.13
All patients experienced at least one ae during the study and aes were 
more frequently reported in patients receiving bg00010 versus placebo. 
There was no clear increase in the incidence of the most frequent aes for 
the higher- versus lower-dose cohorts or in the cohorts where bg00010 was 
administered three times during 1 week versus once weekly for 3 weeks. 
One of the most frequently reported aes in this study was mild or moderate 
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pruritus, starting approximately 1–3 days following administration of Dose 
1. The exact mechanism of the pruritus is not known, but pruritus was also 
seen in a single ascending-dose study where it was more common with 
higher bg00010 doses (≥100 µg kg⁻1).13 In our study, with weekly dosing, 
patients who received the highest bg00010 dose (800 μg kg⁻1) experi-
enced pruritus aes of longer duration than patients in the other treatment 
groups. However, in Part ii of the study, when bg00010 was dosed every 48 
h, there was no clear indication of pruritus aes having a longer duration 
with increasing bg00010 dose. The single case of anti-bg00010 antibodies 
being detected in a patient receiving placebo was a false positive result, not 
unexpected as the assay cut point incorporates a 5% false positive rate.
The effects of bg00010 on neuropathic pain behaviour have been studied 
extensively in rats. Three rat models of neuropathic pain have been exam-
ined: spinal nerve ligation,3 chronic constriction injury of the sciatic nerve17 
and distal root crush.18 In these models, bg00010 substantially attenuated 
neuropathic pain behaviour. Exposure to bg00010 at single doses of 400 or 
800 μg kg⁻1 in humans was comparable to exposure in rats at doses that 
have shown efficacy in these nonclinical pain models. In this study, based 
on the nrs and vas of the sf-mpQ, the Part ii multiple-dose bg00010 regi-
men resulted in greater pain reduction versus placebo and the lower-dose 
regimens, although a clear dose-response relationship was not seen. These 
limited data suggest that bg00010 may benefit patients with sciatica and 
that further development of this compound for the treatment of neuro-
pathic pain is warranted.
No formal sample size calculation was performed for the efficacy end-
points; therefore, owing to the small sample size of each cohort, no final 
conclusions can be made about the efficacy of bg00010 at this point. 
Nociceptive testing was included as an exploratory measure. With only 
three subjects per dose group, large variability was observed in baseline 
values of the different nociceptive tasks. No effects of bg00010 on evoked 
pain were observed. Likely the group size was too small to detect clear 
effects on evoked pain.
A recent review19 concluded that available evidence does not clearly 
show favourable effects with nonsteroidal anti-inflammatory drugs, cor-
ticosteroids, antidepressants, or opioid analgesics for the treatment of 
sciatica. There has, however, been significant progress over the last 20 years 
in the understanding of the biology of pain sensory neurons and the discov-
ery that neurotrophic factors play an important role in neuropathic pain 
has provided several new therapeutic targets. Although sciatica probably 
has mixed neuropathic and nociceptive/inflammatory components, neu-
rotrophic factors such as the gdnf family of ligands may address certain 
aspects of the underlying causes of neuropathic pain.
In conclusion, pk results were consistent with those observed in previ-
ous research. There were no dlts and a mtd was not identified. These data 
from a small sample suggest that further evaluation of bg00010 in patients 
with sciatica is warranted. Additionally, a phase II study in patients with 
radiculopathy has recently been completed.
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Table 1 
Summary of the pk parameters for Parts i and ii of the study
Part i (weekly dosing) Part ii (dosing every 48 h)
bg00010  
50 µg kg-1 
(n = 3)
bg00010  






800 µg kg-1 
(n = 3)
bg00010  






1200 µg kg-1 
(n = 3)
Injection 1
 auC(inf)h ng ml⁻1 45.0 (9.1) 156.7 (36.7) 399.0 (37.3) 652.7 (243.2)
 auC(tau)* h ng ml⁻1 40.7 (12.7) 142.3 (28.4) 347.0 (27.5) 606.0 (247.7) 180.7 (5.0) 294.7 (51.5) 313.7 (113.6)
 Clearance (l h⁻1 kg⁻1) 1.1 (0.2) 1.0 (0.2) 1.0 (0.1) 1.3 (0.4)
 Cmax (ng ml⁻1) 33.2 (2.6) 76.4 (17.3) 156.0 (32.9) 149.3 (29.5) 100.9 (9.7) 174.7 (52.3) 84.0 (18.1)
 t½b (h) † 24.1 (9.6) 54.9 (8.5) 63.8 (16.5) 49.9 (4.0)
 vss (L kg⁻1) 18.3 (7.4) 44.5 (2.5) 62.3 (11.0) 71.4 (27.6)
Injection 2
 Cmax (ng ml⁻1) 28.5 (3.6) 84.1 (12.4) 118.9 (35.9) 135.0 (32.9) 118.3 (25.8) 154.7 (22.0) 135.0 (43.6)
Injection 3
 auC(inf) h ng ml⁻1 52.1 (22.6) 159.7 (20.5) 435.7 (121.2) 516.3 (70.5)
 auC (0-168) h ng ml⁻1 47.6 (20.5) 149.7 (16.5) 354.7 (52.5) 471.3 (73.0) 232.3 (8.1) 386.0 (61.1) 487.7 (167.9)
 Clearance (l h⁻1 kg⁻1) 1.1 (0.4) 0.9 (0.1) 1.0 (0.2) 1.6 (0.2)
 Cmax (ng ml⁻1) 38.8 (15.2) 65.2 (7.8) 140.3 (47.9) 106.8 (23.2) 96.9 (24.4) 175.0 (47.9) 121.3 (30.4)
 t½c (h) ‡ 41.5 (27.1) 48.4 (12.7) 86.6 (53.4) 53.8 (14.2) 66.1 (15.5) 62.5 (15.8) 99.0 (37.5)
 vss (L kg⁻1) 25.3 (8.5) 40.5 (9.2) 74.8 (32.1) 91.2 (23.5)
All values are mean (±sd). auC, area under the concentration₋time curve; auCtau, auC during a dosing interval at steady  
state; auC(inf), auC from time zero to infinity; Cmax, maximal plasma concentration; t½, half-life; vss, steady-state volume  
of distribution. *auCtau: Tau =0-168 for Part i; 0-48 for Part ii; † For Dose 1, Part i, mean terminal t½ values are based on  
concentration data to 168 h post-dose; ‡ For Dose 3, Part i, mean terminal t½ values are based on concentration data to  
120 h post-dose.
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Nociceptive testing data, Part i cold pressor test, pain tolerance threshold in seconds, mean 
(± Standard deviation)




50 µg kg⁻1 
(n = 3)
bg00010  
150 µg kg⁻1 
(n = 3)
bg00010  
400 µg kg⁻1 
(n = 3)
bg00010  
800 µg kg⁻1 
(n = 3)
Baseline 15.5 (11.8) 20 (4.7) 18.2 (9.4) 50.2 (60.5) 16.6 (4.1)
Day 1-4 h post-dose 10.5 (6.8) 17.2 (4.4) 15.7 (5.8) 48.9 (61.7) 14.9 (3)
Day 2 12 (7) 15.9 (4.4) 15 (4.6) 48.2 (62.1) 15.1 (5.1)
Day 3 18.5 (13.7) 18.5 (4.6) 17.9 (5.2) 47.6 (62.7) 19.6 (11.4)
Day 8-60 min pre-dose 13.1 (10.2) 18.5 (8.2) 17.1 (4.9) 49.7 (61.2) 19.2 (2.9)
Day 8-4 h post-dose 12.4 (8.5) 17.5 (9.4) 17.5 (4.9) 49.5 (61.4) 14.9 (4.6)
Day 9 9.3 (4.7) 16 (6.2) 18.6 (2) 47.7 (62.8) 15.4 (8.2)
Day 10 13.1 (7.9) 15.3 (5) 18.9 (4.1) 49.8 (60.8) 19.5 (10.8)
Day 15-60 min pre-dose 13.3 (2.9) 14.7 (2.5) 20.5 (6.3) 49.9 (61) 14.7 (7.1)
Day 15-4 h post-dose 12.8 (2.6) 15.5 (5.4) 18.9 (6.7) 48.8 (61.7) 11.7 (2.5)
Day 16 14.1 (2.3) 15.1 (2.8) 17.4 (5.1) 47.8 (62.6) 12.5 (5.9)
Day 17 19.5 (9) 16.9 (6.3) 19.5 (4) 47.6 (62.8) 13.4 (7.3)
Day 29 21.6 (10.8) 10.8 (4.8) 22 (6.8) 48.2 (62.3) 15.9 (5.8)
Day 43 12.1 (6.8) 16.9 (3.9) 20.5 (7.3) 48.2 (62.4) 15.3 (5.5)
Day 71 24.7 (9.2) 13.9 (2.9) 16.4 (6.7) 47.4 (63) 15.8 (3.7)
Table 2b 
Nociceptive testing data, Part i, electrical pain test, pain tolerance threshold in mA, mean  
(± Standard deviation)




50 µg kg⁻1 
(n = 3)
bg00010  
150 µg kg⁻1 
(n = 3)
bg00010  
400 µg kg⁻1 
(n = 3)
bg00010  
800 µg kg⁻1 
(n = 3)
Baseline 36.2 (16.9) 24 (10.5) 31.9 (7.9) 28.3 (19.1) 23.2 (7.5)
Day 1-4 h post-dose 28.2 (17.2) 23.8 (12.1) 28.1 (4.2) 29.3 (18.9) 23.5 (12.1)
Day 2 30.9 (16.6) 18.1 (9.2) 28.3 (3.7) 27.5 (19.8) 17.7 (10.9)
Day 3 34 (17.1) 20.1 (10.1) 28.6 (5.3) 28.4 (18.8) 30.3 (15.4)
Day 8-60 min pre-dose 36 (16.1) 23.7 (12.8) 30.4 (2.5) 31.6 (17.4) 25.8 (17)
Day 8-4 h post-dose 32.1 (14.8) 24.6 (18.9) 33.2 (2.3) 31.4 (17.2) 26.3 (21.3)
Day 9 39.7 (17.4) 25.3 (16.9) 34.1 (2.1) 31.6 (17) 24.6 (22.2)
Day 10 36 (19.4) 24.5 (21.4) 34.9 (3.8) 32.1 (18.1) 32.3 (15.5)
Day 15-60 min pre-dose 42.2 (1.2) 17 (8.7) 36.3 (4.4) 32.5 (15.8) 26.9 (19.5)
Day 15-4 h post-dose 30.4 (7.9) 18.2 (8.1) 31.6 (0.8) 33.4 (14.9) 23.6 (19.3)
Day 16 35.9 (5.8) 20.1 (11.5) 33.3 (4) 32.2 (15.7) 24.1 (22.7)
Day 17 41.1 (12.4) 20.8 (10.9) 36.7 (8) 32.4 (15.5) 27.4 (19.6)
Day 29 23.8 (0) 17.1 (8.5) 36 (11.7) 35.8 (17.2) 24.6 (20.8)
Day 43 33.2 (17.9) 25.7 (10) 34.5 (12.2) 28.2 (18.9) 23.2 (18.7)
Day 71 35.6 (19.1) 17 (3.7) 33.8 (5.8) 27.5 (19.6) 25.7 (21.3)
Table 2c 
Nociceptive testing data, Part i, pressure pain test, pain tolerance threshold in kPa, mean  
(± Standard deviation)




50 µg kg⁻1 
(n = 3)
bg00010  
150 µg kg⁻1 
(n = 3)
bg00010  
400 µg kg⁻1 
(n = 3)
bg00010  
800 µg kg⁻1 
(n = 3)
Baseline 43.3 (15.6) 44.1 (23.4) 45.6 (19.3) 46.5 (17.1) 51.2 (31.1)
Day 1-4 h post-dose 55.5 (31) 41.1 (19.7) 40.7 (8.5) 44.1 (19) 55.3 (29.9)
Day 2 55.9 (30.6) 42.7 (18.2) 38.3 (11.7) 42.5 (19) 51.6 (16.1)
Day 3 53.6 (31.9) 44.5 (22.1) 41.7 (12.9) 37.3 (16.4) 50.3 (28.6)
Day 8-60 min pre-dose 51.4 (24) 44.1 (16.8) 45.1 (8.7) 40.6 (18) 34.7 (15.2)
Day 8-4 hour post-dose 51 (26.1) 35.8 (20.4) 40.1 (14) 39.7 (13.7) 55.3 (35.2)
Day 9 54.5 (33.5) 38.7 (20.3) 40.7 (10.9) 44.5 (17) 45.1 (29.2)
Day 10 38.8 (15.2) 44.5 (14.4) 45.4 (13.9) 42.4 (14.2) 57.6 (32.9)
Day 15-60 min pre-dose 47.8 (11.7) 31.8 (5.3) 42.2 (9.2) 37.9 (11.9) 49.4 (34.9)
Day 15-4h post-dose 46.3 (7.6) 37.3 (9.5) 45.3 (18.2) 37.6 (13.5) 46.8 (30.4)
Day 16 44 (8.4) 37 (12.8) 39.7 (10.4) 37.4 (13.1) 46.9 (31.1)
Day 17 54.1 (12.9) 38.1 (17.4) 40.5 (12.9) 45.6 (17.8) 51.3 (34.9)
Day 29 58.8 (18) 39 (11) 48.2 (19.3) 46.1 (17.3) 46.1 (31.1)
Day 43 39.9 (13.9) 32.8 (9) 47.2 (16.2) 47.5 (22.2) 38.9 (28.4)
Day 71 39.3 (2.5) 32.4 (11.3) 47.5 (16.3) 45.4 (22.8) 27.6 (14.2)
Table 2d 
Nociceptive testing data, Part ii, cold pressor test, pain tolerance threshold in seconds, mean 
(± Standard deviation)




400 µg kg⁻1 
(n = 3)
bg00010  
600 µg kg⁻1 
(n = 3)
bg00010  
1200 µg kg⁻1 
(n = 3)
Baseline 22 (9) 35.8 (46.1) 15.1 (5.3) 8.8 (1.3)
Day 1-4 h post-dose 20.4 (4) 23 (16) 19.2 (10.8) 8.6 (1.1)
Day 2 16.6 (4.1) 17.1 (11.9) 15.7 (7) 6.7 (0.5)
Day 3-4 h post-dose 18.2 (9.4) 15.4 (10.2) 15.4 (9.2) 7.9 (0.8)
Day 4 19.2 (2.1) 20.3 (14.4) 19.2 (12.9) 7 (1.3)
Day 5-4 h post-dose 37.2 (39.8) 20.9 (15) 21.6 (15.8) 8 (2.2)
Day 6 35.6 (37.9) 18.4 (13.3) 24.3 (17.6) 8.8 (3.2)
Day 7 44.2 (39.3) 21.4 (14.9) 19.1 (14.8) 11.5 (2.1)
Day 19 37.5 (38.4) 24.8 (25.1) 17.5 (11.5) 12.8 (0.4)
Day 33 18.9 (7.7) 25 (19.5) 23 (16.5) 11.6 (4.3)
Day 61 18.8 (8.3) 17.3 (12) 17.8 (12.7) 16.4 (11.8)
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Nociceptive testing data, Part ii, electrical pain test, pain tolerance threshold in mA, mean  
(± Standard deviation)




400 µg kg⁻1 
(n = 3)
bg00010  
600 µg kg⁻1 
(n = 3)
bg00010  
1200 µg kg⁻1 
(n = 3)
Baseline 32.7 (17.6) 26.3 (16.5) 32.8 (15.3) 15.2 (7.5)
Day 1-4 h post-dose 31.5 (10) 26.3 (12.4) 29.1 (7.8) 15.9 (6.5)
Day 2 26.1 (5.2) 25.4 (12.1) 26.6 (12.3) 13.6 (5.5)
Day 3-4 h post-dose 30.7 (4) 24 (8.9) 25.1 (6) 17.4 (1.6)
Day 4 28.1 (2.9) 24.1 (11.5) 26.7 (12.5) 18.9 (9.2)
Day 5-4 h post-dose 32.7 (10.3) 21.9 (10.4) 30.8 (13.8) 15.6 (8.4)
Day 6 31.5 (6) 25.3 (9.2) 31.7 (9.1) 13.3 (3.3)
Day 7 38.3 (9.8) 26.2 (13.8) 31.2 (13.1) 16 (5.3)
Day 19 37.5 (10.9) 39.5 (12.4) 49.9 (0) 20.2 (12.7)
Day 33 41.3 (10) 38.9 (5.8) 37.8 (7.3) 18.7 (12.1)
Day 61 34.5 (18) 33.9 (10.8) 25 (9.6) 16.7 (7.2)
Table 2f 
Nociceptive testing data, Part ii, pressure pain test, pain tolerance threshold in kPa, mean  
(± Standard deviation)




400 µg kg⁻1 
(n = 3)
bg00010  
600 µg kg⁻1 
(n = 3)
bg00010  
1200 µg kg⁻1 
(n = 3)
Baseline 64.9 (26.6) 36.6 (12.4) 35.9 (18.3) 27.2 (8.1)
Day 1-4 h post-dose 62.5 (30.9) 33.5 (11.5) 35 (9.7) 25.9 (4.9)
Day 2 56.8 (30.8) 31.3 (5.1) 23.2 (5.1) 29.5 (11.1)
Day 3-4 h post-dose 46 (7.5) 27.9 (3.3) 31.7 (13.2) 24.9 (4.2)
Day 4 48.6 (4.7) 28.8 (6.7) 23.2 (4.9) 24.9 (4.4)
Day 5-4 h post-dose 42.1 (1.8) 29.1 (2.5) 26.8 (8) 22.7 (5)
Day 6 58.1 (30.7) 27.9 (8.6) 28.4 (6.3) 23 (5.6)
Day 7 65.3 (21.4) 30.9 (7.5) 30.4 (7.5) 33.7 (12.8)
Day 19 66.7 (30.5) 35.8 (13.1) 37.1 (6.7) 33.4 (0.6)
Day 33 58 (21.3) 30.5 (13.4) 34.6 (10) 37 (13.3)
Day 61 58.5 (50.5) 23.3 (6.7) 34.5 (7.5) 23.2 (3.4)
figure 1 
Mean (+ sd) serum bg00010 concentration vs. time by cohort in Part i (a) and Part ii (b).
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Dosing: up to 3 times weekly for 1 week
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Adverse-event overview in Part i (a) and Part ii (b) for pruritus events. *Patient received 
placebo. Severity: 1=mild; 2=moderate.
figure 3 
Median (± range) change in ienfd from baseline by treatment and visit in Part i (a) and 
Part II (b). 
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Mean (± se) nrs pain general assessment change from baseline for Part i (a) and Part ii (b).
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Use of human evoked pain models in chronic pain patients and 
comparison to healthy subjects
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  159 evoked pain models in ChroniC pain patients and Comparison to healthy subJeCts
absTracT
Tests that can measure nociceptive thresholds are widely used in healthy 
subjects in early drug development to predict therapeutic potential of 
analgesics. Early phase trials can be performed in the target patient popu-
lation instead of in healthy subjects. We compared baseline measurements 
from seven studies in order to identify possible differences in nociceptive 
thresholds between healthy subjects and patients with a chronic pain state. 
Data from 7 studies in healthy subjects and different pain patient popula-
tions in which a battery of human pain models was used were included to 
perform an exploratory analysis on mean baseline values of all subjects. 
Differences between healthy subjects and patients with sciatica, diabetes 
(dm), painful diabetic neuropathy (pdn) and chronic idiopathic axonal 
polyneuropathy (Ciap) were analysed. Furthermore, we investigated if 
age and body mass index were covariates in the analysis. The test battery 
consisted of a sequence of tests eliciting cutaneous electrical, mechanical 
(pneumatic-) and thermal (cold pressor)-pain. Pain detection thresholds 
(pdt) for electrical pain were lower in pdn and Ciap patients; pain toler-
ance thresholds (ptt) for cold pressor pain and pressure pain were lower 
in dm and Ciap patients compared to healthy subjects. Intra-subject vari-
ability of pain thresholds tended to be higher in patients than in healthy 
controls. Significant differences in pain thresholds exist between healthy 
subjects and patients, which may influence the extent to which results of 
analgesic effects using evoked pain tests in healthy subjects can be extrapo-
lated to patients with chronic pain conditions. 
inTroducTion
Tests that can measure nociceptive thresholds are widely used in healthy 
subjects in early drug development to predict the therapeutic potential of 
analgesics. The advantage of the use of human evoked pain models is that 
they can be performed in controlled circumstances. Although pain is a sub-
jective experience, which is difficult to objectify, several evoked pain tests 
correlate well with clinical pain syndromes.1 By using evoked pain tests in 
humans in an early stage of the clinical development of a new drug, the pos-
sible analgesic potency can be investigated.2⁻5
Early phase clinical trials with new analgesics can be performed both 
in healthy subjects and in a target patient population. When performing 
early phase clinical drug studies in a target patient population, traditional 
safety and pharmacokinetic endpoints can be investigated together with 
exploratory endpoints on the possible desired analgesic effects of a new 
compound. In addition to subjective pain scales such as visual analogue 
scales (vas) and numeric rating scales (nrs) on the current pain condition, 
more objective methods can be used to assess other analgesic properties of 
a compound. If no positive evidence for the efficacy of a drug in the chosen 
target patient population can be found, the use of one or more human pain 
models can give further insights in the possible effect of a compound for the 
treatment of pain with another aetiology.4
Evoked pain tests have previously been performed in pain populations 
to investigate the effects of chronic pain conditions on the experience of 
pain.6 Patients with chronic pain have a tendency to respond differently 
to painful stimuli. Changes in pain tolerance levels, pain modulation and 
augmented brain responses have been found in several chronic pain popu-
lations, such as sciatica,7,8 diabetic painful neuropathy,9 chronic whiplash 
associated disorders,10 rheumatoid arthritis,11 vulvodynia12 and fibromy-
algia.13 Quantative sensory testing (Qst) is regularly used to determine 
sensory profiles of patients with pain syndromes.7,14 The aim of the cur-
rent analysis was to identify possible differences between healthy subjects 
and patients with a chronic pain state in their response to a battery of pain 
models and to investigate potential confounding factors. Possible differ-
ences may be important in the design of early phase clinical drug studies in 
which multi-modal pain testing is considered. Comparing and contrasting 
the way healthy subjects and patients respond to pain testing, can help to 
bridge results obtained in healthy subjects to patient populations. Patients 
with sciatica, diabetes mellitus (without polyneuropathy) (dm), painful 
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diabetic polyneuropathy (pdn) and chronic idiopathic axonal neuropathy 
(Ciap) were included in this analysis. Findings from this analysis can be 
used in decisions to perform a study in a patient population or to use noci-
ceptive tasks in healthy subjects.
meThods
Data collection 
Data from 7 studies performed at Chdr in which a battery of human pain 
models was used were included to perform an exploratory analysis on the 
baseline values of all subjects. Each subject had two baseline measurements 
on each test. Differences between groups (healthy vs. different patient pop-
ulations) were analysed. Furthermore, we investigated if sex, age and body 
mass index were covariates in the analysis. All the studies were approved 
by the local ethics committee and were conducted according to the Dutch 
Act on Medical Research Involving Human Subjects (Wmo) and in compli-
ance with Good Clinical Practice (iCh-gCp) and the Declaration of Helsinki. 
Subjects
Main study and subject characteristics are listed in Table 1. All subjects 
gave written informed consent. All subjects underwent a full medical 
screening, at least including medical history taking, a physical examination 
and vital signs. Healthy subjects were excluded if they had any clinically 
significant findings as determined by the medical screening. Patients with 
sciatica included male and female patients, aged 18-85 years with a diagno-
sis of unilateral sciatica, including pain radiating down the leg following a 
dermatome, suggesting L4, L5, S1 nerve root involvement, with symptoms 
present for > 3 months prior to screening visit and pain rated at >40 mm 
on a 100 mm visual analogue scale (vas). Patients with diabetes mellitus 
but without neuropathy included subjects with dm according to the World 
Health Organization criteria,15 with a stable glycaemic control regimen 
and without neuropathy. Patients with painful diabetic neuropathy includ-
ed subjects with diabetes and polyneuropathy according to aan criteria.16 
Pain had to be attributable to a symmetrical stocking distribution neu-
ropathy in the lower limbs and average daily pain scores were ≥4 on 0-10 
numeric rating scale (nrs). Chronic idiopathic axonal neuropathy patients 
had to be diagnosed with Ciap as defined by Visser and colleagues.17 
Patients were included if average daily pain scores were ≥4 on 0-10 nrs 
scale.
Subjects that were regular user of any illicit drugs or had an history of 
drug abuse, a positive drug screen at screening, consumption of more than 
8 units of (methyl)xanthines per day or smoking more than 5 cigarettes/
day were excluded. Use of xanthine-containing products and alcohol was 
not allowed from one day prior to admission to the clinical research unit 
and during the stay at the research unit. Healthy subjects were not allowed 
to take analgesics within 3 days of the nociceptive assessments. If patients 
used medication, they had to be stable on their medication 2 weeks prior to 
the first study visit.
In studies 1, 2, 3 and 6, subjects were excluded from study participation 
if they indicated the nociceptive tests intolerable during a training session 
or achieved >70% (studies 1 and 2) or >80% (studies 3 and 6) of maximum 
input intensity for any of the nociceptive tasks. For studies 4, 5 and 7 sub-
jects were excluded from this analysis if they achieved >80% of maximum 
input intensity for any of the nociceptive tasks during the first session.
Evoked pain tests
Nociceptive (pain) detection and tolerance thresholds were measured 
using a battery of evoked pain tests. The test battery is an integrated range 
of tasks for measuring different modalities of nociception. It aims to assess 
as objectively as possible the levels of pain induced by several noxious 
mechanisms in human subjects. At baseline the evoked pain tests were 
performed twice. A training session was included in all studies to reduce 
learning effects during the study. The battery of pain tests was performed 
multiple times during the day. Exact timing of the tests was different in the 
individual studies. All tests had previously been shown to be sensitive to the 
effects of analgesics in healthy adults.4 All measurements were performed 
in a quiet room with ambient illumination. Per session, there was only one 
subject in the room, to avoid any distraction or other external influence. 
Pain intensity was measured continuously (beginning from when the 
first stimulus was applied until the predetermined end of the test) for each 
nociceptive test using an electronic visual analogue scale (evas) scale rang-
ing from 0 (no pain) to 100 (most intense pain tolerable). Equipment was 
programmed to cease giving stimuli if pain intensity reaches the maximum 
possible score. For each test the pain detection threshold (pdt) and pain 
tolerance threshold (ptt) were calculated.
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For cutaneous electrical pain, Ag-AgCl electrodes (3M Red-Dot™) were 
placed on cleaned, scrubbed, and if required, shaved skin, 10 cm distal from 
the patella overlying the tibia. Electrical resistance between electrodes was 
to be less than 2 kW. The electrical stimulus was delivered as two differ-
ent paradigms by a computer-controlled constant current stimulator (ds5, 
Digitimer, Cambridge, uk). 
For the single stimulus, adapted from methods previously described,18,19 
each single stimulus (10 Hz tetanic pulse with a duration of 0.2 ms), current 
intensity increased from 0 mA in steps of 0.5 mAs-1 (cutoff 50 mA). 
For the repeated stimulus, adapted from methods previously 
described,20 each single stimulus (train of five, 1 ms square wave pulses 
repeated at 200 Hz) was repeated 5 times with a frequency of 2 Hz at the 
same current intensity with a random interval of 3 to 8 seconds between the 
repetitions. Current intensity increased from 0 mA in steps of 0.5 mA (cutoff 
50 mA). Pain detection threshold was taken as the value (mA) whereby a 
subject indicated either: all 5 stimuli were painful, or the train of 5 stimuli 
started feeling non-painful but ended feeling painful (vas > 0). The pain 
intensity for each stimulation was measured using the evas slider, until 
pain tolerance threshold was reached or a maximum of 50 mA was reached. 
pressure sTimulaTion Task
The method of mechanical pressure pain induction was based on meth-
ods previously described, and was shown to primarily assess nociception 
generated from the muscle with minimal contribution by cutaneous noci-
ceptors.21,22 Briefly, an 11 cm wide tourniquet cuff (vbm Medizintechnik 
GmbH, Sulz, Germany) was placed over the gastrocnemius muscle with a 
constant pressure rate increase of 0.5 kPas⁻1. The pneumatic pressure was 
increased until the subject indicated maximum pain tolerance using the 
evas slider, or a maximum pressure of 100 kPa was achieved, at which point 
the device released pressure to the cuff.
cold pressor Task
The method of cold pressor pain was based on the methods previously 
described23,24 and is the most commonly used test to induce inhibitory 
conditioned pain modulation (Cpm, also known as ‘diffuse noxious inhibi-
tory control’).25 Subjects placed their non-dominant hand into a water bath 
(minimal depth 200 mm) at 35 ± 0.5°C for 2 min. At 1 min 45 s a blood pres-
sure cuff on the upper-arm was inflated to 20 mmHg below resting diastolic 
pressure. At 2 min the subject then moved that hand from the warm water 
bath, directly into a similar sized bath at 1.0 ± 0.5°C. The subjects were 
instructed to indicate when pain detection threshold was reached (first 
change in sensation from cold non-painful to painful) as well as the pain 
intensity, by moving the evas slider. When pain tolerance or a time limit 
(120 s) was reached, subjects were instructed to remove their hand from 
the water, at which point the blood pressure cuff deflated.
condiTioned pain modulaTion 
Conditioned pain modulation is the activation of the pain-modulatory 
mechanism, as part of the descending endogenous analgesia system.25
The degree of inhibitory conditioned pain modulation (Cpm) was assessed 
by comparing the electrical pain thresholds for the single stimulus para-
digm before and within 5 min after the cold pressor task.
Statistics
All baseline measurements and pre-dose measurements were included 
to estimate the average values, intra-subject and inter-subject coefficient 
of variation (Cv). All pdt and ptt variables followed a log-normal distri-
bution and were therefore log-transformed before analysis. Transformed 
parameters were back-transformed after analysis.
To estimate the difference between group and between sex, parameters 
were analysed with a mixed model with group (healthy, sciatica, dm, pdn, 
Ciap), sex (male, female) and measurement (1, 2) as fixed factor and with 
subject as random factor. In order to assess the confounding effects of gen-
der by group, age and bmi, a mixed model analysis with fixed factor group, 
sex and measurement and covariate age and bmi respectively were per-
formed. Contrasts between groups are reported along with 95% confidence 
intervals. To assess the confounding effects of age and bmi p-values were 
calculated. A p-value below <0.05 was considered as a significant covari-
ate. No correction for multiple testing was applied. All calculations were 
performed using sas for windows V9.1.3 (sas Institute, Inc., Cary, nC, usa). 
resulTs
In total 171 subjects were included in the analysis. 108 healthy subjects were 
included (62 male, 46 female), 23 patients with unilateral sciatica (7/16), 15 
patients with diabetes mellitus without polyneuropathy (9/6), 11 patients 
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with painful diabetic neuropathy (6/5) and 14 patients with Ciap (10/4). 5 
patients with sciatica from study 4, 18 healthy subjects from study 5, 12 sub-
jects (4 healthy, 1 with dm, 5 with pdn and 2 with Ciap) from study 7 were 
excluded from the analysis because they achieved >80% of maximum input 
intensity for any of the nociceptive tasks during the first session.
Means, intra-subject Cvs and inter-subject Cvs for the outcome variables 
for the different pain tasks for healthy subjects and different patient pop-
ulations are presented in Table 2. The intra-subject Cvs were larger for the 
pdt variables than the ptt variables in all populations. Inter-subject Cvs 
were largest for the pdt variables in all populations, except for the cold 
pressor test in sciatica subjects. Variability was largest for the Cpm vari-
ables, in both groups the largest intra- and inter subject Cvs were observed 
for this test. Overall, intra-subject variability tended to be higher in patient 
populations compared to healthy subjects. Inter-subject variability was not 
consistently different in healthy subjects versus pain populations. 
Least squares means for groups and p-values for the effects of sex, age 
and bmi are presented in Table 3 and Figure 1. No differences in cold pdt 
were observed. Cold ptts were lower in dm (contrast versus healthy 
-34.2%, (95%Ci -54.7%, -4.5%), P<0.05) and in Ciap patients (-36.3%, 
(-58.5%, -2.4%), P<0.05) compared to healthy volunteers. Compared to 
healthy volunteers, electrical (repeated) pdt was lower in Ciap patients 
(-41.3%, (-63.3%, -6.1%), P<0.05). No differences were observed in toler-
ance thresholds. For the electrical single stimulus task pdt was lower in 
pdn patients compared to healthy volunteers (-40.7%, (-60.9%, -9.9%), 
P<0.05). No statistically significant differences were observed between 
healthy subjects and patients for Cpm. Compared to healthy subjects, dm 
(-26.9%, (-41.4%, -8.9%), P<0.01), pdn (-26.6%, (-42.5%, -6.3%), P<0.05) and 
Ciap patients (-23.8%, (-40.1%, -3.2%), P<0.05) had lower tolerance thresh-
olds for the pressure pain test. Sex was a significant covariate for the pdt 
of both electrical pain tests. Female subjects reported lower pdts for both 
tests (electrical repeat, -43.8%, (-59.8%, -21.3%), P<0.001; electrical single, 
-34.9%, (-51.4%, -12.9%), P<0.01). Age was not a significant covariate in any 
of the tests. bmi was a significant covariate for the pdt of both electrical 
tests and the pressure pain test, but not for the ptts of these tests. 
discussion
In the present study results from 7 studies were pooled in order to compare 
differences in pain detection and pain tolerance thresholds in different 
patient populations and in healthy subjects. The aim of the current analy-
sis was investigate the differences between healthy subjects and patients 
with chronic pain in their response to a battery of pain models. The analysis 
showed that the pain detection threshold for electrical pain was lower in 
patients with pdn (single stimulus) and Ciap (repeated stimulus) com-
pared to healthy subjects. Also the pain tolerance threshold for cold pressor 
pain and pressure pain was lower in patients with dm and Ciap compared 
to healthy subjects. No differences were observed between healthy subjects 
and sciatica subjects. Cpm did not show significant differences between the 
different populations. Intra-subject variability tended to be higher within 
the patient cohorts. Inter-subject variability for the different nociceptive 
tests was not consistently different in patients compared to healthy sub-
jects. In general pain detection threshold outcomes were more variable 
than pain tolerance thresholds. 
Several studies have previously investigated pain sensitivity in chronic 
pain patients. These mostly involved one chronic pain condition with one 
pain testing modality. This is the first time that pain sensitivity in four dif-
ferent chronic pain conditions were compared using a multi-modal battery 
of pain models. Pain and sensitivity in patients with chronic lower back 
pain was previously investigated. Patients with sciatica have an impaired 
sensitivity for warm and cold sensory thresholds measured in the affected 
dermatomes.26 Another study previously performed evaluated the effects 
of intradermal capsaicin administration in both the affected and the unaf-
fected leg in sciatica patients and an increased hyperalgesia response was 
observed in both legs in sciatica patients compared to healthy subjects.8 
Another study used Qst to create a complete sensory profile of Clbp 
patients. Widespread changes in somatosensory sensitivity were found in 
the affected body parts but also at sites distinct from the region of pain.7 
In contrast to the hyperalgesic response observed previously, in our study 
no changes in pdt or ptt compared to healthy subjects for any of the pain 
tests were observed. We only performed measurements in sciatica subjects 
in unaffected body parts, but since others also found impaired sensitivity in 
unaffected extremities, this does not explain the differences between our 
and other studies.
In our study we found no differences in pain detection and pain tolerance 
thresholds for electrical pain in patients with diabetes without neuropathy. 
In patients with pdn, a lower pdt for electrical pain compared to healthy 
subjects was observed. For the other pain modalities cold ptt and pressure 
ptt were lower in patients with diabetes compared to healthy subjects. In 
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pdn subjects a lower pdt and ptt for pressure pain compared to healthy 
subjects were observed. In a study previously performed, patients with 
diabetes had higher thresholds and tolerance for electrical pain both in 
the lower and upper extremity compared to healthy subjects. Patients with 
diabetes and neuropathy had higher thresholds than patients with dia-
betes without neuropathy.9 In another study, glucose infusions in healthy 
subjects resulted in decreased pain detection and tolerance thresholds. 
In the same study patients with diabetes were hyperalgesic compared to 
healthy subjects.27 In contrast, Luft and colleagues found no differences 
in cold pressor pain intensity between healthy and diabetic subjects.28 
Results from literature are contradictory as some studies show a hyper-
algesic and other a hypoalgesic response in diabetic subjects with or 
without neuropathy. However, it is certain that these patients have alter-
ations in their somatosensory nervous system and hence changes in their 
pain response.29 Therefore, reliable measurements of pain detection and 
tolerance thresholds in this patient category in studies where analgesic 
compounds are tested might be challenging.
We found a lower ptt for the cold pressor task and the pressure pain 
task in Ciap patients, indicative of increased sensitivity to pain in these 
patients. No prior studies are available in which pain detection and toler-
ance thresholds are determined in Ciap patients. 
Differences were observed between pain thresholds in healthy subjects 
compared to patients with diabetes, pdn and Ciap. No differences were 
observed between healthy subjects and subjects with sciatica. The elec-
trical pain paradigm, the pressure pain paradigm were performed on the 
lower extremities, the cold pressor test on the upper extremity. In diabetes, 
pdn and Ciap nerve fibers of all extremities can be injured;30,31 in sciati-
ca only the nerve root of the affected leg is injured. In the sciatica patients 
measurements were performed in the unaffected leg. So in all patient 
populations except for the sciatica patients, pain measurements were per-
formed in a possibly compromised part of the nervous system. Performing 
these measurements in less affected parts of the nervous system would 
possibly have yielded other outcomes.
Recent studies suggest a role of an impaired inhibitory conditioned pain 
modulation in patients with chronic pain states.10,32 Here, no differences 
in Cpm values were observed between healthy subjects and patients. Of all 
pain measurements, Cpm had the largest intra- and inter-subject variability. 
We compared the electrical pain detection and tolerance thresholds before 
and within 5 min after the cold pressor task to quantify Cpm. The study by 
Deanen and colleagues measured Cpm by comparing pain intensity (and 
not pain detection and tolerance) during (and not after) the conditioning 
stimulus.10 The study by Olesen measured Cpm by performing somatic 
pressure stimulation direct, 2 and 5 min after immersion of the hand of a 
cold water bath. Maximum Cpm response was observed directly after the 
cold pressor test. The highly variable noted for the Cpm in our study is 
the most likely reason why we were not able to detect differences in Cpm 
between the different patient groups.
Sex was a significant covariate in electrical pain (pdt) and pressure 
pain (ptt). In all cases where differences between male and female sub-
jects were observed, female subjects had lower detection and tolerance 
thresholds compared to male subjects. A systematic review about sex 
differences in experimental pain perception mentions that there is strong 
evidence that female subjects tolerate less thermal and pressure pain com-
pared to male subjects and the female and male subjects have comparable 
thresholds for cold and ischemic pain.33 Body mass index was a significant 
covariate for the pain detection thresholds for both electrical pain para-
digms and for pressure pain. Higher bmi was associated with higher pdts. 
A recent review observed a tendency towards higher pain threshold in 
obese subjects compared to non-obese subjects.34 Although obese subjects 
were excluded from our studies, a trend towards higher pdts with increas-
ing bmi was observed. 
The Qst battery is used as tool to determine somatosensory profiles in 
different pain disorders. Several studies showed distinct somatosensory 
profiles in different neuropathic pain disorders.35,36 We only observed 
differences between healthy subjects and patients in a small number of 
outcome measurements. Subjects who achieved more than 80% of the 
maximum input intensity for any of the nociceptive tasks were excluded 
from participation or excluded from the analysis. Therefore, the present-
ed values might be an underestimation of the actual differences in pain 
threshold and tolerance within the groups. This, in combination with the 
high variability in baseline outcome measurements, makes the battery of 
human pain models not a useful tool to quantify somatosensory profiles of 
pain syndromes. The battery is more suitable as a screening tool to predict 
analgesic and pharmacological potential of existing and new compounds. 
Due to the variability of the measurements and confounding effects of sex, 
setting up studies that are placebo-controlled with a crossover design are 
preferable. Furthermore, outcomes should always be corrected for individ-
ual baseline values. 
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In this study we aimed to make a comparison between healthy subjects and 
different patient populations. Results from seven studies were used to do 
this exploratory analysis. Study designs were different and were not spe-
cifically designed to look at the endpoints described in this analysis. The 
patient population differed from the healthy subject population in base-
line characteristics such as weight, age and concomitant medication use. 
Healthy subjects were not allowed to use concomitant medication, patients 
were allowed to use medication if the use was stable 2 weeks prior to the 
first study visit. This could have influenced the outcomes in the patient 
populations. 
If patients respond to the pain tests in a similar way as healthy subjects 
do, these tests can be implemented in pharmacological studies in patient 
populations. Subsequently, if a correlation exists between outcomes in 
pain tests and clinical efficacy after a pharmacological intervention, results 
from pain tests can be used to predict clinical efficacy. Results of pain tests 
performed in healthy subjects can then be genuinely extrapolated to clin-
ical efficacy in patient populations. However, significant differences were 
observed between healthy subjects and patient populations for several of 
the pain tests. Intra-subjects variability tended to be higher in the patient 
populations. These differences may influence the extent to which results of 
analgesic effects using evoked pain tests in healthy subjects can be extrap-
olated to patients with chronic pain conditions. Pharmacological validation 
studies in patients using this battery of pain models could be performed 
in order to further explore how this battery of pain models responds in 
patients. As pointed out previously, a possible point of improvement to 
future studies would be to perform pain tests in parts of the body unaffect-
ed by the pain condition. 
This is the first time that a study is reported in which pain sensitivity 
in four different chronic pain conditions are compared using a multi-mod-
al battery of pain models. It can be concluded that patients with a chronic 
pain state respond differently to pain tests than healthy subjects. Future 
studies are needed to investigate if a correlation exists between outcomes 
in pain tests and clinical efficacy after a pharmacological intervention in 
chronic pain patients. 
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Table 1 
Overview of original studies 







1 Healthy Healthy, aged 18-65 years, bmi 18-30 kg m⁻2,  









2 Healthy Healthy, aged 18-65 years, bmi 18-30 kg m⁻2,  









3 Healthy Healthy, aged 18-65 years, bmi 18-30 kg m⁻2,  











Aged 18-85 years, unilateral sciatica, pain 
radiating L4, L5 or S1. For at least 3 months 
prior to screening. Must rate their pain at  








5 Healthy Healthy, aged 18-65 years, bmi 18-30 kg m⁻2, 








6 Healthy Healthy, aged 18-45 years, bmi 18-30 kg m⁻2,  

















-Healthy, aged 18-80 years, bmi 18-32 kg m⁻2,  









-DM, aged 18-80 years, bmi 18-32 kg m⁻2, 








-pdn, aged 18-80 years, bmi 18-32 kg m⁻2, 
according to aan criteria16, average daily  







-Ciap, aged 18-80 years, bmi 18-32 kg m⁻2, 
diagnosis as defined by criteria in Visser  








dm, diabetes mellitus; pdn, painful diabetic neuropathy; Ciap, chronic idiopathic axonal polyneuropathy. *values are pre-
sented as median (range)
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Least squares means for pdt and ptt for the different pain tasks in different populations. 
A represents the cold pressor task; B, electrical stimulation repeated stimulus; C, electrical 
stimulation single stimulus; D, pressure stimulation task and E, conditioned pain modulation 
(only ptt).
pdt, pain detection threshold; ptt, pain tolerance threshold; s, seconds; kPa, kilopascal; mA, milliampere;  
pdn, painful diabetic neuropathy; Ciap, chronic idiopathic axonal polyneuropathy.
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summary and general discussion
Drug development scientists are on a search for suitable biomarkers that 
can assist in predicting the therapeutic potential of analgesic medication 
and, therefore, it’s efficacy in the target population. This is particularly 
appropriate for human pain where models can assist to bridge the preclin-
ical and clinical findings. These models can provide valuable information 
about the mechanism of action of existing and new drugs. However, a 
single human pain model cannot be used exclusively to screen the phar-
macological mechanism of a compound as it inherently only tests a single 
mechanism.
In this thesis the performance of a battery of pain models (PainCart) 
was investigated. Three main topics were investigated. (1) The validation 
of the PainCart was described in which the effects of different classes of 
analgesics on this battery of pain models were explored. (2) The PainCart 
was used in different chronic pain populations. (3) The performance of the 
battery during the development of new analgesic compounds was studied. 
The PainCart can potentially act as biomarker to assess the effect of anal-
gesics on pain in early phase drug studies. A biomarker has to meet the 
following four criteria;1
 » There must be a consistent response of the biomarker across studies 
(preferably from different research groups) and drugs from the same 
mechanistic class. 
 » The biomarker must respond clearly to therapeutic (not 
supratherapeutic) doses. 
 » There must be a clear dose- or concentration-response relationship. 
 » There must a plausible relationship between the biomarker, 
pharmacology of the drug class, and disease pathophysiology. 
In this chapter of the thesis the main outcomes are summarised. The bio-
marker criteria in relation to the PainCart are discussed point by point and 
limitations and future perspectives are discussed. 
Main outcomes
Chapter 2 describes the methodology of the different PainCart measure-
ments. In Chapter 3 the ability of the battery of pain models to detect 
analgesic properties of commonly used analgesics in healthy subjects is 
investigated. The study consisted of two parts. Subjects were administered 
fentanyl, phenytoin, (s)-ketamine and placebo (part i), or imipramine, pre-
gabalin, ibuprofen and placebo (Part ii). In this chapter it was shown that 
the battery of pain models is able to detect changes in pain detection and 
pain tolerance thresholds after administration of different classes of anal-
gesic compounds in healthy male and female subjects. Compounds with 
different mechanisms of action demonstrated a distinct response pattern 
on the different pain models. 
In Chapter 4, the analgesic effects of a novel compound for treatment 
of acute pain, Xen2174, were assessed with the PainCart. Xen2174 is a small 
peptide, derived from the venom of a marine cone snail. This peptide 
binds to the norepinephrine transporter, which results in inhibition of 
norepinephrine uptake. The study was performed to assess the pharma-
codynamics and the pharmacokinetics in plasma and cerebrospinal fluid 
(Csf) of Xen2174 in healthy subjects. In a randomised, blinded, placebo-con-
trolled study, 25 subjects were administered Xen2174 or placebo. Csf was 
sampled for 32 hours using an intrathecal catheter. Pharmacodynamic 
assessments were performed using the PainCart. This study showed that 
the highest dose of Xen2174 administered intrathecally was able to influ-
ence pain thresholds in several pain models. The pain models showed an 
increase in pain tolerance thresholds for the electrical pain models and 
the pressure pain model following administration of the highest dose of 
Xen2174 tested, although statistical significance was not reached. At the 
highest dose level tested in this study, concentrations of Xen2174 in cere-
brospinal fluid exceeded the required exposure limit based on nonclinical 
safety margins, making it unlikely that the compound can be used in prac-
tice for the treatment of acute pain. However, in this study it was shown 
that intrathecal drug administration in combination with performing a 
battery of evoked pain tasks in humans is feasible, even with concurrent 
Csf sampling.
Chapter 5 describes a study which investigated the synergistic effects 
of milnacipran and buprenorphine in healthy subjects using the PainCart. 
Buprenorphine is known to be a potent opioid agonist. Animal studies 
suggest that milnacipran co-administered with opioids may potentiate the 
analgesic effect of μ-opioid receptor agonists. A randomised double-blind-
ed, placebo-controlled, 4-way cross-over, multiple dose clinical trial to 
investigate the analgesic effects of buprenorphine in combination with 
milnacipran in healthy subjects was performed. Buprenorphine showed a 
dose dependent analgesic response, but no potentiation or synergy on a 
battery of evoked pain tasks could be observed after co-administration of 
both milnacipran and buprenorphine.
The studies presented in the previous chapters were all performed in 
healthy adult subjects. Chapter 6 described the use of the PainCart in a 
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population of healthy adolescents. In this two-day crossover, randomised, 
double-blind, placebo-controlled study, 16 adolescents (aged 16 or 17 years) 
received paracetamol or placebo on separate study days. Paracetamol con-
centrations were measured in saliva. Plasma paracetamol concentrations 
were predicted using measured saliva concentrations and pharmacokinetic 
data taken from published studies. Paracetamol did not have a statistically 
significant effect on any of the pain parameters. Nonetheless, a majority of 
the adolescents would participate again in the study. In this chapter it was 
demonstrated that pain research using the PainCart with concurrent saliva 
sampling is feasible and acceptable in a population of healthy adolescents.
Chapter 7 describes a study in which a novel neurotrophic factor, 
bg00010, was administered in patients with sciatica. The main objectives of 
this study were to evaluate the pharmacokinetic and safety profiles and to 
determine the effects on pain of ascending doses of intravenous injections 
of bg00010 in patients with sciatica. In this randomised, blinded, place-
bo-controlled multiple-dose study, different dose levels of bg00010 were 
examined. Safety and efficacy assessments were used as endpoints. Efficacy 
assessment of pain were performed by using a numerical rating scale of the 
sciatic pain. PainCart measurements were included in this study as explor-
atory measurements. In this study no notable trends were observed within 
the PainCart measurements. The main conclusion of this chapter is that 
bg00010 may have a benefit for patients with sciatica. Although no effects 
of bg00010 on the PainCart were observed, it was shown that performing a 
battery of pain models at the same time as the more traditional endpoints 
in a clinical trial in patients with sciatica was feasible. 
In Chapter 8, an analysis was performed in which data from 7 PainCart 
studies were analysed. Healthy subjects and patients with sciatica, dia-
betes mellitus (dm), painful diabetic neuropathy (pdn) and chronic 
idiopathic axonal polyneuropathy (Ciap) were included in this analysis. 
Significant differences in pain thresholds existed between healthy subjects 
and patients. These observed differences may influence the extent to which 
results of analgesic effects using evoked pain tests in healthy subjects can 
be extrapolated to patients with chronic pain conditions. 
The PainCart as biomarker for analgesic efficacy
As discussed previously, in order to assess if a measurement or a combina-
tion of measurements can be used as biomarker, it has to fulfil four criteria. 
There musT be a consisTenT response of The biomarker across 
sTudies (preferably from differenT research groups) and drugs 
from The same mechanisTic class
The PainCart is not the first multimodal battery of pain models that is 
described in the literature. Other groups also describe a multimodal 
approach to investigate effect of analgesics. Staahl et al. assessed the 
reproducibility of a pain test battery that consisted of pain models evoking 
pain in skin, muscle and viscera.2 This battery of test was later used to 
compare the analgesic potency of both morphine and oxycodone. All pain 
models used in this study were sensitive to the effects of strong opioids.3
Olsesen et al. used a multi-modal, multi-tissue approach to explore 
which models were able to assess morphine analgesia in a group of healthy 
subjects.4 They concluded that models that provide deep tonic stimula-
tion including C fibre activation (muscle pressure, bone pressure, cold 
pressor and visceral pressure) were more sensitive to morphine analgesia 
than models that stimulate superficial structures with phasic impulses. 
The findings from literature are in agreement with our observations. The 
strong opioids that were used in Chapter 3 and Chapter 5 increased pain 
tolerance in a broad range of pain models (Table 1). The effects on evoked 
pain tests of the other compounds described in this thesis are also shown 
in Table 1. If this table is compared with Table 1 from Chapter 1, most drug/
pain model combinations show comparable results. The agreement of the 
results observed in this thesis with the findings found in literature suggests 
that the individual models from this battery show consistent responses 
across studies. However, in order to draw any definite conclusions about 
the reproducibility of the PainCart between studies similar or equal com-
pounds should be tested repeatedly. 
The biomarker musT respond clearly To TherapeuTic  
(noT supraTherapeuTic) doses
The following doses were administered in the studies described in 
Chapter 3, 5, and 6; fentanyl 3 µg kg⁻1 in 30 min, buprenorphine 0.5-3 µg 
kg⁻1, ibuprofen 600 mg, imipramine 100 mg, phenytoin 300 mg, pregaba-
lin 300 mg, (s)-ketamine 10 mg and paracetamol 1000 mg. For ibuprofen, 
imipramine and pregabalin these doses are on the upper limit of normal, 
but not supratherapeutic. For the other compounds, dosages adminis-
tered are within the normal range prescribed. For all compounds, except 
paracetamol, a statistically significant effect on one of the pain models 
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was observed. Therefore, it can be concluded that the PainCart responds 
clearly to therapeutic doses. Furthermore, in Chapter 5 three ascending 
doses of buprenorphine were administered; a subtherapeutic dose of 0.5 
µg kg⁻1, a dose of 1 µg kg⁻1 dose which was expected to lead to minimal-
ly therapeutic plasma concentrations and a 3 µg kg⁻1 infusion, which was 
expected to lead to therapeutic plasma concentrations of buprenorphine. 
The subtherapeutic did not lead to pronounced effects on the PainCart 
while the minimally therapeutic and the therapeutic doses did (Figure 1). 
There musT be a clear dose- or concenTraTion-response relaTionship
In Chapter 4 three ascending doses of Xen2174 were administered. After 
administration of 0.5 mg Xen2174 and 1 mg Xen2174, no changes in pain 
detection and pain tolerance were observed. After administration of 2.5 
mg Xen2174 an increase in ptt was observed for the electrical pain and the 
pressure pain tests. As discussed, in Chapter 5 three ascending doses of 
buprenorphine were administered. Similar observations as in Chapter 
4 were made in Chapter 5. A clear dose response and concentration-re-
sponse was observed for the different doses administered in this study 
(Figure 1). 
There musT a plausible relaTionship beTween The biomarker, 
pharmacology of The drug class, and disease paThophysiology
The individual models of the PainCart induce pain via different mecha-
nisms. As described in Chapter 1, electrical stimulation directly stimulates 
sensory nerve endings.5 The pressure stimulation test assesses nocicep-
tion generated from the muscle.6 Cold pain induced by the cold pressor 
test mainly activates C-fibers.7 The pain response from the thermal stim-
ulation initially activates Aδ fibers, followed by C-fiber activation. After 
induction of uvb inflammation, cytokines are produced which lead to sen-
sitisation of cutaneous nociceptors.8 The drugs administered in the studies 
all have their own specific effects on these pain pathways. For instance, 
opioid receptors are widely distributed in the brain, the spinal cord and 
the periphery. Opioids have direct central effects, where they modulate 
descending pathways which exert a strong inhibitory effect on pain trans-
mission in the dorsal horn. They also inhibit pain transmission by directly 
acting on the dorsal horn and by inhibiting excitation from peripheral noci-
ceptors.9 Nonsteroidal anti-inflammatory drugs inhibit cyclo-oxygenase 
enzyme (Cox) 1, 2 and 3. In this way they inhibit conversion of arachidon-
ic acid into prostaglandins and consequently inhibit the inflammatory 
response by elicited by cytokines.9 The extensive distribution of opioid 
receptors throughout the body might explain the broad overall effect of 
fentanyl and buprenorphine on the PainCart. Ibuprofen only had a signifi-
cant effect on the heat pdt of uvb irradiated skin, this can also be explained 
by the mechanism of action of nsaids. Therefore, it can be concluded that 
there is a plausible relationship between the pharmacology of the drugs 
administered and their effect exerted on the PainCart. Based on the four 
criteria previously mentioned, the collection of pain models combined in 
the PainCart can act as biomarker to assess the pharmacodynamic respons-
es of analgesic drugs. As mentioned previously, a single human pain model 
cannot be used exclusively to screen the pharmacological mechanism of a 
compound as it inherently only tests a single mechanism. Therefore, it is the 
combination of pain models that makes the PainCart useful as a biomarker. 
The use of the PainCart in clinical drug development
We concluded that the PainCart can act as biomarker for the assessment of 
the pharmacodynamic effects of analgesic drug. But if an effect is observed 
in human pain models in healthy subjects, does this also predict clinical 
efficacy? If effects observed on evoked pain models are predictive for clin-
ical efficacy is discussed in Chapter 1. Lotsch et al. concluded that a small 
set of pain models seemed predictive for efficacy in the clinic.10 In this 
study nine experimental pain models are mentioned that predict analge-
sia in drug development. Of these nine models, three models are included 
in the PainCart battery, namely uvb + contact heat, blunt pressure and 
electrical pain. This suggests that pharmacodynamic effects observed 
on the PainCart might predict clinical efficacy. However, the review from 
Lotsch and colleagues only provided an indirect link from healthy subjects 
to chronic pain patients. For this reason the study described in Chapter 
8 was performed. The aim was to identify possible differences between 
healthy subjects and patients with a chronic pain state in their response 
to the PainCart. If patients respond to the pain models in a similar way 
as healthy subjects, extrapolation of results obtained in healthy subjects 
to patient populations may be better justified. The results from this study 
showed that there are differences in pain perception between healthy sub-
jects and chronic pain patients. This is in agreement with previous research 
which showed that chronic pain patients and chronic opioid users have a 
tendency to respond differently to painful stimuli.11⁻14 Therefore, although 
the PainCart is perfectly suitable as a tool to assess effects of analgesics in 
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healthy volunteers, in order to draw conclusions about the extrapolation of 
PainCart results from healthy subjects to pain patients, further research in 
this specific area needs to be performed. This future research is challenged 
by the fact that the ‘pain patient’ does not exist. In patients with chronic 
(neuropathic) pain, different sensory profiles exist. These profiles possibly 
match with different neurobiological mechanism of pain.15 Selecting and 
clustering the patients in groups is necessary to obtain meaningful results.
Limitations of the PainCart
As previously discussed in Chapter 3, the large number of pain models that 
were used in this study, yielded an even greater number of outcome vari-
ables. No correction for multiple testing was applied in any of the studies as 
this were early phase clinical studies designed to explore the pharmacody-
namics of the analgesic compounds. This multi-modal test battery should 
be considered as a screening tool for analgesic properties of compounds in 
development for the treatment of pain, and not as a way to definitely prove 
effects on a specific evoked pain model with statistical significance. When 
the analgesic effect of a new drug on a certain pain mechanism has already 
been established, predefining a primary outcome measure would prevent 
the need to correct for multiple testing.
The magnitude of a placebo response can be large in pain research, espe-
cially in neuropathic pain.16 However, large placebo responses are also 
reported in healthy subjects. Olofsen et al. reported that placebo analge-
sia contributed to 20% of the total analgesic effect after administration of 
alfentanil in healthy subjects,17 although this study reported that the place-
bo response was additive to the alfentanil effect. It is of utmost importance 
to use cross-over study designs when pain models are used to reduce vari-
ability and correct for potential placebo effects. 
In this thesis no pharmacokinetic-pharmacodynamic (pk/pd) modelling 
and simulation techniques were used. A review of Martini et al. shows the 
usefulness of pk/pd modelling of analgesics to assess not only their efficacy, 
but also to estimate potency, identify sources of variability and predict time 
course of drug effects.18 In Chapter 5 pk/pd data was used to estimate the 
timing and dosages of the buprenorphine infusions. Other studies described 
in this thesis report the pk and pd results somewhat separately. For instance, 
in Chapter 3 and 4 besides the PainCart measurements, concentrations of 
the different compounds used were also measured. Only a non-compart-
mental analysis was performed. However, these data could be very well used 
to do more advanced analyses, such as defining responders and non-re-
sponders and predict a more specific time course of the drug effects. 
As discussed in Chapter 8 significant differences were observed between 
healthy subjects and patient populations for several of the pain tests. 
These differences may influence the extent to which results of analgesic 
effects using evoked pain tests in healthy subjects can be extrapolated to 
patients with chronic pain conditions. Pharmacological validation studies 
in patients using this battery of pain models could be performed in order 
to further explore how this battery of pain models responds in patients. 
This way, clinical efficacy can be directly correlated to the effects on the 
PainCart measurements. However, the larger variability that was observed 
in patients compared to healthy volunteers should be taken into account 
when designing these studies.
Future of the PainCart
In all studies in this thesis, the battery of pain models included two par-
adigms for electrical stimulation, the pressure stimulation test, the cold 
pressor test and a paradigm for conditioned pain modulation. Chapter 3 
also included the uvb model and the thermal grill test. However, choices 
have to be made about what pain models should be included in the battery. 
An example is the thermal grill test. In Chapter 3, no significant decrease on 
thermal grill maximum unpleasantness or maximum pain ratings could be 
observed in this study, while other research groups report significant out-
comes after the use of this test.19 Due to the apparent necessity to tailor this 
method to each individual subject, it is difficult to standardise this method 
and incorporate it into our battery of pain models. Also, the thermal grill 
test does not fit the first two biomarker criteria as mentioned earlier in 
this chapter (consistent response of the biomarker across studies prefer-
ably from different research groups / the biomarker must respond clearly 
to therapeutic (not supratherapeutic) doses). Therefore, the thermal grill 
does not prove to be an added value to the PainCart setup. 
Another example is the Cpm paradigm that is used in the PainCart. It is 
the test with the highest inter- and intra-subject variability in their outcome 
parameters (Chapter 8). To quantify Cpm, the electrical pain detection and 
tolerance thresholds were compared before and within 5 minutes after the 
cold pressor task. A study by Deanen and colleagues measured Cpm by com-
paring pain intensity (and not pain detection and tolerance) during (and 
not after) the conditioning stimulus.20 A study by Olesen measured Cpm 
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by performing somatic pressure stimulation directly, 2 and 5 minutes after 
immersion of the hand of a cold water bath. Maximum Cpm response was 
observed directly after the cold pressor test. It appears that Cpm measured 
in our way leads to more variable Cpm. Cpm is an important measurement 
of the pain perception in healthy subjects and chronic pain patients, how-
ever if a measurement of Cpm is considered as a valuable addition to the 
PainCart, another method of measuring Cpm should be selected. 
Two methods for electrical stimulation were used. A single stimulus 
method in which intensity of a current gradually increases and the repeat-
ed stimulus method in which each single stimulus pulse is repeated 5 times 
with a frequency of 2 Hz at the same current intensity and the repeated 
stimulus intensity increases gradually. This repeated application of a stim-
ulus over time induces an integrated and more painful response, known as 
temporal summation. It is suggested that temporal summation might act 
as a biomarker of drug effects on neuropathic pain.21 However, a statisti-
cally significant treatment effect for the electrical repeated stimulus is only 
observed after administration of buprenorphine (Table 1). And in this spe-
cific case buprenorphine also increased the single stimulus ptt. It could be 
argued that discarding one of the electrical tests could be an improvement 
for the PainCart. 
expansion of models included in The paincarT
Currently the battery focuses on nociceptive and inflammatory pain mod-
els. There are pain models that are not included in the PainCart, which 
could be of value for this battery. 
For instance, induction of chemical pain by intranasal gaseous Co2 stim-
uli and punctate heat induced by laser heat stimuli. Both methods have the 
advantage that they are using short-lasting stimuli and that evoked poten-
tials can be used as possible read out. Both methods have been shown to be 
predictive of clinical analgesia.10 
Stimulation of the viscera is also not a part of the PainCart. Visceral pain 
can be evoked by applying distension to hollow organs, such as the oesoph-
agus, small intestines or rectum. Other evoked pain methods inducing 
visceral pain include electrical, thermal or chemical stimulation of a part of 
the gastrointestinal tract.7 Distension techniques have been used to evalu-
ate the effects of several nsaids and opioids.22 If the PainCart is considered 
as a screening tool for potential analgesic effects of compounds, then addi-
tion of a methodology of visceral stimulation would give a wider range 
of possible analgesic findings. However, major disadvantages of visceral 
stimulation include that they are highly invasive (which limits tolerability 
by the subjects), technically difficult to perform (for instance insertion of a 
gastroesophageal probe), more difficult to include in a study setup where 
measurements are performed throughout the day and the pain is more dif-
ficult to measure to the diffuse nature of the pain. 
Another model that the PainCart is lacking, is a model for neuropathic 
pain. Numerous models exist that evoke neuropathic pain in animals. For 
instance central neuropathic pain is evoked by injecting excitotoxic agents 
(e.g. picrotoxin or kainate) into the somatosensory cortex and peripheral 
neuropathic pain is evoked by ligating or transecting peripheral nerves.23
For obvious reasons these models are not performed in human subjects. 
Models that are frequently used to induce symptoms that are also observed 
in neuropathic pain include models that evoke pain via intradermal cap-
saicin, uvb irradiation or a freeze lesion.24 These models evoke several 
symptoms that are typically observed in neuropathic pain such as allodyn-
ia and/or hyperalgesia, but do not lead to chronic neuropathic pain as such 
is normally caused by a lesion or disease of the somatosensory system.25 
The uvb model that is incorporated in the PainCart causes hyperalgesia 
and is a good model for inflammatory pain. Hyperalgesia is a symptom 
observed in neuropathic pain, however, none of the compounds of which 
you would expect an effect on neuropathic pain (imipramine, pregabalin 
or phenytoin) increased the pain detection threshold of this test. It may be 
that neuropathic pain is too complex to be imitated by a human pain model. 
A possible strategy to predict efficacy of analgesic drugs against neuro-
pathic in pain models is to back-translate results from the clinic to studies 
in healthy volunteers as suggested by Lotsch and Oertel.10,26 For instance, 
if pregabalin is effective against neuropathic pain; and pregabalin affects 
the cold pressor test; then this test might be a predictor for a drug’s effect 
on neuropathic pain. Besides, neuropathic pain is not a single entity, it is a 
group of syndromes that is caused by a lesion or disease of the nervous sys-
tem. Neuropathic pain can manifest itself in many ways; such as peripheral 
sensitisation, central sensitisation and deafferentation.27 A single model 
for neuropathic pain as an entity is unnecessary, if all these manifestations 
can be mimicked in a model separately. For instance, dorsal horn sensitisa-
tion can be induced by intradermal injection of capsaicin.28
readouTs of The paincarT
The psychophysical readout of the PainCart is a combination of a response- 
dependent and a stimulus-dependent methods (see also Chapter 1). In 
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the response-dependent method the subjects rates the intensity of a given 
stimulus, with the PainCart this is done continuously with the evas slider. 
In the stimulus-dependent threshold, the stimulus increases until a certain 
threshold (pain detection threshold, pain tolerance threshold) is reached; 
this is also done in the PainCart measurements. In the studies performed, 
the primary outcomes were pain detection threshold, pain tolerance 
threshold and area under the pain-intensity curve. These readouts have in 
common that they provide a subjective rating of the pain. More objective 
readouts include electrophysiological readouts such as somatosensory 
evoked potentials, electroencephalography (eeg) and functional magnetic 
resonance imaging (fmri). Although they have a larger variation in out-
come measurements and are technically more difficult to perform in a large 
group of subjects, a more objective outcome measurement would be valu-
able addition to the PainCart.29⁻31
Overall conclusion
While the PainCart has demonstrated that it is robust, reliable and sensitive 
to a wide range of analgesics, one should realise that the PainCart is not a 
static entity, it is a dynamic process in which we continuously have to search 
for opportunities to improve the overall outcome of this methodology. 
As discussed previously targets of novel analgesic drugs can fall into 
three main classes: (1) incremental improvement on an existing drug mech-
anism, (2) novel selective mechanism arising from better understanding 
of the mechanism of an existing analgesic drug and (3) completely novel 
mechanism arising from basic biological studies or from human patho-
physiological or genomic studies.32 In all these classes the PainCart can 
assist the development of new analgesics. In PainCart studies where 
improvement on an existing drug mechanism is tested, the original com-
pound should be used as a positive control. If novel mechanisms are tested; 
the PainCart can be used to screen for analgesic properties of a drug and 
benchmark the compound with existing analgesics. 
Possible new drug targets include anti-nerve growth factor (ngf) 
antibodies, tropomyosin receptor kinase (Trk) A inhibitors, cannabinoid 
agonists, selective sodium channels blockers, transient receptor potential 
vanilloid 1 (trpv1) receptor antagonists.33⁻36 Based on the expected phar-
macokinetic and pharmacodynamic properties of these new targets, trials 
can be set up with a tailored study design using the PainCart. For instance, 
anti-ngf antibodies mediate anti-inflammatory responses. The uvb model 
would be an excellent model to assess pharmacodynamic properties of this 
class of drugs in healthy subjects. 
In 1998 the European Medicines Agency issued a guideline named “Note 
for guidance on general considerations for clinical trials”. In the intro-
duction they state “The essence of rational drug development is to ask 
important questions and answer them with appropriate studies”.1,37 In this 
thesis, the battery of pain models was able to answer some of these import-
ant questions in early phase, analgesic drug development. Although there 
is still room for improvement of this current methodology, at this stage 
the PainCart can be used to benchmark analgesic properties of new drugs 
against established analgesics in early phase clinical studies.
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Least squares means of different pain tasks at baseline and after administration of three 
ascending doses of buprenorphine.
ptt, pain tolerance thresholds; s, seconds; kPa, kilopascal; mA, milliampere.
Table 1 
Overview of analgesics described in this thesis and their effect on different pain models.
















Fentanyl ptt � 
(P<0.05)
ptt  � 
(P<0.10)
ptt  � 
(P<0.10)
ns ptt  � 
(P<0.10)
pdt  � 
(P<0.05)









ptt  � 
(P<0.05)
ptt  � 
(P<0.05)
ns ptt  � 
(P<0.05)
np np np
nsaid Ibuprofen ns ptt  � 
(P<0.10)




tCa Imipramine ptt  � 
(P<0.10)
ns ns pdt  � 
(P<0.05)






Phenytoin ns ns pdt  � 
(P<0.05) 
ptt  � 
(P<0.05)
ns pdt  � 
(P<0.10)




Pregabalin pdt  � 
(P<0.05) 
ptt  � 
(P<0.05)
ptt  � 
(P<0.10)




ptt  � 
(P<0.10)
ptt  � 
(P<0.05)





(s)-ketamine ns ptt  � 
(P<0.10)
ptt  � 
(P<0.05)
ns ns pdt  � 
(P<0.05)
ns ns
Other Paracetamol ns ns ns ns pdt  � 
(P<0.10) 
ns np np
Xen2174 ns ptt  � 
(P<0.10)
pdt  � 
(P<0.10)
ns ptt  � 
(P<0.05)
np np np
Cpm, conditioned pain modulation; uvb, ultraviolet b; ptt, pain tolerance threshold; pdt, pain detection threshold; ns, 
not significant; np, not performed; nsaid, nonsteroidal anti-inflammatory drug; tCa, tricyclic antidepressant and nmda, 
n-methyl-d-aspartate. 
Cold pressor ���  
(0 - 40 s)  
Electrical repeat ��� 
 
(0 - 30 mA) 
Electrical single ���  
(0 - 30 mA) 
Pressure stimulation ���  
(0 -75 kPa)
Baseline
Buprenorphine 0.5 µg kg-1
Buprenorphine 1.0 µg kg -1
Buprenorphine 3.0 µg kg -1 
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Een voorbeeld van het gebruik van biomarkers in geneesmiddelonder-
zoek is het gebruik van pijnmodellen in mensen. Klinische pijn in 
patiënten wordt beïnvloed door veel factoren, waaronder emotionele, psy-
chologische en cognitieve. Door pijnmodellen te gebruiken in onder andere 
gezonde proefpersonen kunnen deze factoren worden gecontroleerd. Een 
pijnmodel bestaat uit twee onderdelen; een externe pijnlijke stimulus 
wordt toegediend en deze stimulus wordt gemeten. De stimulus kan onder 
andere een mechanische, thermische, elektrische of chemische prikkel 
zijn. De prikkel kan op verschillende weefseltypes zoals huid, organen en 
spieren worden uitgevoerd. Het meten van de pijn kan met behulp van psy-
chofysische-, elektrofysiologische- en beeldvormingstechnieken worden 
gedaan. De psychofysische uitkomsten bestaan uit twee componenten; 
een stimulus-afhankelijke bepaling en een respons-afhankelijke bepaling. 
Bij de stimulus-afhankelijke bepaling neemt de intensiteit van de stimu-
lus toe totdat een bepaalde drempel wordt bereikt (bijvoorbeeld een pijn 
detectiedrempel of een pijn tolerantiedrempel). Bij de respons-afhanke-
lijke bepaling wordt gevraagd de intensiteit van een bepaalde prikkel te 
beoordelen (bijvoorbeeld met een visuele analoge schaal of een numer-
ieke schaal). Een voorbeeld van een elektrofysiologische meetmethode is 
elektro-encefalografie (eeg). Beeldvormingstechnieken kunnen bestaan 
uit metingen met behulp van een fmri (functional magnetic resonance 
imaging) en een pet (positron emission tomography) scan. De grootste 
voordelen van het gebruik van pijnmodellen ten opzichte van klinische pijn 
zijn dat de intensiteit, duur en modaliteit van de stimulus zijn te control-
eren, dat de reactie op een pijnprikkel kwantitatief kan worden bepaald 
en dat deze reactie kan worden vervolgd in de tijd. Een van de belangri-
jkste nadelen van pijnmodellen in mensen is dat de pijnlijke stimuli van 
kortdurende aard zijn en klinische pijn, die vaak langer duurt, niet goed 
nabootsen. Daarnaast zal een bepaald pijnmodel hooguit voldoende zijn 
om één specifieke vorm van pijn na te bootsten. Door meerdere pijntesten 
te combineren kunnen meerdere vormen van pijn worden onderzocht. Om 
die reden is dan ook het onderzoek, dat beschreven is in dit proefschrift, 
uitgevoerd. Hierbij is onderzocht of een multimodale benadering, waarbij 
meerdere receptoren en pijnbanen gestimuleerd worden, beter in staat is 
de potentiële pijnstillende effecten van middelen op te sporen.
nederlandse samenvaTTing
Acute pijn, te definiëren als pijn die minder dan 12 weken aanhoudt, is 
onderdeel van het normale leven en wordt regelmatig ervaren door bijna 
iedereen. Daarnaast wordt geschat dat ongeveer 19-31% van de Westerse 
bevolking lijdt aan chronische pijn; pijn die meer dan 12 weken aanhoudt. 
Chronische pijn komt vaker voor bij het toenemen van de leeftijd en meer 
bij vrouwen dan bij mannen. Veel gebruikte medicijnen tegen pijn zijn 
paracetamol, niet-steroïde anti-inflammatoire medicijnen (zoals ibupro-
fen en diclofenac) en opioïden (zoals morfine en tramadol). Ook worden 
antidepressiva en anti-epileptica gebruikt bij de behandeling tegen pijn. 
Door bijwerkingen en soms ook beperkte effectiviteit, blijft een continue 
zoektocht gaande naar nieuwe pijnstillers. 
Men kan nieuwe pijnstillers ontwikkelen door bestaande aangrijp me-
chanismen te verbeteren of op basis van nieuwe aangrijpmechanismen 
die vanuit fundamenteel geneesmiddelenonderzoek of vanuit menselijk 
pathofysiologisch onderzoek ontdekt worden. Ook al zijn er in de afgelo-
pen jaren diverse nieuwe pijnstillers op de markt zijn gekomen, zijn er toch 
veel nieuwe geneesmiddelen tegen pijn die gedurende de ontwikkelings-
fase sneuvelen. Met name als dat laat in de klinische fase plaatsvindt, zal 
dat gepaard gaan met zeer hoge kosten. Een methode die bij zou kunnen 
dragen aan een meer succesvolle ontwikkeling van geneesmiddelen in het 
algemeen is het gebruik van biomarkers. Een biomarker is een ‘kenmerk dat 
objectief gemeten en geëvalueerd kan worden als een indicator voor een 
normaal biologisch proces, een pathogeen proces of een farmacologische 
respons op een therapeutische interventie.’ Biomarkers die zijn bedoeld om 
farmacologische activiteit te meten, kunnen worden gebruikt om te bepalen 
of een middel aan een specifiek moleculair aangrijpingspunt bindt en wat 
de concentraties en doseringen zijn waarbij farmacologische activiteit op-
treedt. Het gebruik van biomarkers in vroege-fase-geneesmiddelonderzoek 
heeft als voordeel dat in een vroege fase kan worden bepaald of een potenti-
eel geneesmiddel zijn beoogde effect heeft. Op die manier kan het falen van 
een geneesmiddel in een latere fase door gebrek aan effectiviteit worden 
voorkomen. Daarnaast zorgt het aantonen van afwezigheid van effectiviteit 
in een vroege fase, voor de mogelijkheid vroegtijdig te kunnen stoppen met 
de ontwikkeling van een middel, met belangrijke kostenbesparingen tot 
gevolg.
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proefpersonen het koude water niet meer tolereren. Hierna wordt de hand 
uit het water verwijderd. De koud water test wordt ook gebruikt om gecon-
ditioneerde pijn modulatie te induceren. Geconditioneerde pijn modulatie 
is het principe waarbij een pijnlijke prikkel op een bepaald lichaamsdeel 
ervoor zorgt dat pijnlijke prikkels naar andere lichaamsdelen verminderd 
doorkomen. Deze geconditioneerde pijnmodulatie is een natuurlijke res-
pons van het lichaam om de pijnwaarneming bij te sturen. Dit proces wordt 
aangestuurd door het centraal zenuwstelstel en maakt onderdeel uit van 
de endogene pijn aansturing van het lichaam. 
Bij de hitte stimulatie test wordt pijn geïnduceerd door een thermode 
op de rug te bevestigen. De temperatuur van de thermode loopt langzaam 
op. Aan de proefpersonen wordt gevraagd om aan te geven wanneer de 
hitteprikkel als pijnlijk wordt ervaren. De uv test is een toevoeging aan de 
hitte stimulatie test. Hierbij wordt een stuk huid van de rug van 3 x 3 cm 
bestraald met uv licht. Dit zorgt voor een verbranding van de huid (zonne-
brand). Deze verbranding veroorzaakt hyperalgesie en een verlaging van 
de detectie grens voor warmte pijn. Het uv model wordt gebruikt als model 
voor inflammatoire pijn. 
Dit proefschrift beschrijft de validatie van deze batterij van pijnmodellen, 
het gebruik van de batterij in verschillende groepen en het gebruik van de 
batterij bij de ontwikkeling van nieuwe geneesmiddelen. De belangrijkste 
vraag van dit proefschrift is of de batterij gebruikt kan worden als biomar-
ker voor klinische effectiviteit in de ontwikkeling van nieuwe pijnstillers. 
 
Validatie van de PainCart
De methodologie van de afzonderlijke testen van de PainCart wordt uitge-
breid beschreven in hoofdstuk 2. Hoofdstuk 3 beschrijft een studie waarin 
de validatie van de pijntest batterij wordt uitgevoerd. Deze studie bestaat 
uit twee delen. In het eerste deel heeft een groep van 16 gezonde proef-
personen op vier verschillende studiedagen een eenmalige intraveneuze 
dosering van fentanyl, fenytoïne, (s)-ketamine en placebo gekregen. In deel 
2 kregen 16 andere gezonde proefpersonen een orale dosering imipramine, 
pregabaline, ibuprofen en placebo. In dit hoofdstuk wordt aangetoond dat 
de pijntest batterij in staat is verschillen in pijn detectie en pijn tolerantie 
na toediening van verschillende klassen pijnstillers te detecteren. Wij ont-
dekten dat middelen met verschillende werkingsmechanismen een uniek 
uitkomstenprofiel vertonen op de verschillende pijntesten. 
De PainCart
De PainCart, de pijntest batterij beschreven in dit proefschrift, is een batterij 
van testen die verschillende pijnmodellen combineert. De verschillende 
pijnmodellen induceren pijn via verschillende stimuli en in verschillende 
weefsels. De pijnmodellen die onderdeel uitmaken van de PainCart zijn uit-
gebreid gebruikt in eerder onderzoek. Een uniek aspect van de PainCart 
is dat het verschillende pijnmodellen combineert waardoor op een gecon-
troleerde manier meerdere pijntesten in een relatief korte tijd uitgevoerd 
kunnen worden. De specifieke pijnmodellen die onderdeel uitmaken van 
de PainCart zijn gekozen op basis van de mogelijkheden om pijnprikkels 
via verschillende modaliteiten (elektrisch, mechanisch en thermisch), in 
verschillende structuren (oppervlakkige en diepe structuren) en met ver-
schillende duur (kort, lang) toe te dienen. De PainCart bestaat uit modellen 
voor nociceptieve en inflammatoire pijn. De batterij bevat de volgende 
modellen; elektrische stimulatie test, druk stimulatie test, koud water test, 
hitte stimulatie test (met en zonder ultraviolet (uv) inductie) en methoden 
om de verwerking en modulatie van pijn door het zenuwstelsel te meten 
(geconditioneerde pijn modulatie en temporele summatie).
Bij de elektrische stimulatietest worden twee elektroden bevestigd op 
het scheenbeen. Door middel van een computer aangestuurde stimulator 
wordt elektrische stroom door de elektroden geleid. De elektrische stroom 
neemt langzaam toe in intensiteit en dit veroorzaakt pijn. De proefperso-
nen wordt gevraagd om aan te geven wanneer de prikkel pijnlijk begint aan 
te voelen (de pijn detectiegrens) en om aan te geven wanneer zij de prikkel 
niet meer kunnen verdragen (de pijn tolerantiegrens). Bij het bereiken van 
de pijn tolerantiegrens stopt de elektrische stroom direct. 
Bij de druk stimulatie test wordt een tourniquet om de kuitspier beves-
tigd. Via een luchtpomp wordt het tourniquet langzaam opgeblazen. Dit 
veroorzaakt pijn, met name door stimulatie van pijnvezels in de spier. 
Hierbij wordt eveneens aan de proefpersonen gevraagd om de pijn detectie 
en de pijn tolerantiegrens aan te geven. 
De methode van de koud water test bestaat uit een bad met koud water 
van ongeveer 1°C en een warm waterbad met een temperatuur van onge-
veer 35°C. Proefpersonen plaatsen hun hand eerst in het bad met warm 
water en na een bepaalde periode plaatsen zij hun hand in het koude water. 
De pijn detectiegrens is de tijd waarna de proefpersonen de koude sen-
satie als pijnlijk ervaren. De pijn tolerantiegrens, het moment waarop de 
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pijndrempels of op de andere testen. Uit dit hoofdstuk kan worden gecon-
cludeerd dat buprenorfine en milnacipran tezamen in deze studieopzet 
geen versterkend effect op pijn hebben.
Paracetamol is een van de meest gebruikte pijnstillers ter wereld. Niet 
alleen in de volwassen populatie, maar ook bij jongeren. In hoofdstuk 6 
wordt een onderzoek beschreven waarin paracetamol werd toegediend 
aan een groep adolescenten (16- en 17-jarigen). Hierbij werd gekeken naar 
de effecten van paracetamol op de pijntest batterij en werden de concen-
traties van paracetamol in het speeksel gemeten. Aan de adolescenten 
werd aan het eind van de studie gevraagd hoe zij het onderzoek hadden 
ervaren. De resultaten van het onderzoek toonden aan dat paracetamol 
in vergelijking met placebo bij deze populatie geen statistisch significant 
effect had op de PainCart metingen. Wel kan worden geconcludeerd dat 
het uitvoeren van pijntesten in een groep minderjarigen goed uitvoerbaar 
is. Het merendeel van de adolescenten zou opnieuw deelnemen aan een 
dergelijk onderzoek. 
Het gebruik van de PainCart in patiënten
De studies beschreven in de vorige hoofdstukken werden uitgevoerd in 
gezonde proefpersonen. Hoofdstuk 7 beschrijft een onderzoek waarin de 
PainCart werd gebruikt in een groep patiënten met lage rugpijn, uitstralend 
naar een van beide benen. In dit onderzoek werd BG00010 onderzocht. 
bg00010 is een neurotrofe stof; een eiwit dat zorgt voor een herstel en 
groei van zenuwcellen. Dit middel wordt ontwikkeld als mogelijke therapie 
voor neuropathische pijn. Het onderzoek beschreven in dit hoofdstuk was 
het tweede onderzoek waarin dit middel aan mensen werd gegeven. Het 
vaststellen van de farmacokinetiek in het bloed en van het effect van het 
middel op pijn waren de belangrijkste onderzoeksdoelen. De studie was 
gerandomiseerd, dubbelblind, en placebo-gecontroleerd. In het onderzoek 
werd aan de patiënten in totaal 3 doseringen van bg00010 toegediend. In 
totaal namen 28 patiënten aan het onderzoek deel. Bij hogere doseringen 
van het middel werd een afname in pijnklachten waargenomen, maar er 
was geen duidelijk dosis-gerelateerd effect. De bijwerkingen die door de 
patiënten het meest gerapporteerd werden, waren jeuk, hoofdpijnklachten 
en een warm gevoel na toediening. Er werd geen duidelijk effect gevonden 
van het middel op de testen van de PainCart. Op basis van dit onderzoek 
kan worden geconcludeerd dat bg00010 in de toekomst mogelijk een ther-
apie zou kunnen zijn voor de behandeling van neuropathische pijn. In deze 
Het effect van nieuwe en bestaande pijnstillers op de PainCart
De PainCart kan worden gebruikt om de pijnstillende effecten van zowel 
bestaande als nieuwe geneesmiddelen te onderzoeken. Een van de onder-
zochte nieuwe stoffen is Xen2174. Xen2174 is een klein eiwit, dat is afgeleid 
van het gif van een zeeslak die leeft in de Great Barrier Reef in Australië. Dit 
eiwit bindt aan de norepinefrine transporter en zorgt voor remming van de 
heropname van norepinefrine in het zenuwstelsel. Dit versterkt de dem-
pende werking die de hersenen uitoefenen op de pijnprikkels die vanuit het 
lichaam naar de hersenen lopen. De studie, die wordt beschreven in hoofd-
stuk 4, is uitgevoerd om het farmacokinetische en farmacodynamische 
profiel van Xen2174 te onderzoeken. Hiervoor hebben 25 proefpersonen, 
in een gerandomiseerde, dubbelblinde studie, een intrathecale toediening 
van een dosering Xen2174 of placebo gekregen. Vervolgens is in de 32 uur 
na toediening liquor (ruggenmergvloeistof) afgenomen door middel van 
een intrathecale catheter. De farmacodynamische metingen zijn gedaan 
door middel van de PainCart. Deze studie heeft laten zien dat de hoge dosis 
van Xen2174 de pijndrempels van een aantal pijntesten gunstig kan beïnv-
loeden. Tijdens dezelfde studie bleek echter ook dat de concentraties van 
het middel in het liquor hoger waren dan de vooraf vastgestelde veilighe-
idslimiet. Het is dan ook onwaarschijnlijk dat dit middel verder ontwikkeld 
zal worden voor de behandeling van pijn. Wel toont deze studie aan dat het 
uitvoeren van pijntesten en het doen van liquor afnames na toediening van 
een geneesmiddel via een ruggenprik goed mogelijk is. 
Van sommige pijnstillers is bekend dat ze elkaars werking versterken 
indien ze in combinatie met elkaar worden gebruikt. Zo is in dierstudies 
aangetoond dat wanneer milnacipran in combinatie met buprenorfine 
wordt toegediend, zij elkaars werking versterken. Buprenorfine is een 
potente opioïd receptor agonist. Milnacipran is een serotonine norepine-
frine heropname remmer. In hoofdstuk 5 wordt een gerandomiseerd, 
dubbelblind, cross-over onderzoek beschreven waarin het effect van mil-
nacipran in combinatie met buprenorfine wordt onderzocht in een groep 
gezonde mannen. De effecten van beide middelen, apart en in combi-
natie, op pijn werden onderzocht met behulp van de PainCart en op een 
aantal functies van het zenuwstelsel (zoals stabiliteit, oogbewegingen, 
pupilgrootte en aandacht) met behulp van de NeuroCart testbatterij. Na 
toediening van buprenorfine werd een dosis-afhankelijke toename in 
pijnstilling waargenomen. Na toediening van alleen milnacipran werd een 
toename van de pupilgrootte geconstateerd, maar was er geen effect op 
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Vervolgens dient de volgende vraag zich op; indien van een bepaald mid-
del een pijnstillend effect wordt aangetoond met behulp van de PainCart, 
beïnvloedt dit middel dan ook de spontaan optredende pijn bij patiënten? 
Er bestaan diverse overzichtsartikelen die deze vraag hebben onderzocht. 
Het lijkt zo te zijn dat een aantal pijntesten goed voorspellend zijn voor 
klinische effectiviteit. Een aantal van deze modellen maakt deel uit van de 
PainCart. Dit zijn de hitte pijntest in combinatie met de uv inflammatie, 
drukkende pijntest en de elektrische stimulatie test. Het eerder gepubli-
ceerde artikel suggereert dat de PainCart in sommige gevallen klinische 
effectiviteit kan voorspellen. Het is echter belangrijk te beseffen dat deze 
overzichtsartikelen alleen indirect bewijs tonen voor deze relatie. Voor 
direct bewijs zou men nieuw vergelijkend onderzoek in patiënten moet-
en uitvoeren. Daarnaast kan de voorspellende waarde van de PainCart 
worden bewezen als middelen, waarbij met de PainCart een pijnstillend 
effect is aangetoond, in latere klinische studies in patiënten ook effectief 
tegen pijn blijken.
Toekomst van de PainCart
Een groot aantal verschillende pijnmodellen wordt gebruikt in de studies 
die in dit proefschrift worden beschreven. Het ene model is gevoeliger voor 
het aantonen van pijnstilling dan het andere model. In hoofdstuk 3 wordt 
bijvoorbeeld de ‘thermal grill’ pijntest gebruikt, maar werden geen duideli-
jke effecten van de toegediende pijnstillers op deze test gevonden. In de 
literatuur blijkt dat veel verschillende onderzoeksgroepen net iets andere 
meetmethoden voor deze test gebruikten. Daarnaast wordt deze test per 
proefpersoon net iets anders ingesteld. Om deze redenen concludeerden 
wij dat dit pijnmodel minder geschikt is als model binnen de PainCart. 
De PainCart bevat een methode voor het onderzoeken van gecondi-
tioneerde pijn modulatie. Ondanks dat deze meting in alle hoofdstukken 
wordt uitgevoerd, wordt in bijna geen van de studies een effect aangetoond 
met deze meting. Een van de redenen is de hoge variabiliteit van de meting 
binnen individuele proefpersonen en tussen de proefpersonen. Andere 
onderzoeksgroepen vinden wel regelmatig verschil in geconditioneerde 
pijn modulatie, maar zij gebruiken vaak een net andere meetmethode dan 
beschreven in dit proefschrift. De huidige methode van de PainCart om 
geconditioneerde pijn modulatie te meten zal dan ook kritisch moeten wor-
den geëvalueerd en eventueel worden vervangen door een andere methode. 
De PainCart bestaat voornamelijk uit nociceptieve en inflammatoire pijn-
studie kon geen relatie tussen de effecten van bg00010 op klinische pijn en 
de effecten van dit middel op de PainCart worden aangetoond.
Behalve in het onderzoek beschreven in hoofdstuk 7, werd de PainCart 
vaker gebruikt om de pijn drempel en pijn tolerantie te onderzoeken in 
patiënten. Naast patiënten met lage rugpijnklachten uitstralend naar het 
been, werd de batterij gebruikt in patiënten met diabetes mellitus, met 
pijnlijke diabetische neuropathie (pdn) en met chronische idiopathische 
axonale neuropathie (Ciap). Hoofdstuk 8 beschrijft een analyse waarin de 
pijn detectie drempel en pijn tolerantie drempel in deze patiënten groepen 
werd vergeleken met gezonde proefpersonen. Voor deze analyse werden 
de resultaten van zeven PainCart gebruikt. De pijn detectie grenzen voor 
elektrische pijn bleken lager in patiënten met pdn en Ciap. De pijn toleran-
tie gemeten met de koud water test en de drukstimulatie test waren lager in 
patiënten met diabetes en Ciap in vergelijking met gezonde proefpersonen. 
Deze analyse laat zien dat er verschillen bestaan in de PainCart metingen 
tussen gezonde proefpersonen en patiënten. Uitkomsten gevonden in 
gezonde proefpersonen kunnen dus niet zo maar geëxtrapoleerd worden 
naar patiënten met chronische pijn. 
De PainCart als biomarker
Om een bepaalde meting als biomarker te kunnen gebruiken moet deze aan 
een aantal voorwaarden voldoen; 
 » Er moet een consistente respons zijn van de biomarker tussen 
verschillende onderzoeken en tussen geneesmiddelen met hetzelfde 
werkingsmechanisme.
 » De biomarker moet een duidelijke respons hebben op therapeutische 
doseringen van een middel (en niet op subtherapeutische doseringen). 
 » Er moet sprake zijn van een dosis-respons of een concentratie-respons 
relatie.
 » Er moet een logische relatie zijn tussen de biomarker, de farmacologie 
van het onderzoeksmiddel en de pathofysiologie van de ziekte. 
Aangezien de PainCart voldoet aan al deze vier criteria, kan geconcludeerd 
worden dat de PainCart als biomarker gebruikt kan worden om de far-
macodynamische respons van pijnstillers te onderzoeken. Daarbij is het 
belangrijk dat één enkel pijnmodel niet gebruikt kan worden om het effect 
van een pijnstiller te onderzoeken. Het is de combinatie van pijntesten die 
de PainCart bruikbaar maakt als biomarker. 
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onderzoek is om belangrijke vragen te stellen en deze te beantwoorden met 
geschikte studies’. In dit proefschrift, is de batterij van pijnmodellen in staat 
om enkele van deze belangrijke vragen te beantwoorden in vroege-fase-ge-
neesmiddelenonderzoek. Ook al bestaat nog ruimte om de methodologie 
verder te ontwikkelen, de PainCart kan in dit stadium gebruikt worden 
om de pijnstillende effecten van nieuwe middelen te onderzoeken. De 
gevonden resultaten kunnen worden vergeleken met de effecten die reeds 
bestaande pijnstillers eerder vertoonden op de PainCart. 
modellen. De weefsels die geprikkeld worden zijn huid en spieren. Hierin 
zou de PainCart kunnen worden uitgebreid. Er bestaan modellen die pijn-
prikkels kunnen toedienen aan de interne organen (bijvoorbeeld slokdarm 
en endeldarm). Toevoeging van een orgaanmodel zou een bredere uitkomst 
opleveren wanneer de mogelijke pijnstillende effecten van een middel op 
pijn aan de ingewanden worden onderzocht. Een nadeel van dergelijke 
modellen is echter de invasiviteit van de meting en de ongemakkelijkheid 
voor de proefpersoon. 
Daarnaast ontbreekt in de PainCart een model voor neuropathische pijn. 
Een lastig aspect hiervan is dat neuropathische pijn een complexe aan-
doening is, die een grote groep aan verschillende syndromen bevat. Deze 
verschillende syndromen hebben als gemeenschappelijke overeenkomst 
dat er schade of ziekte is aan een onderdeel van het sensibele zenuwstelsel. 
Uiteindelijk is het met pijnmodellen alleen mogelijk om symptomen van 
neuropathische pijn na te bootsten. Zo kan bijvoorbeeld met intraderma-
le injectie van capsaïcine, de pitte stof in rode pepers, centrale sensitisatie 
worden nagebootst. 
Bovenstaande voorbeelden geven aan dat continu kritisch moet worden 
gekeken naar de afzonderlijke testen van de PainCart. Voegt een bepaalde 
meting nog wel iets toe? Is er misschien een andere meetmethode beschik-
baar? De PainCart is geen statische methode. Het is een dynamisch model 
waarin continu gezocht wordt naar verbeteringen van de methodologie. 
Conclusie
Eerder is al benoemd dat potentieel nieuwe pijnstillers kunnen worden 
ontwikkeld door bestaande aangrijpmechanismen te verbeteren of door 
nieuwe aangrijpmechanismen te ontdekken vanuit fundamenteel (genee-
smiddelen)onderzoek. In dit proces kan de PainCart zijn nut bewijzen. Als 
een studie wordt uitgevoerd met een nieuwe stof, waarbij een bestaand 
aangrijpingsmechanisme is verbeterd, kan het reeds bestaande genee-
smiddel met een vergelijkbaar werkingsmechanisme worden gebruikt als 
positieve controle. Indien een nieuw mechanisme wordt onderzocht, kan 
de PainCart worden gebruikt als screeningsmiddel van de pijnstillende 
activiteit en kunnen de uitkomsten gebruikt worden om de plaats te bep-
alen van dit nieuwe middel ten opzichte van reeds bestaande pijnstillers. 
In 1998 bracht de Europese Geneesmiddelen Autoriteit een richtlijn uit 
met de titel ‘een richtlijn voor algemene overwegingen voor klinische trials’. 
In de inleiding hiervan staat: ‘de essentie van rationeel geneesmiddelen- 
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